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4Abstract
The strategy of Government to improve translational clinical research in England is
being driven through a policy framework that aligns investment to the requirement for
collaborative NHS Trust – University arrangements. This has resulted in the creation of
new partnerships that in theory should better facilitate the effective delivery of
translational clinical research. The study presents new knowledge into how these
macro level policy interventions are being translated at the meso (organisational) and
micro (individual) levels, utilising Huxham and Vangen’s theory of collaborative
advantage as the lens through which to view the perspectives of clinical academics
from two case study NHS-University partnerships.
A comprehensive analysis of the policy environment from the launch of ‘Improving
National Health: Improving National Wealth’ in 2003 through to 2015, provides an
insight to Government’s ambition to increase the volume and quality of translational
clinical research. The study contrasts this ambition with data gathered from
qualitative, semi-structured interviews of senior clinical academics working in two case
study NHS-University partnerships. A detailed analysis of how policy levers are being
translated in the two case study settings is provided, revealing data that has a wider
application to other similar partnerships in the Health and University sectors.
The study also presents data which demonstrate that whilst funding for translational
clinical research has increased at a national level, the majority of this is focussed upon
partnerships operating mainly in London and the Southeast. The study’s two case
study partnerships have been purposively selected to sit outside of these areas, such
that the national policy decisions could be tested in regions that historically receive
less funding for translational clinical research. This was aligned to the central
hypothesis that that the national policy developments will not be sufficient to increase
the volumes and quality of translational clinical research across England.
5The data analysis revealed that both of the NHS-University partnerships displayed
individualistic attributes that are not necessarily in-step with, or conducive to, the new
national policy environment. These included a lack of clarity with respect to joint
performance measures, made more challenging by virtue of the different cultures and
priorities that exist within the NHS and University sectors, and a lack of joint leadership
to provide the necessary impetus and vision with regards to a strategy for translational
clinical research.
At an individual level, these pressures were translating into a frustration around the
high volume of Government initiatives to which clinical academics are expected to
contribute, with the suggestion that a move towards devolved regional approaches
would allow partnerships a degree of necessary flexibility.
The research also found that the national shortage of clinical academics is a particular
issue for NHS-University partnerships based outside of London and the Southeast.
Without the necessary numbers of clinical academic staff, the objectives of the new
national policy environment for translational clinical research will not be realised, and
this is therefore an important finding.
The study brings new knowledge and perspectives to an area which has been under
researched within the literature, by focussing on two non-accredited NHS-University
partnerships, operating outside of London and the SouthEast that have been formed in
response to the national policy environment. Its conclusions and recommendations
therefore provide a useful insight into how this macro level framework is translated at
a local level.
As a piece of practitioner research, the study utilises the data analysis to support a
series of recommendations that could be applied within the two case study
environments or within similar NHS-University settings. It also presents a proposed
suite of joint performance measures, suggesting that these might be a useful stimulus
at the early stage of NHS-University partnership formation.
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Abbreviation Term
ACF Academic Clinical Fellow
AHSN Academic Health Science Network
AHSC Academic Health Science Centre
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CLAHRC Collaboration for Leadership in Applied Health Research Centre
DoH Department of Health
Golden Triangle of
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School of Economics, UCL, and Oxford.
HRA Health Research Authority
MRC Medical Research Council
NIHR National Institute for Health Research
NOCHR NIHR Office for Clinical Research Infrastructure
Northern
Powerhouse
Political concept introduced by the then Chancellor George Osborne to
mean the collective economic strength of the North of England
OSCHR Office for the Scientific Coordination of Health Research
QR Mainstream quality related research funding
RCUK Research Councils UK
REF Research Excellence Framework
TRPs Translational Research Partnerships
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Chapter 1. Introduction to the research
Since 2003, there has been a succession of Government policy and funding initiatives that
have aimed to improve the clinical research environment, making it more conducive to
successful translational research. These have included ‘Best Research for Best Health’
(Darzi; 2006), ‘A review of UK Health research funding’ (Cooksey; 2006) and the
establishment of the National Institute of Health Research NIHR in 2006.
Subsequently, the funding for translational clinical research has increased (UK Clinical
Research Collaboration; 2014), providing new opportunities for supporting research in
collaborative NHS-University settings, including Biomedical Research Centres (BRCs),
Collaborations for Leadership in Applied Health Research & Care (CLAHRCs), Academic
Health Science Centres (AHSCs) Academic Health Science Networks (AHSNs) and a series of
competitive grant programmes aimed exclusively at joint NHS-University projects.
The driver that have influenced the shift towards this new policy environment has been an
ambition by Government to increase the volume and quality of translational clinical
research in England, as part of a wider strategy to grow the life sciences sector, and to
improve the health of the national population by applying research outcomes into practice.
For example, the UK Strategy for UK Life Sciences (Dept. for Business Innovation & Skills;
2011) sets out a vision for a new eco-system consisting of NHS Trusts, Universities, Industry
and Charities working more closely together to achieve translational clinical research.
The majority of health funding in England is focused upon a small cluster of University and
NHS Partnerships that mainly operate in London, the Southeast, and East Anglia, referred
to in my thesis as the ‘Golden Triangle’, and defined within the Glossary of Terms as the
universities of Cambridge, Imperial, Kings College London, London School of Economics,
University College London, and Oxford. It is a term well used and understood within the UK
higher education sector to include those elite universities that attract the highest level of
research income in the country. The UK Clinical Research Collaboration’s UK Health
Research Analysis 2014 demonstrates that 60.78 percent of health research funding in the
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UK is committed to these areas. However, it is the ambition of Government to grow the
volume and quality of translational clinical research on a national level, so therefore the
new national policy environment shall have to impact beyond the Golden Triangle and in
those regions which together share the remaining 22.7 percent of health research funding
in England, these being the Northwest, Yorkshire & Humber, the Southwest, East Midlands,
the North, and the West Midlands.
I hypothesized that the new macro level policy environment for translational clinical
research will not in itself be sufficient to meet the Government’s objectives, requiring
instead positive action and culture change at meso (organisational) and micro (individual)
levels. I tested this hypothesis via a qualitative research study designed with an
interpretative approach that asked,
‘How can NHS-University Partnerships collaborate to deliver translational clinical
research?
The lens through which I explored this research question was that of two case study NHS-
University partnerships, each operating outside of the ‘Golden Triangle’, and comprising
NHS Trusts and Universities that have contrasting histories, cultures, and systems of
governance. Case study partnership one comprises a research intensive university and a
number of NHS Trusts. The University in this partnership has over one hundred years of
history and grew out of its Medical School. Case study two partnership consists of one
University and one NHS Trust. The Medical School in this partnership is less than twenty
years of age and its NHS Trust is embryonic in terms of its research culture. The two
partnerships therefore provided the opportunity to reflect on the interpretation of the
national policy environment within two different local contexts, but which share the
characteristic of operating outside of the Golden Triangle.
My study participants were a small sample of the key players that are involved in the
delivery of translational clinical research within my case study NHS-University partnerships.
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They represent senior clinical academics that, along with their delivery of clinical care and
research, are also involved with various leadership and administrative responsibilities.
Drawing upon constructivist principles of knowing and ‘truth’, and through my subjective
understanding of the perceptions of my study participants, I bring new knowledge to the
phenomena of NHS-University research partnerships. My study provided the opportunity
to construct a new dialogue around the phenomena, based around the perceptions of my
participants. I gathered data from a series of open ended, semi-structured participant
interviews. These data were analysed hermeneutically and using a manual coding
technique. To support my research I have used Huxham & Vangen’s (2004) well established
theoretical framework as a lens through which to consider the data gathered. A series of
common themes emerged and I drew these into a set of recommendations for future action
and further research.
The key underpinning concept to the study is ‘translational clinical research’ but, despite
many attempts by both academics and policy makers to define it, I found a lack of clarity
in the literature, alongside evidence that the term had become increasingly politicized in
the quest to shift public investment from ‘basic discovery science’ to ‘translational clinical
research’ (UK CRC 2014). After some searching, the definition suggested by Hanney et al.
(2015) was the one that I selected for the purposes of my study, specifically their ‘human
research and review track’, which encompasses Phase II clinical trials through to projects
that review ‘effectiveness and safety’ (p 3-4).
This definition was appropriate because both of my case study partnerships contain within
them translational clinical research activities that span this full continuum, and therefore
this was a practical choice that reflected the current state of my two units of analysis.
My thesis is relevant to a range of settings in the higher education and health sectors.
Given the importance of health and life sciences to productivity, it may also be of interest
to the new Combined Authorities and those working in economic regeneration. It offers
new knowledge to practitioners and academics concerned with the delivery of
16
translational clinical research in an NHS-University setting, and provides some new
thinking around leadership in NHS-University collaborations, the centrality of the ‘clinical
academic’ to the new NHS-University partnerships, and the establishment and delivery of
NHS-University research partnerships.
My study is also of direct relevance to the new concept of non-academic ‘research
impact’, something that will be of specific note to those working within the higher
education sector. Its findings and recommendations can be drawn upon by established
and new universities that wish to engage with the NHS, to the NHS itself, to researchers
who wish to engage with, or better understand, University-NHS partnerships and to
Government bodies and the funders of research.
I begin the thesis with a review of the different definitions that have persisted around the
central concept of ‘translational clinical research’, before providing a comprehensive
documentary analysis of the national policy environment, detailing how this has evolved
over the past decade to its current state, and explaining how this has created a network of
new NHS-University partnerships. The academic literature review follows, before I outline
my methodological framework, along with my chosen methods. Chapters Four and Five
present my Findings, Analysis and Recommendations, including a series of suggestions for
future actions and potential further research into the dynamic and still evolving
phenomena of NHS-University research partnerships.
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Chapter 2. Literature review
2.1 The definition of translational clinical research
My study explores how two case study NHS-University partnerships are responding to the
new policy environment for translational clinical research.
The definition of ‘translational clinical research’ has been studied by a range of authors
over the past decade, in parallel with the development of a new policy framework for
translational clinical research in England. However, the first well documented attempt to
define the term ‘translational clinical research’, came from the United States, when, in
2003, the IOM Roundtable (the ‘Roundtable’) developed a definition that was based
around the blocks to achieving translation, with a view to influencing future action by
funders and policy makers.
The Roundtable brought together a range of stakeholders to promote increased
investment into the application of results from basic science into clinical outcomes. They
suggested two translational stages, ‘T1 and T2’, with T1 being the translation of basic
science into clinical science, and T2 the translation of clinical science into public health,
outlining the blocks that they felt were impeding translation in both stages. The
Roundtable blocks, presented in Figure 2.1 below, are, for T1 (basic to clinical science) the,
‘lack of willing participants, regulatory burden, fragmented infrastructure, incomplete
databases and lack of qualified investigators’, and for T2 (clinical science to public health)
are ‘career disincentives, practice limitations, high research costs and lack of funding’
(Sung et al. 2003 p. 2)
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Figure 2.1: The Clinical Research Roundtable definition of the clinical research continuum (Sung et al.
2003; p.1279)
Subsequent to the Roundtable’s two stage definition of translational clinical research
came attempts to redefine it, with some authors suggesting a three stage model of T1
(basic science to clinical science), T2 (clinical practice) and T3 (health improvements)
(Westfall, Mold & Faguan; 2007), and others a four stage approach, comprising translation
to humans; translation to patients; translation to practice; translation to populations; that
became known as the ‘four Ts’ (Drolet & Lorenzi 2011) (Figure 2.2 below):
Figure 2.2 Drolet & Lorenzi’s four stages of translation
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The four T’s model has similarities to the IOM definition, in that it is also based around the
perceived blocks towards achieving translational clinical research, defined by Drolet &
Lorenzi in Figure 2.2 above as ‘chasms’.
A practitioner perspective of the ‘four Ts’ was offered by Dr. Maria Briones of the
University of California’s Clinical & Translational Science Institute, in a presentation given
in May 2013 (retrieved fromhttp://www.ctsi.ucla.edu/education/files/view/docs/CTSI_ResearchWkshop051013.pdf.) Briones outlined the activities that could sit within each of the pathways, and these
are presented in Table 2.1 below, alongside a further column that I have added to link
Briones’s descriptors to the UK Government definition of clinical trials.
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Drolet &
Lorenzi’s
Translational
Stage
Briones’s Definition Practical Application UK Government Definition (Column added by me to link Briones’s
descriptors to the UK Government definition of clinical trials).
T1: Translation to
Humans
Basic discovery research
findings are tested for
clinical effect & feasibility
Preclinical and animal
studies, first in human,
proof of concept, Phase 1
clinical trials
Phase I trials test a small number of subjects to find out how the treatment works in the
body. This type of trial aims to find the lowest dose at which the treatment is effective
(the minimum therapeutic dose) and the highest dose at which it can be taken without
causing harm.
T2: Translation to
Patients
Clinically test
interventions in controlled
environments to
determine clinical
application. Results yield
knowledge about safety &
efficacy
Phase 2 and Phase 3
clinical trials Phase II trials test the treatment in several hundred people with a given disease or
condition. They aim to find out how well the treatment works in larger numbers, identify
common side effects, and refine the dose and length of treatment.
Phase III trials typically compare the treatment across several thousand patients to
gather more detailed information on how well it works in groups of patients and its
safety. The results influence the prescribing and patient information of a medicine once
it is marketed.
T3: Translation to
practice
Explore ways to
implement
recommendations from
clinical studies to general
practice
Phase 4 clinical trials,
health services research,
clinical outcomes
research
Phase IV trials are carried out after a medicine has been licensed and put on the market.
These trials are designed to find out more about the long term harms and benefits of a
medicine and to discover new uses for it.
T4: Translation to
Population Health
Examine factors and
interventions that
influence the health of the
population
Population outcomes
research, social
determinants of health
Table 2.1: Practical definitions of Drolet & Lorenzi’s four stages of translation (Briones 2013)
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In the mid to late 2000s, the literature around the definition of translational clinical
research was having an impact upon the evolving policy and funding framework, as
exemplified by the work of Woolf (2008), who suggested that the Roundtable definition,
in categorizing clinical research as ‘T1’ and applied health research as ‘T2’, had created an
over emphasis of funding towards basic research, and away from translational research.
This funding in-balance was also highlighted by Professor Sir John Bell, then the chair of
the Office for the Scientific Coordination of Health Research (OSCHR), in a presentation
that he made in 2007. Drawing on 2004/2005 health research investment data from the
UK Clinical Research Collaboration, Bell demonstrated that 69 percent of health research
funding in the UK in that year was being spent on basic discovery science (Figure 2.3):
UK Health Research Analysis
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Figure 2.3 UK health research funding analysis presented at the inaugural address of the
Chair of the OSCHR (2007). The figure can be accessed via the UK-CRC website
(http://www.ukcrc.org/wp-content/uploads/2014/03/Health-Analysis-Report-FULL-
final.pdf)
The academic and policy debates developed in parallel such that, in 2006, Sir David
Cooksey recommended in ‘A review of UK Health Research Funding’, that there should be
a shift in the UK policy and funding environment to better support translational clinical
research (Cooksey 2006; p.32).
Subsequent data from the UK Clinical Research Collaboration (UK CRC), in its UK Health
Research Analysis 2014, demonstrates the impact that this policy environment had on
funding allocations, noting that the balance of public funding for health research had
shifted, post-Cooksey, ‘from basic to translational research’. The UK CRC linked this shift
directly to the work undertaken by the OSCHR to implement Cooksey’s recommendation
of increasing the funding for translational medicine (p. 32). One could assume therefore
that the external policy environment has made a positive influence on the overall
framework for translational clinical research, across England. My research project tests
this proposition by asking how the macro level policy and funding environment has played
out at the organisational (meso) and individual (micro) levels, taking an interpretative
methodological approach to the study, in order that both organisational and individual
factors are highlighted.
From 2006 onwards the academic literature looked to some of the post-Cooksey
initiatives as a vehicle via which to define ‘translational clinical research’, providing a
further example of the co-terminus nature of academic literature and external policy
developments at that time. Delaney (2010), for example, in his review of Academic Health
Science Centres (AHSCs), argued that the traditional linear description of ‘bench to
bedside’ failed to understand the cyclical nature of translational research. He contrasted
this theoretical definition with the work done by the renal impairment team of the Kings
Health Partners Biomedical Research Centre. Here, a whole system approach to
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translational clinical research was taken, with clinical care informing basic science, which
informed new discoveries, in a mutually beneficial and co-enforcing relationship,
something that Delaney argued was a more accurate representation of ‘translation’ in
practice. Kenneth & Pienta (2010), however, suggest a more linear definition, saying that,
‘translational research encompasses the effective movement of new knowledge and
discoveries into new approaches for prevention, diagnosis, and treatment of disease’ (p.
316).
Morgan et al. (2011) also use a practical example with which to define their understanding
of translational clinical research, this being the MRC funded ‘Knowledge Translator’
placement programme. Morgan et al.’s study provides a perspective into the status and
standing of ‘translational clinical research’ and how this plays out amongst basic and
clinical scientists. In their interviews with clinical researchers and basis scientists in the
University-Hospital partnership, the researchers found a range of views and
understandings amongst the community, with the basic scientists inclined to be more
wary or cautious about the new funding for translational research, whilst clinical scientists
were more positive. A common feature across both groups, however, was a lack of clarity
around the definition of translational clinical research.
Cremades, Baulbastre-Benavent & Dominguez (2014) studied a successful Research
Institute in Spain, and defined translation as the, ‘translation of medical research to
clinical practice and the productive sector’ (p. 380). Also in 2014, Hanney, Musford, Grant
& Buxton suggested that translation is initially research related, the publication of
research articles in journals for example, before being followed by further research,
leading onto to clinical policies and guidelines, and finally to application and adoption (p.
941). Van der Laan and Boenink (2015) suggest that translational clinical research should
not be seen as a linear process but rather as a ‘nexus or web’ (p.46) in which the design of
research should be continuously viewed in light of the future impact that may arise from
it. Thus, they suggest a move away from a simple translational pathway with a set of
external factors, to a system within which translation happens in many different ways and
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is delivered by a range of actors, all of whom should be asking what the potential future
benefit of the research could be, in order to factor this into research and study design (p.
44-46).
Hanney et al. (2015), like the Roundtable over ten years previously, focus their definition
of translational clinical research on the gaps or ‘time lags’ (p.1) that impede the
translation of basic science into clinical application. In their definition I found a practical
and accessible way of defining translational clinical research. They suggest a matrix
approach, which was tested on seven case studies of ‘interventions in cardio-vascular
disease and mental health’ (p. 2) and is presented in Figure 2.4 below. It suggests that
there are two main tracks that sit within the translational pathway, ‘human research and
review’ and ‘public policy development’, with activities in each track being ‘not linear’ but
over-lapping. The Hanney et al. (2004) matrix presents the translational pathway from the
‘most relevant basic research’ through to ‘clinical practice using the intervention’. Whilst
their main aim was to identify the places in the pathway in which gaps or time-lags most
often occur, by presenting their understanding of the concept in a matrix format, they
provide a really useful practical overview of what translational clinical research looks like
in practice.
25
Figure 2.4: Hanney et al.’s conceptual matrix for understanding and measuring time lags within translational clinical research
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The research that took place within my two case study partnerships reflects the
breadth of activity in Hanney et al.’s ‘human research and review’ track, commencing
from Phase II clinical trials through to the ‘research review and synthesis on
effectiveness and safety’ (p. 3-4).
Hanney et al. couch their definition of translational clinical research within the context
of ‘gaps’ to translation, and this concern around the ‘gaps’ to achieving the outputs
from research, is a further example of the links that exist between academic literature
and the policy framework in this area. Outlined in Section 2.2 and Table 2.2 below is a
documentary analysis of the external policy framework that was developed by
Government with a view to addressing these gaps and facilitating an increased volume
and quality of translational clinical research.
2.2 Translational clinical research: policy framework
A national policy framework has developed over the past decade to improve the
conditions for translational clinical research in England. A chronological summary is
presented in Table 2.2 below. A comprehensive documentary analysis of this policy
environment has been provided on the basis that it provides an ‘important base for
the research’ (Finnegan, in Sapsford & Jupp (1996, p. 138).
My research question is concerned with the way in which my two case study
partnerships have responded to the national policy environment for translational
clinical research. Taking an interpretative approach to understanding the views and
perceptions of ten senior clinical academics that are operating within the partnerships,
I investigate how the policy framework is playing out on the ground and ask whether it
leading to its ultimate goal, which is to support the NHS and Universities to work
together to deliver research with impact. It is therefore important that this policy
framework is presented in detail, such that the scale and ambition of it can be
contrasted with the perceptions, reactions, and interactions with it by my two case
study NHS-University partnerships.
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It was also important to demonstrate the breadth of the policy environment and the
way in which policy direction from the Government has influenced the way that NHS
Trusts and Universities must work together in order to access funding for translational
clinical research. Taken together the documents presented in this section demonstrate
a parallel agenda, shared by Government, academia and clinical medics, that the
national environment for translational clinical research required a fundamental shift in
order that a range of outcomes could be achieved, including public health, growth of
the life sciences sector, research and innovation. Therefore, by including a
comprehensive review of the policy environment I demonstrate how Government and
other influential bodies are attempting to change behaviours at a local level, (Duffy in
Bell 2010 p. 131) and I later contrast this policy and theory against my study data in
Chapter Five, Analysis and Recommendations.
The rationale for the development of this new policy environment is explained by
Ovseiko et al. (2010) who argue that a new policy approach was needed to address the
issues created from the separate governance and funding arrangements for NHS Trusts
and Universities, which were themselves created by policy decisions of the past. They
highlight as deeply unhelpful the fact that legislation for Foundation Trusts ‘permits
rather than mandates’ research and ‘gives limited representation to academic partners
in governance and management structures’ (p. 1288) and in a later paper Ovesiko et al.
(2014), state that in England, ‘university medical schools and their partner healthcare
providers employ disparate finance and performance reporting metrics and indicators’
and hence there is a lack of cohesive arrangements across the tripartite mission’ with
the system of separate Ministerial responsibility creating ‘barriers to cross
departmental working’ (p. 2).
The policy environment that has been created from 2003 onwards has been intended
to address these problems, by creating a more facilitative environment within which
NHS Trusts and Universities can deliver an increased volume and quality of
translational clinical research. It is presented in chronological order in Table 2.2 below,
prior to an analysis of some of the most significant developments.
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Date Report or Policy Development
2003 ‘Strengthening Clinical Research’ (Academy for Medical Sciences): highlighted
a concern that UK clinical research had not kept pace with advances in basic
scientific discovery, to the disadvantage of patients
‘Improving National Health; Improving National Wealth’ (Dept. of Trade
Industry, Bioscience & Innovation Growth Team): an attempt to create an
integrated strategy for Biosciences & Innovation which included as a key
ambition the objective of improving the ease with which clinical research can
happen in the NHS.
2004 Government announces increased funding for NHS Research & Development
of £100m per annum by 2008, and the establishment of the UK Clinical
Research Collaboration (UK-CRC).
2005 ‘Medically & dentally qualified academic staff: Recommendations for
training the researchers and educators of the future’ (UK-CRC and the
‘Modernising Medical Careers’ Group): a report and set of recommendations
aimed at improving the career path for clinical academics via a more
integrated and easily accessible clinical academic training programme for
those who demonstrate an aptitude for clinical academic research during
under-graduate studies.
2006 ‘Best Research for Best Health’ (Lord Darzi): set out the blue print for a new,
collaborative NHS-University clinical research environment. Recommended
the creation of National Institute for Health Research (NIHR)
‘A review of UK Health Research Funding’ (Sir David Cooksey): endorsed ‘Best
Research for Best Health’, and suggested that the NIHR be a physical rather
than virtual entity; also recommended that research be afforded a higher
status in the NHS via ring-fencing budgets for research, that the HTA be
provided with more funding to support the effective pathway of drugs to
market, and that a new culture of research in the NHS be supported by the
introduction of clinical scientists and fellowships awards.
The NIHR is established.
2007 NIHR launches first competitive round of funding for Bio-medical Research
Centres and Bio-medical Research Units – new centres of excellence
delivered by ‘leading NHS and University partnerships’, led by an NHS Trust.
Eleven Biomedical Research Centres are established.
The Office for the Scientific Coordination of Health Research (OSCHR)
established, in response to the Cooksey Report, to provide funding and policy
integration across the Medical Research Council (MRC) and NIHR, with a view
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Date Report or Policy Development
to improving the transition from basic science to translational research in the
UK.
2008 Sixteen Biomedical Research Units are established.
NIHR launches eight pilot CLAHRCs (Collaborations for Leadership in Applied
Health Research & Care), to address Cooksey’s second translational gap of
moving research findings into clinical practice (http://www.clahrcpp.co.uk)
2009 ‘The Life Sciences Blueprint’ (Office of Life Sciences): Committed Government
to creating an ‘integrated sector’ of NHS, Industry and Universities, and to
establishing a Life Sciences super-cluster.
‘High Quality Care for All’ (Lord Darzi): Recommended the creation of
accredited Academic Health Science Centres, as new governance structures
for NHS-University partnerships that would improve both clinical service and
translation of clinical research into improved health care.
First five accredited NIHR Academic Health Science Centres announced
following a national competition (Cambridge, Kings, UCL, Imperial and
Manchester).
‘Biomedical research – a platform for increasing health and wealth in the
UK’: (Academy of Medical Sciences): States that an increasingly coordinated
approach to the UK’s life sciences sector will deliver economic benefits.
2011 ‘A new pathway for the regulation and governance of health research’
(Academy of Medical Sciences): States that the overly complicated and slow
governance structures of health research in England is seriously impeding the
delivery of clinical research and relates outcomes. In response, the NIHR
adopts the Research Support Services framework, intended to facilitate a
proactive start up to research in the NHS.
‘Plan for Growth’ (Dept. for Business Innovation & Skills): Announced the
continued commitment of UK Government to health research funding,
committed to the establish of a new health research regulatory agency to
streamline health research governance processes along with new metrics to
measure performance on clinical trials.
‘Strategy for UK Life Sciences’ (Dept for Business Innovation & Skills, and the
Office for Life Sciences): Sets out a vision for a new way of working across
NHS, Universities, Charities and Industry to create a life sciences eco-system,
underpinned by continued NIHR investment and announcing new investment
of £310m of Government funding to support stratified medicine (£130m) and
commercialisation of biomedical advances (£180m). Contains a commitment
to developing a talent base across research, innovation and clinical care, and a
commitment towards working with MHRA to reduce governance barriers to
clinical research.
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Date Report or Policy Development
Innovation, Health & Wealth’ (Dept. of Health): proposed a set of measures
to improve the take-up of innovation in the NHS, including Academic Health
Science Networks to move innovations into take-up across NHS networks.
The Health Research Authority (HRA) established, with an objective to
‘streamline the regulation of research’ (http://www.hra.nhs.uk)
2012 ‘Faster Easier Clinical Research’ (NIHR): Briefing document setting out NIHR’s
commitment to working alongside the HRA to streamline clinical trials
governance processes and speed up trial start times.
2013 The second round of NIHR Academic Health Science Centres announced, as
Cambridge, Kings, Oxford, UCL, Imperial, and Manchester
NHS establish fifteen Academic Health Science Networks, in response to the
‘Innovation Health & Wealth’ Strategy to establish effective networks with the
NHS, Universities and Industry to implement innovation at ‘scale and pace’
(http://www.nwcahsn.nhs.uk/about.php)
Responsibility for public health transfers from the NHS to Local Authorities:
‘one of the most significant extensions of local government powers and duties
in a generation’ (www.local.gov.uk).
Healthcare commissioning responsibilities transfer to the new NHS Clinical
Care Commissioning Groups and NHS Commissioning Board.
NHS England R&D Strategy (out for consultation)
https://www.england.nhs.uk/2013/12/development-strategy-consult/
2014 NHS Five Year Forward View (NHS England): included a commitment for ‘test
bed sites’ for research into the improvement of care via the combination of
different technologies.
For the first time the NHS Standard Contract issues by NHS England contains
important conditions relating to research.
The NHS planning guidance issued by NHS England, Everyone Counts:
Planning for Patients 2014/15 to 2018/19, highlights the importance of
research to Providers and Commissioners as a means of delivering high-
quality care for all.
CLAHRC Programme re-launched by NIHR with thirteen partnerships across
the UK.
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Date Report or Policy Development
The HRA receives funding to develop and roll out a new centralized NHS
review and approval process for research projects, this to replace local NHS
R&D review.
The Dept. for Business Innovation & Skills and Dept. of Health combine their
life sciences functions to create a joint and extended Office for Life Sciences
Non-academic research impact forms part of the Research Excellence
Framework (2014) for the first time
2015
HRA announces that the first cohort of health research projects to be taken
through the new centralised NHS approval process will be health services
research projects involving NHS staff.
2015 HRA announces the second and third phases of the new centralised NHS R&D
approvals.
NIHR opens new call for Biomedical Research Centres, announcing at the
same time that BRUs will be discontinued.
Population health systems – Going beyond integrated care (The Kings Fund):
Challenges Local Authorities, NHS, and community groups to work together in
a system of ‘population health. (p.6).
Innovative Medicines and Medical Technology Review announced by
Government: into plans to give NHS patients quicker access to innovative
medicines and medical technology. Chaired by Sir Hugh Taylor, Chair of Guy’s
and St. Thomas’ NHS Foundation Trust. He will be supported by an expert
advisory group headed by Professor Sir John Bell, Regius Professor of
Medicine at Oxford University
(https://www.gov.uk/government/news/review-into-medical-innovation-and-
technology-further-details).
Table 2.2: Clinical research in the UK: Funding and policy Environment, 2003-2015
In 2003, the problems facing the UK were exemplified by ‘Strengthening Clinical
Research’ and ‘Improving National Health; Improving National Wealth’ produced by
the Academy for Medical Sciences (AMS) and the Department of Business, Innovation
& Skills (BIS) respectively. Both warned that the standard of translational clinical
research in the UK was lagging behind basic science, due to a number of barriers to
making research happen in the NHS. The reports concluded that unless there were
improvements made to the current environment, industry investment into the UK life
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sciences sector was at risk, a point confirmed by Kinapse (2008) who highlighted that
‘the UK’s share of global patient recruitment in clinical trials dropped from 6% in 2000
to 2% in 2006’. Both reports observed that the funding of the translation of basic s
into translational science had to improve, with a more integrated approach to funding
and policy required. This led to a succession of policies and funding vehicles that were
intended to address the problems facing translational clinical research in England.
In 2006, Lord Darzi produced ‘Best Research for Best Health’, setting out a new vision
for the way that research would be promoted, facilitated, and governed in the NHS. It
committed to the establishment of the National Institute for Health Research (NIHR),
which would provide funding for translational clinical research. In the same year, and
in response to a Government commission, Sir David Cooksey produced ‘A review of UK
Health Research Funding’. This supported Darzi’s ambitions in ‘Best Research for Best
Health’ but went further, proposing that the NIHR be a physical, rather than virtual,
entity. The NIHR was subsequently established just twelve months later.
Cooksey also offered his views on the funding for translational research in comparison
to basic or discovery science, stating that ‘perverse incentives’ had created an in-
balance away from the former, and suggesting this be remedied. Cooksey
recommended that translational research should be a ‘joint responsibility’ of the
Medical Research Council (MRC) and the NIHR (Smyes & Wynick 2007 p. 543) but
stopped short of recommending a merger, instead proposing the establishment of an
Office for the Scientific Coordination of Health Research (OSCHR) to oversee the
funding and performance of both organisations, reporting in this regard directly to BIS
and the Department of Health.
The OSCHR was formed in 2007, consisting of Members from BIS, the Department of
Health, the National Institute for Health Research (NIHR) and the Medical Research
Council (MRC). It selected five work-streams as its priorities, Translational Medicine
Research; Public Health Research; E-Health Records Research; Methodology Research;
and Human Capital (retrieved from (http://pharmaboardroom.com/companies/office-
for-the-strategic-coordination-of-health-research-oschr/). From 2007 to 2011, it had
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some notable successes in improving NHS ‘electronic data capabilities for research’
and in creating a ‘research programme for public health and greatly enhanced
translation science’ (retrieved from www.cso.scot.nhs.uk/funding-2/office-for-
strategic-coordination-of-health-research-oschr/).
In 2008, the OSCHR Partners worked together on one of Cooksey’s key
recommendations, to agree a ‘set of health research priorities for the UK that target
the biggest and most important health challenges for the UK for the coming decade’
with these being named ‘The Health Research Opportunities’ and being published in
2009 (retrieved from
www.publications.parliament.uk/pa/ld200910/ldselect/ldsctech/104/10011203.htm)
From 2011 onwards the OSCHR shifted into a monitoring and advisory role.
The first significant programme launched by the NIHR following its creation came in
2007, with the announcement of the first round of competitive funding for Biomedical
Research Centres and Biomedical Research Units (BRCs and BRUs), new collaborative
centres of excellence delivered by ‘leading NHS and University partnerships, to drive
progress on innovation and translate research in biomedicine into NHS practice’ (www.
nihr.ac.uk/documents/about-NIHR/Briefing-Documents/2016/4.02-Biomedical-
Research-Centres.pdf ). These were a significant addition to the translational clinical
research environment because they insisted upon a collaborative approach to NHS-
University partnerships, thereby creating a new environment within which large
amounts of funding for translational clinical research was made dependent on closer
working between NHS Trusts and Universities. One year later, the NIHR launched its
network of CLAHRCs (Collaboration for Leadership in Applied Health Research
Centres), collaborative partnerships involving NHS service providers, commissioners,
and universities that operated further along the translational pathway than
BRCs/BRUs, being concerned with the ‘applied health’ and patient ‘outcomes’
(www.clahrcpp.co.uk ). Then in 2013 came the NIHR Academic Health Science
Networks (AHSNs), operating beyond the CLAHRCs, to ‘implement innovation at ‘scale
and pace’ (www. nwcahsn.nhs.uk/about.php)
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The UK Government Office for Life Sciences produced the ‘Life Sciences Blueprint’ in
2009, in partnership with industry. It committed to increasing the integration of NHS,
industry, academia and government, creating a new environment for translational
clinical research, underpinned by a more innovative NHS (pp. 18, 20) and leading to
increased numbers of patients accessing UK clinical trials (p. 14-15). It was in this same
year that Lord Darzi published ‘High Quality Care for All’, which recommended that the
successful Academic Health Science Centre (AHSC) model of North America and
Sweden be applied in the UK as national policy. AHSCs brought together clinical care,
teaching and research into one joint governance arrangement, and subsequent to
Darzi’s recommendation, in 2009, the Department of Health launched a competition to
establish a network of AHSCs in England, with the first five being announced as
Imperial College London, University College London, Cambridge, Kings College London
(all within the Golden Triangle) and Manchester.
This new initiative was a further example of attempts at a policy level to create new
working arrangements for NHS Trusts and Universities, aligning collaborative
partnerships to large scale government funding for translational clinical research.
Ovseiko, Oancea, & Buchan (2012) neatly summarise the position by stating that,
‘following the formation of the NIHR in 2006, the majority of NHS R&D funding
is now awarded competitively to NHS/University partnerships on the basis of
peer review and bibliometric indicators’ (p. 12).
Public funding, and its importance to the UK’s ‘life science’s eco-system’, was a point
strongly made by the AMS in its 2011 briefing ‘Biomedical research – a platform for
increasing health and wealth in the UK’. Later that year, the Government announced a
new investment of £310m of Government funding in its Life Sciences Strategy, whilst
the AMS conducted a review into the current environment for research within the
NHS. The resultant report, ‘A new pathway for the regulation and governance of health
research’ (2011) was scathing in its assessment of the current arrangements, stating
that the ‘process of obtaining NHS R&D permissions is the most significant barrier to
health research in the UK’ (p. 38). A recommendation was made for the formation of
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new, centralized NHS governance procedures, to be established at a national level via
the formation of the new Health Research Authority, which Government subsequently
established with a mandate to streamline the governance systems for clinical
translational research.
In 2012 ‘A strategy for UK Life Sciences One Year On’ emphasized the need to support
‘the ‘life sciences eco-system’ by funding collaborative research proposals, removing
barriers to research via a new centralized process to be developed by the Health
Research Authority, and by an increased emphasis on innovation within the NHS. Also
in 2012, ‘The New UK Life Sciences Prospectus’ set out the Government’s commitment
towards innovation in the life sciences, including particularly the importance of
collaborations with business, the NHS and universities. In 2013, the second round of
NIHR Academic Health Science Centres were announced, with Oxford joining the
original five, and in the same year the NIHR expressed its commitment to streamlined
governance, in ‘Faster Easier Clinical Research’, by imposing performance metrics onto
NHS Trusts aimed at reducing the time taken to commence trials from the date of
funding approval.
Also relevant to the creation of a new environment for translational clinical research,
was the decision by Government to include a new expectation for non-academic
research impact in the Research Excellence Framework 2014.
The Research Excellence Framework (REF) is the UK’s national system of research
assessment, undertaken every six or seven years, and underpinned by a system of
expert peer review. It assesses the quality of research within universities in the
categories of research outputs (65% of the overall assessment), non-academic
research impact (20%) (first introduced to the REF 2014) and environment (15%). The
REF is critical to universities, in terms of funding, with performance in the REF driving
the allocation of mainstream ‘Quality Related’ (QR) grant from Government, and
reputation, performance in the REF driving a selection of university league tables.
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It has been calculated that approximately £1.6 billion worth of public funding over the
next five years will be determined by impact case studies (Kings College London and
Digital Science March 2015). The inclusion of non-academic impact to the assessment
criteria is a strong indicator from Government of a need for universities to change
behaviour on the ground. The quote below, taken from the UK Strategy for UK Life
Sciences (2011), provides an insight into the driver from Government for including
Research Impact in the REF exercise, as part a wider shift within the Higher Education
sector for universities to demonstrate both high quality academic output as well as
translation into non-academic spheres,
‘In life sciences, impact relates especially to improvements to healthcare and
economic, commercial and production benefits. The funding bodies have
agreed that for the first time REF 2014 will include explicit assessment of the
impact arising from excellent research…Industry bodies, such as Confederation
of British Industry (CBI), have endorsed this approach. HEFCE has already
appointed user members to the assessment panels, including representation
from GSK, AstraZeneca, Pfizer, Department of Health, British Heart Foundation
and INVOLVE. Additional user experts (including industry) will be appointed for
the impact assessment phase – to ensure that impact assessment is undertaken
by a broadly equal number of users and academics’ (p. 19).
This REF category, new in 2014, is the first example of national research funding being
allocated on the basis of non-academic impact being applied across a research system
(Jones & Grant, in Dean at al. (Eds) (2013). It places a new demand on universities to
demonstrate the impact of their research in a non-academic context, therefore being
highly relevant to the concept of translational clinical research. In their article detailing
the different usages of the term ‘translational research,’ Van der Laan and Boenink
(2015) go so far as to suggest that the increasing importance of research impact
reflects a ‘change in contract between science and society’ (p. 3), and Dembe et al.
(2014) suggest that in the US, ‘government and private research institutes strive to
justify expenditures and document tangible outcomes from research programs’ (p. 54).
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The UK policy framework appears to be reflecting this thinking, with the Chancellor
suggesting in the Autumn 2015 Spending Review and Budget Statement that non-
academic impact would become more prominent in future REF exercises, in line with
the earlier recommendation made by Sir Andrew Witty (2013) who suggested that REF
Impact be increased from 20% to 25% of the overall assessment.
The new REF driver for non-academic impact should provide a compelling reason for
University Medical Schools to engage in NHS partnerships that deliver translational
clinical research, but will it change behaviours on the ground? This was one question
asked by Ovseiko, Oancea, & Buchan (2012) in their review of HEFCE proposed clinical
research impact indicators, undertaken with reference to 289 clinical medicine faculty
at the University of Oxford, all of whom had been returned in the previous Research
Assessment Exercise 2008. A response rate of 48.1 percent was achieved, with the
authors accepting the potential limitations, in terms of a slight over representation of
women and early career researchers, and a slight under representation of senior
researchers.
Based on data gathered from ’15 open-ended questions structured around the
proposed impact indicators’, the authors suggest that the REF measure itself is not
sufficient to change long term academic behaviours. In order to do so, collaboration
across the sector would be required to develop systems, cultures, and understandings
to allow universities to capture and monitor impact in a ‘continuous’ manner. Morgan
et al. (2011) make a similar point to Ovseiko et al. (2012), suggesting that whilst
translational research is clearly an important element of what funders and government
expect from universities, it is far from the dominant factor, with academic output
remaining a key priority for research universities.
Boaz et al. (2014) also assessed the impact of external policy and funding interventions
on researcher attitudes, in this case within the context of ‘Public Engagement in
Science’ (PES) and ‘Public & Patient Involvement’ (PPI), the former concept being the
communication of science by scientists to the general public, and the latter being a
newer concept which places patients and the public within individual projects giving
them influence over important factors such as project design, for example. Boaz et al.
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explain that there has been a push by the funders of research to increase engagement
in both PES and PPI, and ask if there is evidence that this has influenced a ‘shift in
attitudes amongst researchers’ (p.3) within the translational research community.
They utilise three NIHR accredited BRCs to draw together a sample of nineteen
participants, these being stratified to represent all levels of researcher and involving
research that spans the clinical – health services spectrum (p.3). They conclude that
whilst the participant group gave evidence of having engaged with PES and PPI, and
were able to encapsulate some of the benefits therein, there was evidence across the
group of an unwillingness to ‘sharing power and control in the process of knowledge
generation’ (p. 9). The outcomes of this Study, along with Morgan et al. (2011) and
Ovseiko et al. (2012), therefore suggests that policy and funding levers alone are not
sufficient to change ‘underlying attitudes’ (Boaz et al. p. 4).
My research project takes the national policy context and applies it to organisational
and individual levels, asking how it is being played out on the ground in two localities.
Other researchers have used a similar approach; Adams, Caffrey & McKevitt (2015) for
example contrasted the national policy framework around clinical trials with patient
recruitment on the ground, in a qualitative study comprising interviews with eleven
members of a clinical research group in an NHS hospital. Asking each Participant two
questions focused on ‘what factors support’ and ‘what factors hinder’ patient
recruitment (p.4) the researchers produced a thematic analysis of the responses using
NVivo9 software (p 4).
Certain of the themes that emerged around the barriers to patient recruitment on
trials could be linked by the authors to the national policy environment, with the
dichotomy that the two were at odds with each other, and that the policies themselves
were creating barriers, in what could be seen an unintended consequences of well-
meaning interventions. Taking each in turn; national efforts to ensure the recovery of
‘excess treatment costs’ (p. 5) of research was reported as not being translated to
ward level, leading to patients not being recruited because ward staff were not aware
of the availability or mechanism for recovery of these costs; secondly, that the national
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targets around patient recruitment and associated publication of league tables and
financial penalties around low recruitment served to create unhelpful competition at
the local level, such that clinical groups protected their own patient databases and
acted as a disincentive between groups to ‘share’ patients (p. 5). In addition, the
national efforts to ‘double the numbers of patients in research within 5 years’ by
imposing strict and public rankings, led to the unintended consequence of ‘reducing
collaboration’ at the local level (p. 5). Finally, the participants in Adam et al.’s (2015)
study openly questioned the merit of a high-profile national marketing campaign by
the NHS to encourage patients themselves to enquire about clinical trial participation
(the ‘it’s ok to ask’ campaign), saying that in reality there was often a lack of suitably
experienced personnel on the wards or in the clinics to address any such questions
from patients.
The review of the primary documents outlined here helped me to frame my central
research question; I elected to include the analysis within my thesis to ‘supplement’
the data provided elsewhere and to demonstrate the environment within which the
research question was asked, and had merit. (Duffy in Bell, 2010).
2.3 Academic Health Science Centres
A number of the initiatives outlined in Table 2.1 ‘Policy Framework’ have been
intended to create new collaborative arrangements for NHS and University Medical
Schools, to support the more effective delivery of translational clinical research. This
has been part of a strategy to address the dual funding and governance arrangements
of NHS Trusts and Universities that have increasingly been viewed as a barrier towards
effective collaboration (Ovseiko et al. 2010).
The partnerships that have emerged from the new policy environment have seen NHS
Trusts and Universities attempting to coalesce their strategies for translational clinical
research, influenced by macro level funding and policy decisions. One of the most
significant of these new arrangements is the Academic Health Science Centre (AHSC),
launched by the NIHR in 2006 via a national competition to establish a network of
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NIHR accredited AHSCs. There are now six NIHR-accredited AHSCs in the England, but a
series of non-accredited AHSC-type arrangements have also sprung up around the
country, again reflecting the new national policy context, and creating a network of
new NHS-University collaborative arrangements.
A body of literature has emerged around the AHSC concept, including papers that have
reviewed the governance arrangements of AHSCs in the United States and Canada,
from where the concept originated. In the US context, Weiner et al. (2001) suggested
that there were eight different types of clinical-academic partnerships in the US in the
1990s through to the 2000s, a situation that seemed to be much the same in Canada,
with Ferris et al. (2004) explaining that in Canada, each of the AHSCs operated to a
different governance model:
‘Organisational structures range from operational aggregation – for example, a
university, its medical school and the teaching hospitals are governed more or
less separately from each other…. Where the hospitals are autonomously
governed, the collaboration with a university or medical school is typically
codified in an affiliation or partner agreement’ (p.25).
Michener et al. (2012) focused upon Academic Health Centres in the United States but
raised some generic issues that apply to NHS-University partnerships, including the
need for recognition within academic promotion panels and for partners to address
the issue of finance, in order for this not to become a barrier to meaningful
collaboration, whilst Dzau et al. (2010), also writing in a US context, argued that the
AHSC concept was too narrow, suggesting instead that a whole system approach (the
Academic Health Science System) was required.
Drawing on the developments at Duke University, where they were themselves
employees, Dzau et al. argued that this full system approach should ‘not only include
the traditional medical centres but also a network of community hospitals and
practices working to shared values and strategies’ (p. 949). Echoes of this idea can
been seen in the NIHR’s attempt to create collaborations at every stage of the
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translational pathway, from BRCs and BRUs, through to CLAHRCs and onto the AHSNs.
The NIHR Translational Research Partnerships (TRPs) are also reflective of the
approach illustrated by Dzau et al. These bring together leading research centres with
NHS Trusts in key areas such as Inflammatory Respiratory Disease and Joint and
Related Inflammatory Disease. Members of the TRPs include specialist centres,
research institutes, universities, biomedical research centres (and units), Academic
Health Science Centres, University Hospitals, Foundation Trusts, and Centres of
Experimental Medicine. Together they represent the geographic spread of expertise in
these disease areas from across the country. Each has its own steering committee and
receives assistance from the NIHR Office for Clinical Research Infrastructure (NOCRI)
that provides support for effective partnership work, such as template collaboration
agreements. (NIHR Briefing Document 4.01 ‘Translational Research Partnerships’
January 2014. Retrieved from www.nihr.ac.uk).
There also exists a body of literature written within the context of England’s new
system of NIHR accredited and non-accredited AHSCs. Fish et al. (2003), emphasize the
importance of culture and leadership, rather than governance structures:
‘The culture of the partnership is crucial. Progress relies on the shared vision,
trust and transparency, rather than further contracts between autonomous
partner organisations’ (p. 6).
This is a point also made by Davies & Bennet (2008) in their comparison of the policy
paradigm of academic clinical partnerships in the UK with that of the more established
systems of the US, Canada and the Netherlands, observing that ‘partnerships between
the universities and the NHS are… always built on non-integrated governance and
separate accountabilities’ (p.536) making culture and leadership critical to successful
collaborations. One such leader, Steve Smith (2009), writing as the then Chief
Executive of the AHSC Imperial Health Partners and the Dean of Imperial Medical
School, outlined the challenge as the fact that clinical research in England was not
translating into new innovations at the bedside, and presented this alongside his
ambition for Imperial Health Partners:
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‘This integrated model for an Academic Health Science Centre has the potential
to bring about transformational change in universities and hospitals. The NHS
will have higher regard for innovation and the contributions of research and
development from the university, and in turn universities may come to view
the delivery of high-quality care in such a centre as a legitimate academic goal
and output’ (p.1057).
Grainger (2010) focused on how a specific clinical profession, in this case nursing and
midwifery, could be embedded into the operation and strategy of an AHSC, concluding
that this can be achieved by close communication channels being created between the
partner organisations and the AHSC, allowing for an embedding into the AHSC via a
series of practical measures, which in this case included the training of staff in Masters
and Doctoral programmes (p.239).
In 2014 Ovesiko et al. reviewed the governance arrangements between hospitals and
universities in northwest London. They argued that the divided nature of
accountability across NHS-University organisations impedes the ability to deliver across
the tripartite mission of teaching, clinical care and research, and that AHSCs are not in
themselves sufficient to address this, arguing that whilst the establishment of the NIHR
is helping to create joint accountability in clinical research projects, NHS and
universities still operate ‘parallel structures’ for clinical research (p.6).
French, Ferlie & Fulop (2014) writing at the time as members of the UCL and Kings
AHSCs, argue that the AHSC concept has evolved from its original North American base
to have international significance (p. 382). They present a literature review into the
‘managerial, institutional, political, or cultural aspects of AHSCs’ (p.383) and conclude
that there remains a lack of theoretically driven research into the phenomena,
suggesting that a research framework is now emerging, into which further
investigations into AHSCs would help to develop a better understanding of the local
conditions that are required to make translational clinical research happen (p.389). In
reviewing the different configurations of AHSCs that now exist internationally (in
England these being split between the accredited NIHR AHSCs and the non-accredited
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AHSC type arrangements) French et al. suggest that AHSCs operate on a continuum
between full and loose integration of governance around the functions of clinical care,
teaching, and research.
2.4 Understanding collaborative working:
In addition to the literature around AHSCs, there is a body of work that is concerned
with the development of collaborative working in different healthcare settings.
This includes Schwartz, Young & Hicks’s (2015) research into medical education
practice-based research networks in the United States; research by Long, Cunningham,
Carswell & Braithwaite (2014) into a Translational Cancer Research Network in
Australia; and Rajasekhar, Rees, Rutter, & Hungin’s (2014) experiences of a regionally
based endoscopy network in the north of England. These are relevant in terms of
offering a range of perspectives around collaborations in different healthcare settings.
Schwartz, Young & Hicks (2015) draw on their own experiences of the ‘Association of
Pediatric Program Directors Longitudinal Educational Assessment Research Network
(APPD LEARN), a medical education practice based research network that was formed
in the United States in 2009. At the time of their paper this was one of fifteen such
networks that had emerged since the early 2000s, with a view to creating collaborative
approaches to social sciences research into medical education programmes.
The APPD LEARN network was ‘an organization or consortium consisting of multiple
education sites’ (p.65) specifically focused on pediatric medical education. Schwartz et
al. explain that the network was drawn together via a small central team of research
and administrative staff operating within a governance structure that involved
representatives from each participating university, sharing an IT infrastructure for the
collection, storage and analysis of data.
They provide four recommendations aimed at supporting the future development of
other practice-based research networks for medical education, commencing with the
suggestion that medical faculty shall require some form of development in education
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or social sciences research to support their participation in education research
projects. The authors also recommended that ‘productive and sustainable’ central
resources need to be available for things such as IT support and data collection, and
that the embryonic nature of the networks supports the need for performance
measures to assess success or failure. Finally, they recommend that over the longer
term an ‘international network of networks’ should be considered to share best
practice in medical education practice based research on a global scale (p. 73).
The recommendations offered by Schwartz et al. are specifically focused on a
particular type of healthcare collaboration, but there is a general application to these
recommendations that may apply to other collaborative health settings.
Long et al. (2014) reviewed a research, rather than education based, cancer network
operating in Australia. They conducted an online survey of sixty-eight ‘cancer clinicians
and researchers…from six university and hospital campuses’ (p.3), receiving a 76.5
percent response rate. The survey sought to understand participants’ views of the
importance of a range of factors, including physical proximity, professional allegiance,
past history of collaboration and of translational research. They concluded that
collaborative practices within the network were highly influenced by the clustering of
individuals based upon ‘geographic proximity and previous collaborations’ (p.13).
However, they also found strong evidence to suggest that there was a common
ambition towards wider collaborations, and the authors therefore recommend that
the network, and others like it, consider the ways in which the gaps between
geographical clusters that exist within and between networks can be bridged.
Long et al,’s discovery that there was a tendency towards collaboration outside of the
cancer research network suggests that individuals collaborate beyond the formal
boundaries of a partnership, and therefore it would be interesting to understand what
factors drive this, and why there is a perception by the participants that the required
benefits from collaboration cannot be achieved within the network. Long et al. suggest
that bridges between networks be established such that existing collaborations can be
nurtured and developed further.
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Rajasekhar, Rees, Rutter and Hungin (2014), like Long et al., explore collaborative
working via the lens of a clinical research network, but in this case, the network
operated on a regional rather than a national basis, and was the unofficial clinical
research network for Endoscopy medical professionals operating in the North of the
England (‘The Northern Region Endoscopy Group). The network was formed by
clinicians to aid collaborative working across the different endoscopy units in hospitals
across the North of England. The network in question could demonstrate a level of
success by virtue of its publications record (over twenty papers and sixty abstracts) and
grants portfolio (holding £1.3m of external funding).
Like Schwartz et al., the authors utilise their own experiences of the network to offer
recommendations for future collaborations, suggesting that ‘inclusivity’ is the key
concept that underpins this successful collaboration, basing this on the evidence from
the network that all units that want to collaborate are permitted entry to it, and are
treated as an equal partner, regardless of size and reputation.
Currie & Suhomlinova (2006) also contribute to the research that exists around
‘collaboration’. They reviewed the impact of ‘institutional’ forces (the NHS; the Higher
Education Sector) on collaboration as opposed to the impact of ‘organisational’ forces
(the individual hospital trust; the medical school). The authors selected two case
examples from an academic health centre that included a medical school and NHS
organisations comprising commissioners and providers.
Following initial interviews with 29 individuals from the centre, two units of
assessment were selected with which to test the proposition that it was institutional,
rather than organisational, forces that were having the biggest impact on
collaboration. The two units selected were the clinical areas of ‘digestive diseases’ and
‘vascular surgery’ (p.11). NHS Consultants and Academic Professors were selected as
the participant group on the basis of their influence, and working group meetings of
key stakeholders were also observed as part of the data gathering exercise.
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Currie & Suhomlinova (2006) concluded that institutional pressures were creating a
divergence of priorities at NHS and Higher Education sectoral level, and were therefore
working against the central government policy of inter-organisational collaboration.
The NHS for example was becoming increasingly focused on clinical care and patient
outcomes, whilst the Higher Education sector was being judged upon academic
outputs in the form of high quality journal publications. This led to a ‘struggle to
establish a common ground’ (p.5).
Currie & Suhomlinova (2006) concluded that this divergence at institutional level
affected individuals at a very early stage, for example at the beginnings of the career
path of clinicians, who are expected to purse either a predominantly clinical or
academic career, with the lack of cross-fertilisation between the two contributing
towards an increasing divide between NHS employed clinicians and University
employed academics. Thus, Currie & Suhomlinova (2006) argued that central
government policy makers should pay more attention to institutional forces in order
that collaborations are not impeded by the regulatory, cultural and managerial
differences that otherwise emerge between NHS and University organisations.
Currie & Lockett (2011) make a similar point, arguing that whilst central Government
policy in England is pushing a collaborative, distributed leadership approach, the
parallel institutional target-based polices serve to push individuals in the opposite
direction, towards a less collaborative way of working (p.295).
None of the papers specifically contrast a stated policy objective around increased
collaboration with actions in local settings. This is something that the NIHR wanted to
better understand, and funded Davies, Powell & Nutley (2015) to investigate the
potential potential dichotomy between the meso level interventions by research
producers, funders, and intermediaries, and the translation of these efforts into
practice.
Davies et al.(2015) undertook a multi-methods, multi-phase study into the CLAHRCs
and the UK-CRC Public Health Research Centres of Excellence, conducting interviews
47
with fifty-two participants from across such collaborations, as well as a web-survey
extending to national and international organisations, with a response rate of fifty-six
percent (106 respondents).
They concluded that whilst there was evidence that efforts such as jointly funded
projects and collaborative secondments were intended to aid successful collaboration,
tensions between organisations remained. The authors discovered that organisations
were not learning sufficiently from programme evaluations and recommended that
there should be a facilitation of more cross-sector and interagency learning, of
increased reflection at an organisational level as to what works, and more meaningful
evaluation of programmes and initiatives.
2.5 Summary of key themes and gap in the literature
This chapter commenced with a summary of the literature that has developed over the
past decade around the definition of translational clinical research and demonstrated
the range of organisational structures that have developed to deliver this type of
research. Hanney et al.’s (2015) definition of translational clinical research, specifically
their ‘human research and review’ track, encompasses all of the activities that were
being delivered by my two case study partnerships, these being Phase II clinical trials
through to projects that review safety and effectiveness (p.33), and was therefore of
most relevance to my study.
A detailed analysis of the policy framework followed, and demonstrated a synergy
between academic thinking and the development of external policy. This new policy
framework included the creation of the NIHR, which in turn announced a tranche of
funding opportunities for translational clinical research, all of which were dependent
on a new type of NHS-University collaboration, typified by arrangements such as the
Biomedical Research Centres (BRCs), Biomedical Research Units (BRUs), CLAHRCs,
AHSNs, and AHSCs. I have presented literature that has asked whether policies change
behaviours in the context of non-academic research impact (Ovseiko et al. 2012;
Morgan et al. 2011; Boaz et al.; 2014) and recruitment of patients enrolled on clinical
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trials ( Adams et al. 2015) and these suggest that policy levers are not a guarantee of
changing behaviours.
The more recent examples of academic literature around NHS-University
collaborations (Currie & Suhomlinova; Currie & Lockett; Davie, Powell & Nutley)
suggests that there are institutional factors that impede the successful translation of
policy levers into improved delivery on the ground.
However, there is a lack of knowledge within the literature around the way in which
the new macro level policy environment for translational clinical research has been
responded to at meso and micro levels by organisations and individuals that are
working in the resultant collaborative partnerships.
This gap includes a lack of understanding around the way in which NHS-University
partnerships, operating outside of the Golden Triangle, have responded. Given the in-
balance in public funding for translational clinical research between the Golden
Triangle and the rest of England bringing new knowledge to this area is useful from a
research and policy perspective.
The next chapter presents the theoretical framework within which I sought to answer
the central research question in the context of two local NHS-University partnerships.
It explains how I drew upon a constructivist methodological approach to devise a list of
semi-structured, open interviews with clinical academics, and used the lens of Huxham
& Vangen’s theory of collaborative advantage to frame the interview questions and
analyse the data.
Chapter 3. Methodology & Method
3.1 Methodological preference
A new phenomena of NHS-HEI collaboration has developed in England, in response to
the policy framework that is outlined above. Drawing on the principles of
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interpretative research, I sought to bring new knowledge into this area, by researching
how participants within two NHS-HEI partnerships made sense of the new policy
environment. This approach was underpinned by my view that social environments are
created by the actions, beliefs, and behaviours of the people within them, and that, in
turn, the social environment itself impacts upon the behaviours of its inhibitors, and
those engaging with it. Thus, I embarked upon a study that is grounded within
constructivist ontology, and I do not therefore claim to provide a universal truth.
I begin with the hypothesis that, in England a new policy framework has been
developed, with a view to better facilitating the delivery of translational clinical
research across NHS Trusts and Universities. I test this hypothesis by exploring the
interpretations and understandings of a group of pre-selected participants within two
units of analysis. The constructivist approach that I have taken is grounded within the
key concepts of the socially constructed world, the importance of language and
communication, and the acceptance that whilst truth may be subjective, there are
nonetheless patterns of behaviour that may help us to understand how a social
construct is developed and interacted with, by the people within it.
Moses & Knutsen (2012) provide a history of constructivism, commencing with the
works of Immanuel Kant, whose theory that the world can never be truly objectively
understood was antithetic to the ontology of the natural scientists. However, Kant did
provide them with a paradigm that allowed them to continue with their sensory
perceptions of truth, via his idea of the shared ‘basic preconditioning concepts’ of the
human mind (p.175) which together are what ‘it means to be human’. William
Whewell (1794-1866) provides a lens through which to engage with Kant’s body of
work. Whewell argued that the naturalist paradigm was at its heart arrogant and self-
denying, incorrect in its view that it could offer objective views of truth on the world.
He placed the historical nature of human knowledge at the centre of his argument that
knowledge is collectively owned by groups or societies, and is constantly evolving
through time, such that one form of truth eventually replaces a former (the world is
flat – the world is round, for example). Kuhn (1922-1996) further developed these
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ideas by arguing that shifts in knowledge occur totemically and disrupt periods of
relative stability and gradual evolution.
Whewell also argued that human knowledge transcends individuals and is contextual
to the social environment, a point that was expanded upon by Scheller (1920s)
(‘society of knowledge’), in which the argument goes that societies are ‘pools of
knowledge’ and that knowledge is influenced, but not determined, by social conditions
(p. 185). Later came the ‘Verstehen’ concept, developed from the early 1800s and
beyond by Dilthey, Rikert, Simmel, and Weber (p. 187) and being the counter to the
cause-and-effect naturalist ontology in arguing that social phenomena can be
illuminated by the exploration of social relationships.
Dilthey’s evolution of hermeneutics transferred ideas from theology into a method for
couching knowledge within an observed and iterative understanding of individuals and
context. Similarly, the idea of a ‘cultural apparatus’, as a window through which
individuals view, and formulate, social realities, is underpinned by an appreciation of
the importance of linguistics and communication to the accumulation of knowledge
and ‘truth’. In short, constructivism is not a simple nor easily summarised ontology, but
its theorists share a belief that,
‘Knowledge about the social world is always knowledge in context; it is socially
situated and has social consequences’ (p. 201).
3.2 Interpretive research
‘What constitutes interpretive research is the explicit recognition of the
researcher being engaged in the act of interpretation from the beginning of the
research process to the end’ (Radnor 2001, in the introduction to her book
‘Researching your Professional Practice: Doing interpretative Research).
I draw upon this principle in my study, in which I seek to interpret the new social
phenomena of NHS-University partnerships, by recognising these exist within a wider
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contextual policy framework around translational clinical research. They also exist
within older, more established social pools of understanding, including the worlds of
the NHS, of Universities, of Science, and in bringing these worlds together into new
collaborative arrangements, the partnerships have in themselves created a new form
of social construct that is embryonic in terms of the research that exists around it. The
interpretivist approach is compatible with the hermeneutic style that I have taken to
the observation of the external policy environment and my study data, and is relevant
to Verstehen principles of pooled societal knowledge, and the importance of language
to concepts of truth.
I hypothesized prior to commencing my research that the delivery of the new
phenomena on the ground may not be completely aligned with the objectives of the
policy makers, who were trying to create a new reality for translational clinical
research. I believed that my study participants and the two units of analysis should be
approached from the understanding that knowledge is not rooted purely within
individuals, but is also determined by broader social contexts.
The interpretative approach to research encourages researchers to be aware of their
own subjectivity and to be proactively reflexive in the analysis of data (Radnor; 2001;
p. 31).Throughout my research, I was careful to recognise my own preconceived ideas
about the phenomena being studied, and to ensure that the questions I asked were
objective as possible. To this end, I embarked upon a pilot set of interviews with critical
friends, to remove as far as possible any research bias. At the time, I recorded my
thoughts in my reflexive log, and for the sake of transparency, I have presented the
most relevant of these in the section below ‘myself as the researcher’.
I brought to the study an interpretivist curiosity about how individuals interact with
social environments that have been created for a particular purpose, in this case the
new NHS-HEI organisational structures that had been ‘created’ directly (the accredited
NIHR partnerships) and indirectly (the network of non accredited organisations), by
Government policy. As neither an academic clinician nor a leader of a Medical School
or NHS R&D Office, I felt that I was able to maintain a distance from the participants
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during the interviews, and this allowed me to ask open-ended questions without
having any pre-conceptions about the answers. The collation of the interview data was
a fascinating process that I feel privileged to have been a part of.
The questions that I asked were semi-structured. My epistemological perspective led
me to design open questions that were focused on understanding people’s
interactions and perceptions of the new NHS-HEI arrangements:
• What is the vision for translational clinical research in the University and the
Trust?
• How well understood is this vision (with clinical academics with non-clinical
academics)?
• Is it focused on particular groups or themes at the moment – why is that?
• What have the NHS and University done to engage with each other at senior
and operational levels?
• What do you think are the main opportunities for the University/NHS Trust in
terms of engagement with the local NHS trust(s)?
• How should the organisations manage these?
• What do you think are the main challenges for the University/NHS Trust in
terms of engagement with the local NHS Trust(s) and how should the University
manage these?
• What particular challenges and opportunities does the University/NHS Trust
relationship pose in terms of your own area of research and academic
leadership?
• How would you define ‘translational clinical research’?
• Is there anything else that you would like to tell me about?
Throughout the interviews, I drew upon Mead’s ‘perspective of symbolic
interactionism’ (Radnor 2001; p.6) to observe how my participants interacted with the
social construct of the NHS-HEI collaboration, underpinned by my view that it is this
process of interaction that influences and evolves the world around us. I do not believe
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that these new phenomena, created as they are by the social world, stand still; rather,
I expect them to develop into different social constructs as the individuals within and
around them, interact with each other and with the construct itself to create a new
environment, a new way of being. I sought to better understand whether the new
policy context had created a change in the actions of the organisations and individuals
that interact with it.
My study relates to the new policy environment that has developed to support
translational clinical research, and I explore whether this is leading to new behaviours.
I have conceptualized the new wave of NHS/HEI partnerships and sought to
understand the activities of those within them by taking an interpretive approach,
which accepts the hermeneutic nature of a reality as a learned experience in a social
world that is forever changing. In seeking to bring this new knowledge, I accept that
there are no hard objective facts that are proven by my study, but I do believe that the
qualitative data gathered adds a further layer of understanding to the new NHS-
University collaborations, that can be drawn upon by other researchers to further
extend knowledge of this area.
3.3 The practitioner researcher
I undertook the research project as part of my EdD, at a time when I was still relatively
new to the Higher Education sector, and very new to research in Higher Education. In
fact, a recent promotion to the role of Head of a Research Office was one of the
primary drivers to my enrolment onto the EdD, as I sought to develop a deeper
understanding of the sector as a practitioner researcher. The project that I selected for
my thesis was concerned with an area that I had just begun to get accustomed with;
that of clinical research being delivered by NHS-HEI partnerships. My interests in this
area were piqued by the opportunities to study meso and micro level behaviours
within a dynamic policy environment, in which a new form of partnership had
emerged.
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I had an underlying interest in the way in which individuals interact with each other
within new social constructs, and the added dimension of translational clinical
research into the NHS-University environment gave the area a highly topical dimension
to it. But mainly the key driver for me in selecting this project was an observation of
the frustrations that existed around it, on the ground, for those that were trying to
deliver translational clinical research. I could see that there was a new external policy
context that was meant to facilitate this type of research, so what were the factors at a
local level that were preventing this from being the case? And how could local
partnerships interact in such a way as to deliver this research in an easier and more
effective manner?
I explored these questions within a practitioner based project, and by doing so, added
another study to this developing area of social sciences research, which has its modern
origins within practitioner research in an education context, and has grown in
popularity in recent years alongside the rise of Professional Doctorate (Sikes & Potts
2008 p. 3). Practitioner researchers are often embedded within the phenomena that
they are studying, but seek to achieve enough critical distance from them to develop
legitimately new and robust knowledge that can move a discourse forward (Loxley &
Seery in Sikes & Potts p. 24). I certainly wanted to provide new knowledge to the
phenomena of NHS-University partnerships for translational clinical research, but I had
an existing critical distance by the fact that I was not based within either a Medical
School or an NHS Trust at any point during my study. Rather, I was employed within
the central administration of a University within each of the case study partnerships at
various stages in my study. This provided an element of critical distance, but it was still
the case that I was employed within an organisation that had an interest in the future
direction of the partnerships and therefore it was important that I was aware of my
status as a practitioner researcher in both the design and conduct of my study.
My EdD was self-funded and this provided a further element of critical distance that I
found useful; I did not feel that I had to focus my research towards the priorities of one
or other of the organisations within the case studies.
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Conducting the research provided me with a deeper appreciation of the academic
research process, and the communities of knowledge that sit within this, diverging and
coalescing around different ontological and methodological stances. This changed me
fundamentally as a professional and as a person, whilst also giving me a new currency
with the Academy at my new University. This applied not only to the social science
researchers, but also to the natural scientists. In my role as a University Director of
Research, I have to engage with both and in reading around the different approaches
to knowledge; I gained a deeper understanding of both paradigms.
However, practitioner research has been criticised by many as unable to achieve truly
objective academic output. Hammersley (in Sikes and Potts; 2004 p. 27) , for example,
argues in the context of educational action research (teacher-researcher) that critical
distance cannot be maintained due to an underlying bias that is ingrained within a
teacher’s epistemological approach. This is contested by Loxley & Seery (2008) who
argue that bias can be just as present within non practitioner research and that it is the
ability to think critically, reflectively, and to be able to design and conduct research
that are more important (p.24). Smyth & Holian sum this up nicely by saying that
‘research from within is different to, not better or worse than, other forms of research’
(p. 33) but it is important to ensure that the design, ethics, and analysis are robustly
planned and conducted to ensure credibility and to support the ethical treatment of
the participants. (Smyth & Holian p.39).
As I progressed through my Study, I found that there was sometimes a tension
between my instinct as a practitioner to shift too quickly into practical
recommendations for future action. It was deeply affecting, from a personal and
intellectual perspective, to discover that there is a different way of viewing ‘truth’ and
that an academic approach can allow one to step back and view the social construct
through a different lens. This has fundamentally changed my approach to thinking
about things in both a work and a personal context. It is an outcome of the EdD that I
was not expecting but is something that I shall look to maintain and nurture in the
future.
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In many senses, I found myself to be a different person as a researcher as compared to
my professional context. For example, I was not as comfortable in the interview
situations as I would have been presenting to a room full of people. This was at the
same time frightening and liberating but culminated I hope in a project that spans both
the practitioner and academic facets in a way that offers something to both audiences
(which do not of course have to be mutually exclusive). The process of conducting the
Study has made me much more aware of my own perspective on the world as
someone who subscribes to the constructivist view of realties, whilst the practical
knowledge that I have gained has helped me to develop a number of interesting
professional projects, and I hope to continue as an active researcher in my future
career.
3. Reflexivity
I have explained in the preceding section that my doctoral journey has been one of
personal insight, in which I have developed as both a practitioner researcher and as an
individual. As a practitioner researcher, I was very aware of the need to maintain a
critical distance between myself and my study data, and one of the ways that I did this
was to take a reflexive approach to the research process.
Radnor (2002) defines the process of reflexivity as one in which the researcher is
aware of their own views (and has a deep appreciation of how these views came into
being), their reaction to the participants and the data (p. 32). In my case, I was aware
that as a practitioner researcher, I was naturally drawn to the large policy framework
that underpins the subject area, having experience of translating policy into practice in
a number of settings. This would therefore have influenced my choice of research
question, in that enquiring as to how a significant policy shift was being translated at
the local level, was a matter that was pertinent to me and many of my contemporaries
in University and NHS organisations.
Radnor introduced me to the idea of the researcher as a ‘research tool’ being
intertwined with the process of data collection and analysis in such a way as to be part
57
of the project itself. This is why I outlined my background in Section 3.3 above, to allow
the reader an insight into how I came at the research project, and therefore how I may
have interacted at different levels with it. More fundamentally though, the process of
reflexivity allowed me to understand all of these things as though I were looking in on
myself – a remarkably thought provoking and stimulating process.
To assist my reflexive approach, I did a number of things. Firstly I have maintained a
learning log during the study, starting from the point that I decided on my thesis title
and onto the time of writing. Some of the entries are very brief, but the most detailed
are those in which I explain how I interacted with a particular piece of literature or
study participant. This process of reflection throughout the study allowed me to better
understand my own subjective responses and to address these during the period of
the data analysis, by drawing on certain techniques with a view to ensuring that my
analysis was as robust as it possibly could be.
During the data analysis stage, I began to conceptualize the data in detail, referring it
back to the central research question and applying it both units of analysis. I engaged
hermeneutically with the data (Radnor 2002; p/ 36) reflecting, refining, and revisiting it
such that I was immersed in my study outcomes. Being aware of the need to reduce
bias, I read through the data at different times to establish a critical distance from it as
far as was possible, accepting an element of subjectivity will always be present within
the analysis of qualitative data.
3.5 Theoretical Frameworks
Yin (2012) argues that the use of theory can be particularly useful for case study
research. It supports the researcher to define the nature of the case study, identify the
participants, and specify what is to be explored (p. 28).
In contrast to the natural sciences, the social sciences do not have a small number of
agreed theoretical frameworks that shape research questions and approaches at a
point in time. Instead, there are a number of different theoretical frameworks that
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each view social phenomena through a different lens and have a different approach to
understanding the social world (Kerlinger 1986 in Anfara & Mertz Eds. 2015).
Additionally, there is some disagreement within the social sciences as to whether
theoretical frameworks should be utilised as a way of framing qualitative research
questions (Anfara & Mertz 2015; p. 7). In their review of the literature that exists
around theoretical frameworks in qualitative research, Anfara & Mertz conclude that,
‘theory has an unavoidable place in all but a few of the authors that we
reviewed and plays a substantial role in the research process’ (p. 14).
Strauss (1987) refers to the integral ‘complexity’ (p. 10) of social phenomena and
states that theory is a way in which this complexity can be understood and researched,
arguing that ‘there is no reason not to utilize extant theory from the outset’ providing
that this theory is grounded in strong research data (p.7).
3.5.1 Theory of collaborative advantage
I utilised Huxham and Vangen’s theory of collaborative advantage at two critical stages
of my research, during the design and the analysis of results. Prior to selecting Huxham
& Vangen, I reviewed a number of other frameworks, and I present these here for
completeness, to provide a further rationale for my selection of the theory of
collaborative advantage.
D’Amour, Ferrada-Videla, Rodriguez, & Beaulieu (2005) analyse seven model
frameworks for collaboration with a view to informing future research into inter-
professional collaborations in a health setting. The seven frameworks are initially
analysed according to the level at which they are underpinned by empirical data,
theory, and literature reviews. Each of the frameworks draw heavily on ideas of either
‘structure and process’ or simply ‘process’ (p. 121).
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The seven frameworks are underpinned by a theoretical position, either ‘team working
in organisations’ (West, Borrill, & Unsworth (1998) and Sicotte, D’Amour & Moreault
(2002); the structuration of rules (Friedberg (1993); D’Amour, Sicotte & Levy (1999);
D’Armour, Goulet, Pineault, Ladabie, (2004)), social exchange as a way of
understanding collaborations (Gitlin, Lyons & Kolodner (1994), or the concept of
alliance (Hayward, DeMarco, & Lynch (2000).
D’Armour et al. argue that, in addressing structures and settings rather than
collaborative practices, the frameworks assume that collaboration necessarily ‘affects
patient outcomes’ (p.128), and that collaboration is inherently positive.
Huxham & Vangen argue against this assumption. Bringing together fifteen years of
action research into collaborative ventures to their argument, Huxham & Vangen
describe their theory for understanding collaborations as one in which there are the
two concepts of ‘collaborative advantage’ and ‘collaborative inertia’ (Huxham &
Vangen 2003; p. 62; Huxham & Vangen 2005; p.3).
In their 2003 paper published into their research into the role of partnership managers
in achieving successful collaborations, Huxham & Vangen explain that their concept of
collaborative advantage is one that often underpins the move towards collaborative
working in the first place. Relating this to my subject matter, the notion of
collaborative advantage can be used to conceptualize the rationale behind the
Government’s requirement for formalized NHS-University partnerships, the theory
apparently being that this increasingly collaborative approach will improve the volume
and quality of translational clinical research. However Huxham & Vangen’s concept of
collaborative inertia is often the unintended consequence of such move towards
partnership approaches (2003; p.62; 2005; p.3). In their research into partnership
managers, Huxham & Vangen draw upon data gathered ethnographically from thirteen
public sector partnerships and argue that to achieve success rather than inertia
requires managers to be both ‘facilitative’ and ‘directive’ (p. 74).
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The theory includes a series of practitioner based themes, which both inform practice
and are themselves informed by practitioner research, (p. 6-7). They present the
theory by means of a series of overlapping themes or ‘perspectives’ (p.37) which are
grouped into three areas, firstly, perspectives that have been gathered from
practitioners’ own views about collaborations that they have been involved with;
secondly, themes which are nested in policy drivers, and third, academic perspectives
which are included and intertwined to ensure a robust research base for the overall
theory to reside.
Huxham and Vangen’s theory also incorporates structures and settings referred to by
D’Armour’s (2005) analysis of theoretical frameworks. However, a criticism of their
theory is that not enough attention is paid to the ‘structural properties’ of specific
organisations and regions (Sydow; 2006). This is a valid comment, but the practitioner
focused and reflexive characteristics of the theory meant that it was my preferred
framework, accepting its limitations with respects to structural dynamics.
Whilst the practitioner views form the conceptual themes, Huxham & Vangen argue
that there is a great deal of complexity sitting within the themes. This includes both
linkages and contradictions within and across the themes, and they argue that these
data should therefore be assessed with reference to ‘theoretical and empirical
research by others on these topics’ (Sydow 2006; p.606). In Chapter Five, Discussion
and Analysis, I follow this approach, presenting and analysing my data alongside
relevant policy and academic literature.
Figure 2.5 below presents Huxham and Vangen’s theory of collaborative advantage
with reference to the themes within it. These are not expected to be a ‘prescription’
for success (p.34) but are presented as a framework for practitioners and practitioner
researchers to progress their own collaborations and related research projects.
Therefore, this is a dynamic theory that should evolve as practitioner research and real
life experiences inform it, encapsulated by Huxham & Vangen as ‘an interim statement
which must be viewed as a developing story’ (2000; p. 1165), and they contextualize
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public sector partnerships as part of a wider shift towards ‘joined up’ approaches that
became prevalent in the 1990s (2000; p. 1159). This move has continued and now
includes the subject matter for this thesis, the NHS-University collaborative
partnership that is required by funders in order to access investment into research,
this confirming their earlier observation that collaborations are ‘often externally
imposed by policy makers’ (2000; p. 1166).
Figure 2.5: Huxham & Vangen’s theory of ‘Collaborative Advantage
This conceptualization of issues ‘in a form that is accessible to practitioners’ provided
me with a framework within which I would seek to understand the collaborations
within my two NHS-University case study partnerships (2003; p. 62). In the design
stage of my study, the theory helped me to identify and formulate a practitioner based
approach to understanding the research question, and in the analysis stage, to identify
a series of practitioner based themes underpinned by a detailed analysis, that provides
new data around collaboration from the views of practitioners in each of the thematic
areas.
Membership Structure (cross-cutting theme)
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The practitioner themes that form the basis of Huxham & Vangen’s theory have been
drawn together via a series of action research projects, and represent the factors that,
in the views and perceptions of practitioners, are key to the success or failure of a
collaborative endeavor. This practitioner driven approach resonates with my study, in
which I sought to understand the implications of a new policy environment from the
perspectives of the senior practitioners operating within it. The theory of collaborative
advantage is also one that is continually informed by practice based research and
therefore is an evolving theory. It provides a framework within which each of the
practitioner driven themes can be further investigated in more detail. I followed this
style of analysis in my study, drawing out three practitioner driven themes, within
which I provided an in-depth analysis to present recommendations for future research
and practice in each area.
An example of the complexity behind practitioner generated themes is offered by
Huxham & Vangen with reference to developing and agreeing joint aims. They argue
that, in their experience, this is a complex process that is influenced by ‘organisational’
‘spoken’ and ‘unspoken’ aims, some of which may never be fully understood (2006;
p.4).
Huxham & Vangen’s framework presents these practitioner generated themes against
policy generated and research generated themes, these being the areas that policy
makers and researchers feel are the critical areas. My focus on the collaborative NHS-
University partnerships that have formed in England in response to central
government policy drivers, provides the opportunity for a new interpretation of
Huxham & Vangen’s model, specifically aligned to the area of translational clinical
research. In the data analysis chapter, I present a series of practitioner generated
themes that emerged from my data within which are a series of categories and codes,
these providing additional detail to each of the themes, and thereby following the
Huxham & Vangen structure, whilst offering a new set of themes specific to my area of
research.
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3.6 Absorptive capacity
In asking how the national policy environment for translational clinical research is
impacting on delivery in two NHS-University partnerships, my study could be viewed as
testing the ‘absorptive capacity’ of the case study partnerships to respond effectively
to the new policy environment for translational clinical research. Utilising the concept
in this way would require me to ask how well or badly the organisations in my case
study are embedding the new policy drivers into their internal infrastructures, and how
this in turn then improves their delivery of translational clinical research.
The concept of ‘absorptive capacity’ was introduced by Cohen and Levinthal (1989,
1990, 1994) ‘more than 25 years ago’ (Martinkenaite & Breuning; 2016) as a
mechanism for understanding the ways in which private sector companies become
innovative, dynamic, and competitive. It assumes that innovation is necessary for
success in high technology and knowledge based business environments, and suggests
that the most successful firms are those that can ‘recognise…assimilate…and apply’
external information for commercial benefit (p.700). This is therefore a concept that is
based on the assumption that the most competitive companies are those that possess
this three-stage capacity to recognise the most lucrative information, rapidly assimilate
it into their internal practices, and apply it in practical settings, improving productivity
and hence achieving competitive advantage.
This three stage process of absorptive capacity could be defined as exploration,
transformation, and exploitation, (Aribi & Dupouet 2015; p. 987), and it has been used
by a deal of researchers to explore commercial success of failure in a variety of
innovative commercial settings, on the assumption that the most successful companies
were those that had the absorptive capacity to recognise the most lucrative and useful
information, rapidly assimilate into their internal practices and apply it in practical
settings to their commercial dealings, thus improving productivity, competitiveness
and profit.
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Since its introduction, the concept has been used as a way of explaining success or
failure in different settings. For example, Ahlin et al. (2014) looked at how business
networks impacted on the innovative practices of SMEs, by conducting a
questionnaire-based survey of two groups of entrepreneurs in the US and Slovenia to
understand the different approaches to business networking. They concluded that the
ability to demonstrate an absorptive capacity with regards to external knowledge had
a direct impact on the competitiveness of the business; Aribi & Dupouet (2015) looked
at absorptive capacity with regards to the role of organizational and social capital in
the uptake of innovation by three French industrial firms, whilst Backmann et al.
(2015) developed a tool for assessing the absorptive capacity at the level of a team
rather than organization (p. 861).
Fernhaber & Patel (2012) hypothesized that both absorptive capacity and
ambidexterity were defining factors in the ability of young high-technology firms to
manage a ‘complex portfolio of products or PPC’, this being important for
competitiveness in this sector, but containing the inherent risk that, at a certain point,
the costs of maintaining the portfolio outweigh the benefits. (p. 517-518). Using a
sample of 215 high technology firms, being less than ten years old and each having
between 10 and 250 employees, Fernhaber & Patel tested the hypothesis that
absorptive capacity and ambidexterity could help firms to better manage the costs and
benefits of PPC. They concluded that this was proven across both elements, and that
with regards to absorptive capacity this was proven to help young firms to better
‘integrate eventual external knowledge’ (p. 1531).
Tavani et al. (2013) utilised Tu et al.’s (2006) proposed sub-components of absorptive
capacity, ‘prior relevant knowledge…communications network (and) climate…(and)
knowledge scanning’ (p. 3888) to bring new knowledge to the benefits of absorptive
capacity with regards to new product development by firms. Their research was
underpinned by literature, which argues that effective new product development is
related to commercial success (p. 3385-6). Via a questionnaire survey of 161 Iranian
manufacturing firms, they explore the impacts of Tu et al.’s sub-components on new
product development in manufacturing, and via a process of confirmatory factor
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analysis (p, 3391) conclude that prior related knowledge of both managers and
workers has an impact on the financial and non-financial outputs of new product
development respectively (p. 3995), that a communication climate that is open across
the company supports effective new product development (p. 3996) and that
knowledge scanning contributes to both financial and non-financial outcomes (p.
3996).
Tavani et al.’s findings that an individual’s position within an organisation affects
absorptive capacity (specifically that managers’ prior knowledge impacts on financial
outcomes compared to workers’ prior knowledge impacting on non-financial
outcomes) was confirmed by Tortoriello (2015), who found that positioning of an
externally networked individual impacts directly on the levels of organisational
absorptive capacity.
Tortoriello argues that there has been an over emphasis on industry Research &
Development (R&D) capacity, with the effect that there is a lack of literature around
the process via which firms achieve absorptive capacity (p. 587). In a questionnaire
survey conducted at a ninety-one percent success rate across 276 potential
respondents in a ‘large multi-national semi-conductors’ company (p. 59), he explored
the impact of internal positioning and concluded that a company’s internal
communication networks are a key factor in the ability of an individual to produce or
facilitate the production of, innovations as a result of absorbing external knowledge.
He further concludes that companies should therefore ensure that they have open
communication networks such that individuals who receive external knowledge are
able to effectively assimilate it across the organisation.
Duchek (2015) also argues that much of the literature around absorptive capacity
presupposes that ‘R&D intensity’ is the pre-requisite for industrial absorptive capacity
and consequently there has been a lack of research into the process driven nature of
absorptive capacity such that there is a knowledge gap as to how and in what way
internal processes influence absorptive capacity (p. 2). In his qualitative, interview
based case study research projects into two highly successful German engineering
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firms; Duchek explains the absorptive capacity process with reference to the three
stages of acquisition, integration, and exploitation (p. 6).
He found that whilst formal policies and structures for the sourcing and uptake of new
ideas were in existence in both firms, it was their willingness and ability to flex these
systems that was critical to the achievement of successful absorptive capacity. This
flexible approach meant that ideas there were not raised through formal pathways
were nevertheless still considered within more informal settings, and that this was
critical to ensuring an innovative and responsive approach. Duchek argues that ability
to flex and not be overly constrained by internal rules is required for firms to be
absorptive to new products, processes, and practices (p. 16).
It can therefore be demonstrated that absorptive capacity has been ‘a very influential
framework in the study of organisational innovation’ (Tortoriello 2013; p. 587).
There is evidence that absorptive capacity can also be specifically applied to the
research and knowledge transfer in the higher education sector. Belderbos et al.
(2016) further developed the concept, from simply ‘absorptive’ to ‘scientific
absorptive capacity’. They asked why some businesses maintain university-business
interactions in a more meaningful way than others (p. 32), and concluded that firms
with the most demonstrable scientific absorptive capacity were those with in-house
research teams, who take ownership of their university interactions, as opposed to
those business that rely on external brokerage. This research therefore assumed that
absorptive capacity was a pre-requisite for the maintenance of business-university
relationships.
Denicolia et al. (2016) also worked from this assumption, but arrived at a different
conclusion to Belderbos et al. They asked what the differences were in terms of future
exploitation, between internally produced and externally driven innovation. They
concluded that an internal R&D research infrastructure should not be viewed as a pre-
requisite or guarantee of absorptive capacity in the context of innovation (p. 57),
arguing instead that internal R&D is ‘not a simple proxy for absorptive capacity, but
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rather a basis to create complementary assets and capabilities’ (p. 64). However,
whilst arriving at a different conclusion in terms of the importance of internal R&D
capacity, both Denicolia et al. and Belderbos et al. agree that the concept of absorptive
capacity is a valid way of investigating the ability of a firm to compete more effectively.
Duchek (2016), in his study of organizational structures and their impact on absorptive
capacity, comments that understanding of the different components, drivers, and
impacts of absorptive capacity is presently at an ‘early stage’ (p. 143). It is a concept
that could be utilised in future research into NHS-University partnerships for
translational clinical research. To do so, it would be useful to understand the factors
that the partnerships would be expected to absorb, in order to support more effective
research outputs. I suggest that my research project was undertaken at a step prior to
this, when it was not clear what factors would emerge from the two case study
partnerships as being critical to the overall success of the partnership. I return to the
concept of absorptive capacity in the final chapter, where I suggest that future
research may useful evaluate the absorptive capacity of the two partnerships with
regards to the key emerging factors for successful collaboration that are suggested by
my data analysis.
3.7 Methods
3.7.1 Case Study
My study was exploratory in nature, and was carried out within the theoretical
proposition that a new national policy framework has been developed to support the
increased delivery of translational clinical research, in different local contexts. I wanted
to explore how this was playing out in reality. The new collaborative NHS-University
working structures that had in effect been created by this new framework are both
NIHR accredited and non-NIHR accredited. An academic framework for the business of
collaborating across organisational boundaries was offered by Huxham & Vangen’s
(2005) theory of collaborative advantage.
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I wanted to ask how the new national policy framework for translational clinical
research was being delivered at a local level and why, and in what circumstances,
certain policy levers worked or didn’t. My aim was to investigate a real life and
dynamic phenomena over which I had no influence or control (the new NHS-University
partnerships) and in which an understanding of the ‘contextual conditions’ was
required (Yin 2009 p. 18). The ambition to ask ‘how’ and ‘why’ and to understand the
complexities and subtleties that exist at a local level, led me to select the case study as
my chosen research method. My initial idea to select one unit of analysis subsequently
developed into having two units of analysis, allowing me to research local responses to
the national policy environment in two different local contexts.
Case study partnership one was a non-NIHR accredited NHS-University partnership,
operating outside of the Golden Triangle. It had been formed to facilitate the delivery
of translational clinical research within the new national policy environment for
translational clinical research, and the University within it had over one hundred years
of history that grew out of its Medical School. The partnership also included a number
of NHS Teaching Hospitals, most of which had a long established relationship with the
University, others being less mature; overall however, this was a well-established
health research eco-system.
In contrast, case study partnership two a more recently formed NHS-University
partnership based around a much younger Medical School and University Hospital
Trust (both being less than twenty years old) and in which the research structures and
policies within the NHS Trust could be best defined as embryonic.
Both partnerships had been established as non-NIHR accredited NHS-University
collaborations, with a view to reflecting back the new national policy environment for
translational clinical research, recognising that this was necessary in order to attract
investment from the NIHR and other bodies. Both partnerships operate in regions
outside of the Southeast, and are therefore not a part of the Golden Triangle of
partnerships into which the majority of funding for health related research flows (UK
Clinical Research Collaboration 2014).
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The constitutions and structures of both universities are distinctly different; case study
partnership two University exhibits a flat management structure, in which each
academic Head of Department reports directly to the Vice-Chancellor, but where the
Departments themselves have no degree of financial autonomy from the central
University, thereby creating a culture which was referred to by one participant as
‘strong departments, strong centre’ (2:8), Case study partnership one, in comparison,
has three strong academic faculties, each with a degree of financial devolvement,
where Heads of Departments report into Heads of Research Institutes who in turn
report into Executive Pro-Vice-Chancellors (an Executive position that does not exist in
Case Study Two). The NHS Trusts within the case studies are also very different in
terms of their internal research cultures. A senior participant from within partnership
two was open about the fact that ‘research is still new to our Trust’ (2:6) whereas the
Trust in partnership one has an established research infrastructure. One participant,
for example, spoke in detail about the impact of decisions made back in the ‘1930s by
the then Chair of Medicine’ stating that ‘we live with many of these decisions in terms
of the structure of local hospitals today; they still impact on us and affect how we
deliver research together’ (2:5).
The two NHS-University partnerships had been formed with the same aim in mind; to
reflect back the new national policy environment and to be structured in such a way as
to gain access to national funding for translational clinical research. Within case study
partnership one in particular, there was a driver towards simplifying local structures
for translational clinical research, not only between the University and the NHS, but
also across the NHS Hospitals themselves. This was not as apparent within partnership
two, which had an inherently more straightforward partnership structure to work
within (one University and one NHS Trust as opposed to the multiple NHS Trusts within
case study partnership one).
The Literature Review explained that a network of accredited and non-accredited NHS-
University partnerships has developed as a result of the new policy framework, the
accreditation being deemed as such via a competitive process that was established by
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the NIHR. My Literature Review also demonstrated that funding for translational
clinical research is increasingly dependent on NHS Trusts and Universities operating in
a close partnership arrangement, whether accredited or not, and the actions of the
two case study partnerships in my project are a natural reaction to this new
environment.
Prior to selecting the case study approach, I considered and discounted other
methods. A survey of NHS-University partnerships was one possible route but this was
discounted on the basis of my study’s aim and epistemological approach (I sought to
under the factors of ‘human agency’ at play at a local level; Moses & Knutsen p.11), as
well as the fact that the relative embryonic nature of this new policy area meant that
the literature presented very little in the way of potential variables from which I could
base a set of survey questions. Rather, I was intending to ask open-ended questions so
that I could better understand the ‘subtleties and complexities’ that are present (Burns
2000 p. 13).
Therefore the idea of a survey, whether across the different AHSCs or within one
established AHSC, has a number of limitations with respect to this particular research
question. In addition, it would not have complemented my interpretative approach to
the central research question, in which I wanted to gain an understanding of
participant views in a hermeneutic manner, and I believed that I needed to interview
the participants on a 1-1 basis, so that I could engage with the data (the researcher as
the ‘research tool’ as Radnor (2002) would suggest), and interpret body language,
probe more deeply where required, such that I could not imagine this being possible or
practical within a Survey context,
‘The way in which a response is made (the tone of voice, facial expression,
hesitation, and so on) can provide information that a written response would
conceal’ (Bell 2010; p. 161).
The more traditionally qualitative approaches to research design were also considered,
including ethnography, which was not practical in terms of my status as a practitioner
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researcher employed full-time, and, even setting aside these practical considerations,
would have been time consuming and difficult to frame, as my question involved
participants from across different organisations and operating in different localities
(the hospital, the Medical School). Grounded theory (Glaser; 2006) likewise may have
been more suitable if I was embarking on a larger study but it was neither practical nor
preferable in terms of the desire to establish what elements of the new structures
work best in what circumstances. Action research (Lakin; 2004) was rejected early on
as I was not actively involved in the research project and this therefore would not have
been an appropriate choice. The final method to be reviewed and discounted was
experimental research, most routinely used to study cause and effect’ (Bell 2010 p.13)
and requiring a minimization of variables that would have been at odds with my
research question.
I was aware of the potential limitations in terms of subjectivity and generalizability.
(Flyvbjerg; (2006) and McCutcheon & Meredith (1993)) However, case studies do not
seek to identify causal relationships in the way that experimental research studies do,
and in this sense the two can be complementary to each other (Yin 2009 p.16; Moses
& Knutsen 2012; p.133), and it would provide me with the opportunity to explain
‘causal links that are too complex for the survey or experimental strategies’ (Yin 2009
p.19), and to provide data from ‘real life’ situations to illuminate the practical
applications of the new NHS-University policy environment, in two different units of
analysis. Moses & Knutsen argue that in this sense, and despite the criticism levied at it
by some from the naturalist paradigm, the case study, in the right circumstances, can
be more appropriate than statistical research,
‘the case study may home-in on causal processes as they actually existed in the
Real World, untainted by control techniques’ (p.135).
My epistemological leaning towards an interpretivist view of the world does not
demand that my case studies were wholly interpretivist in their application; rather, I
sought to generate a series of hypotheses from the data, which would be suitable for
further exploration.
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I was attuned to the risk of researcher bias being more likely to occur in a case study
context (although this can be a risk for methods based research too) and carefully
designed my research questions, my units of analysis and my theoretical context,
assessing all of these with the help of a number of critical friends and my thesis
supervisor to minimise bias as much as possible. I was also sensitive to the fact that
my analysis of the data, for which I drew upon a manual coding approach, had the
potential for researcher bias. Bryman (2013) makes the point that,
‘although codes will reflect the perspectives of research participants, when the
qualitative researcher makes sense of the codes, he or she may end up viewing
their social world somewhat differently from them’ (p. 569).
The interpretivist approach allows one to accurately recognise this potential for bias
but believes that it is possible to ethically and accurately deal with this potential for
subjectivity by openly treating the researcher as a ‘research tool’ being involved in the
project from start to finish, and engaging ‘reflexively in the process’, being aware of
their own ‘interpretive framework’ (Radnor 2002 p. 31). By doing so I was able to keep
a ‘critical distance’ from the data during the collection, analysis, and drafting phases of
the project.
With regards to the issue of generalization, I refer here to Yin (2009) who argues that,
‘case studies, like experiments, are generalizable to theoretical propositions
and not to populations or universes’ (p. 16).
Thus whilst my research was not to be generalizable across the whole policy
framework for translational clinical research, it was intended to be an exploratory
study into how different contexts and other factors were at play and influencing
delivery in specific local contexts. It was intended that the results of my study would
bring new knowledge that could be tested within different environments and which
could be easily replicated, in terms of the selection of study participants and units of
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analysis.
Others have used the same approach, for example Currrie & Suhomlinova (2006) and
Adams et al. (2015),
‘We are mindful here that we examined two sites out of the many that might
have been chosen. However, in terms of our findings, our intention is to
generalize in a theoretical/analytical rather than statistical manner’ (Currie &
Suhomlinova; 2006).
‘The study is limited due to its small samples size although the findings are not
invalidated by this since qualitative research seeks theoretical rather than
statistical generalizability’ (Adams et al. 2015)
Whilst Yin states,
‘The case study method has proven that it is suitable for providing new
knowledge on phenomena’ (Yin, 2009, p.15).
3.7.2 The two units of analysis
The two NHS-University partnerships provided a local lens through which to view the
translational of the national policy environment within two distinct local contexts
The literature review demonstrated that the funding and critical mass of translational
clinical research takes place mainly within the Golden Triangle universities. However,
one of the drivers to the new policy environment was to increase the volume and
quality of this research outside of this small area and the two case studies provided an
opportunity to explore this in more depth. The case studies were comparable in that
both were delivering the same types of translational clinical research, and were
operating within the same national policy framework for translational clinical research.
I utilised Yin’s basic type of design for case studies, as outlined in the Figure 3.1 below
(format taken from Yin 2009 p.46).
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Figure 3.1: Diagram of my case, units of analysis, and overall context
The selection of participants was a key element of the research design. I selected ten
senior clinical academics, who, in addition to their clinical and research work had
leadership and administrative portfolios that meant they were critical and influential
stakeholders within the two partnerships. Purposely not selected as part of my study
group were patients, policy makers, funders of research, and university/NHS staff not
directly involved in the leadership and/or delivery of translational clinical research.
Participants were not selected ‘randomly’ (Boardman & Bozeman 2007; p. 437), but
rather were identified as having direct experience of working at the interface of NHS
and University research. My aim was firstly to understand, from the perspectives of
the participants, the way in which their local partnership operated, and to contrast this
with the ambitions of the NIHR to create a national system that is conducive to the
delivery of translational clinical research. I predicted that not all potential participants
would be available, and therefore my long list consisted of twelve individuals, one of
whom declined and the other who moved roles prior to me requesting an interview.
Consequently, I interviewed ten participants (four from Case Study One and six from
Case Study Two).
CONTEXT:
NEW NATIONAL POLICY AND FUNDING FRAMEWORK
FOR TRANSLATIONAL CLINICAL RESEARCH
CASE: NHS-UNIVERSITY PARTNERSHIPS
OPERATING OUTSIDE OF GOLDEN TRIANGLE
Embedded Unit
of
Analysis: 1
Embedded Unit
of
Analysis: 2
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3.7.3 Semi-Structured interviews
Ten interviews were conducted across the two case studies. Access to the study
participants was no doubt helped by my professional links to each of the organisations
within them, although I did not have close working relationships with any of the
participants and therefore it was not difficult to maintain a critical distance during the
interview process, whilst being careful to ensure that the participants were at ease
during the dialogue. Interviews were therefore all arranged to take place within the
participant’s own working environment, with the exception of one participant, who, by
virtue of not having their own office, selected a University meeting room as the venue.
All of the other interviews took place within the participant’s own offices, and were
held during working hours. Interviews lasted on average 45 minutes and all
participants consented to the tape recording of the dialogue. A written transcript of
each interview was sent to the participant afterwards, each of which checked and
approved them. I followed each interview with a short written note thanking the
participant for their time.
In preparing for and conducting the interviews, I was aware that my participants were
each working within senior positions, with the potential for high levels of influence
both within the partnership and in their own organisations. Literature exists that deals
with the issue of interviewing such individuals, often referred to as ‘elites’. Harvey
(2006) drew on his doctoral and post-doctoral experiences of interviewing ‘CEOs, Vice-
Presidents, Directors and Senior Partners’ in the Pharmaceutical and Legal sectors
(p.431) to offer guidance to researchers that are about to embark upon ‘elite’
interviews.
Harvey commences with a review of the literature that exists around the definition of
‘elites’. He draws attention to Smith (2006) who points out that a senior role title does
not necessarily confer elite status, whilst Zuckerman (1972) describes an ‘ultra elite’,
being those individuals that have additional influence within an already powerful
group. Harvey accepts that there is a range of valid perspectives around the term
‘elite’, which for him, and in his research, is defined as ‘those who occupy senior
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management and Board level positions within organizations’ (p. 432-433). This
definition has a resonance with my study given that my participants can all be seen to
be falling within this definition.
Harvey advises that the process of gaining the necessary amount of trust should begin
from the researcher’s first contact with the respondent. This should include an open
and transparent approach with regards to the status of the researcher, the breadth,
methods and purpose of the study, and the methods via which data will be stored and
communicated. The issue of confidentiality is particularly important and the
researchers should clearly state if, and how, anonymity will be assured.
Open ended questions allow elites the freedom that they prefer when framing their
responses, but Harvey suggests that these can be combined with closed questions, if
this is required to gather the data necessary for the study. Time is also a factor, with
Harvey advising that ‘it is important to strike the right optimistic/realistic balance to
achieve the best quality data from the most feasible amount of time’ (p. 436).
It is also important for the researcher to understand as far as is possible the wider
contextual environment inhabited by the respondent at the time of the interview.
Harvey recounts a particularly tense interview that he conducted with an elite
participant that was subsequently revealed to have been influenced by a programme
of large-scale redundancies in the elite’s company, and concluded that this
information, which was publicly available, would have been useful to have known
beforehand (p. 437).
Neal and McLaughlin (2009), like Harvey, point out that there are an increasing
number of social science projects that research ‘up’, in that they involve the researcher
interviewing those in positions of power and influence (p. 690). However, they add to
the work by Smith (2006) and Cochrane (1998) that the definition of elites and their
status is neither linear nor necessarily permanent, but rather can only be understood
within the wider context within which elites not only operate, but are perceived by
others. Like Harvey, Neal and McLaughlin draw on their own experiences, which in this
case was their research into the work of the Commission on the Future of Multi-Ethic
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Britain, which was made up of twenty-three senior figures from public policy, media,
and university sectors.
Neal and McLaughlin add to the literature by explaining that in the context of their
research project, the ‘elite’ status of the participants was challenged by the highly
negative, public, and personal accounts in multiple media outlets that followed in the
wake of the Commission’s report and recommendations. They conclude that their
experience of interviewing the Commissioners, and the data gathered therein, serves
to add to the argument in the existing literature that elite status is neither linear nor
permanent, rather it is multi-layered and constantly shifting across different
environments and in different times.
With regards to my participants, it is true that their senior status would not necessarily
extend outside of their immediate partnership or locality; whilst their roles would
likely confer a certain amount of respect and profile, they would not necessarily be
able to exert influence merely by virtue of their roles or individual profiles. However, a
number of them would have a voice that would be heard by Government as part of a
wider group of senior clinical academic leaders, and all of them had the ability to
influence, to different degrees, their partnerships, organisations, and immediate
localities. In addition, all were working within what would be externally viewed as
senior roles with responsibilities or within highly senior leadership roles, and therefore
I was sensitive to this in terms of both ensuring that my interviews were conducted
such that I was able to gather high quality data, but also in terms of participant
confidentiality.
Each of the participants had received an information sheet (or ‘protocol’) regarding my
research project prior to the interview. This is included as Appendix One. In addition to
this I gave a verbal summary to each participant of myself as the researcher, explaining
my career path to date as well as my progression through the EdD. I also explained the
nature of the study, being qualitative in nature, and in some instances this led to a
short pre-interview dialogue with the participants about the future usage of the
research. I did not include these conversations in the subsequent data analysis but
they may have indirectly influenced my thinking around the applicability of the
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research to practice and to future academic thinking.
This time before the interview allowed me to establish an open and trustful style to
the dialogue, and I attempted to sustain this throughout by actively listening to the
participants, and checking that I had understood their point by saying things such as
‘So if I understand you correctly, you are saying that…’ and ‘Could you tell me a little
bit more about that’. In this sense I would describe my interviews as semi-structured
rather than structured, as I gave myself the option of asking supplementary questions
and prompting participants in terms of how they felt about certain key concepts.
I explained to each of the Participants that I would be using the data in a thesis, which
would be publicly available, and forwarded a transcript of the interview to them for
their review and approval. This followed the ‘democratic principle’ that participants
have the moral right to review their data prior to it being made public (Smith 1984
cited in King & Horrocks (2010) p. 121) but is not without its challenges, particularly
where participants begin to amend what they perceive to be ‘poor grammar’ or
‘colloquialisms’ that the researcher would prefer to retain in order to stay true to the
contextual framework within which the interview took place (King & Horrocks p. 121).
Despite these challenges, I decided that allowing my participants the opportunity to
review the transcripts was ethically sound, and in the event all of my participants
approved my written records of the interviews, without requesting any changes.
In taking care to ensure anonymity of my elite participants, I was aware that aligning
role descriptors to them may be unhelpful, and, despite the fact the such role
descriptors may have added interesting contextual information to the thesis, I decided
that on balance it was preferable to simply identify the participants by the case study
partnership that they were part of (either 1 or 2) and their own participant number,
such that I had the following list of participants,
• 1:1; 1:2; 1:3; 1:4: all being part of case study partnership 1;
• 2:5; 2:6; 2.7; 2.8; 2.9; 2.10 all being part of case study partnership 2.
Thus, for example, participant 1:2 denotes participant 2 from case study 1. My
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approach to protecting the identity of my participants concurs with the guidance of
professional bodies in this area, including for example the British Sociological
Association’s Statement of Ethical Practice (2002; updated 2004). (King & Horrocks;
2010 p. 117), and of scholarly research ethics that participants in research projects
should be protected from harm (Sapsford & Jupp; 1996 p. 319).
A further factor that is relevant in terms of protecting the identities of those that were
interviewed, is the fact that many of the participants have subsequently moved into
different roles, outside of the NHS-University partnership, and therefore this is also
helpful in terms of preserving anonymity.
The semi-structured nature also meant that I didn’t have to ask the question in
regimented style, rather I allowed the conversations to flow, and would ask the
questions as I felt they best worked within the overall dialogue. In terms of both the
questions and my interviewer style, I decided to run three mock interviews in which I
could hone these into a format that I felt would best support the gathering of data in
the interpretative style. The three mock interviews were conducted with a clinical
academic who I had worked with a little on a separate research project, the Director of
an NHS Hospital Research Office, and a colleague from a partner University. All were
outside of the two case studies. The process of running trial interviews made me
realise that my initial questions were closed rather than open; I subsequently
redrafted them to support a more flexible dialogue. I also found the trial very useful
for getting used to the technology; in one of the trial interviews my tape recorder had
not been switched on, and, had it been one of my ‘real’ interviews I would
subsequently have lost all of the data. I learnt from this, and in the interviews was
careful to ensure that the technology was properly set up; relating the previous
mishap to the participants also served as something of an ice-breaker.
3.7.4 Data analysis
A rich set of data emerged from each of the ten participant interviews, which were
transcribed verbatim. A manual coding process initially identified a long-list of 80
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categories. Further analysis was undertaken to identify linkages and synergies between
the categories. The process allowed me to ‘collect and rigorously examine the
narrative accounts’ of the participants within my two case study partnerships (Miller &
Glasser in Silverman 2011, p.144).
A manual approach was taken to the coding of the participant interview data, with the
codes emerging from the data rather than being developed prior to the data collection,
hence being ‘faithful to the data’ (Coleman 2011; p. 560). Other case study researchers
have utilized IT software packages to assist in the transcribing and categorization of
case study data. Carcary (2011) outlines her personal experience of using such a
package in the analysis of data gathered across multiple sites from ’49’ participants
(p.1). Like Carcary, and other case study researchers, I identified ‘in vitro’ (‘codes that
emerge directly from the informants interview transcripts’ p.14) and ‘in vitro’ data
(‘terms that the researcher creates to encapsulate a concept discussion by an
informant’ p.16). However, I took a manual, desk-based approach to this, rather than
using an IT programme to assist me. This was appropriate in terms of the amount of
data being collected, but was also a personal choice to take a hermeneutic approach to
the understanding of the participant’s views and behaviours; emerging myself in the
data, by firstly transcribing and then manually coding it, helped me to do this.
Auerbach and Silverman (2003) provide an example of coding interview transcripts for
a ‘Haitian Father’s Study’ (p.35). Here, the researchers took a ‘step by step’ approach
(p.35); firstly, text that was not relevant to the ‘research concern’ was removed; then
‘repeating ideas’ were identified, these being things mentioned by more than one
participant; groups of repeating ideas were subsequently organized into themes. I
drew upon this approach, and my coding method was undertaken as follows; first, I
transcribed each interview in tabular format, transcribing precisely the taped recording
of the discussion. Thus the table contained the Interviewer asking the question,
followed by the participant’s response to it. The third column was titled ‘Codes’, and in
here I jotted down, in real time, potential codes from the participant’s responses, as
they occurred to me whilst transcribing the data, so the table looked as follows:
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Who Transcript Code
Interview Text Here N/a
Participant Text Here
Table 3.1: Example of my interview transcription table
At the end of each process of transcription and manual coding, I extracted all of the
codes from the table and replicated them in the top right hand corner of the sheet, so
that they were easily visible when referring back to the transcript. I repeated this
process for each of the interviews. At the culmination of the interviews, I created a
separate table for each of my ten interview questions, and into that table I copied each
of the participant responses and potential codes, using the Word copy and paste
option. This allowed me to recognise patterns within the questions, and I manually
analysed each question separately, finishing one before progressing to the other,
following which I began to cross-reference the data within the questions, drawing out
the cross-cutting themes.
My coding progressed from ‘initial coding’ to ‘focused coding’ (Bryman, 2013; p. 569),
with me initially creating a great many codes, on a line-by-line basis. Bryman refers to
this initial process as being the ‘first steps towards making sense’ of the data. During
the second, focused stage of the process, many of the codes were removed as not
being relevant to the research question. Data that were not relevant within the two
units of analysis were removed and stored in a separate document.
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Chapter 4. Findings
4.1 Overview
Ten participants, all senior clinical academics, each with leadership responsibilities,
were interviewed in an interpretive style from across the two units of analysis. After
seven interviews, the data was becoming saturated (Baker & Edwards) 2012. In
addition, the senior and ‘elite’ nature of each of my participants meant that they were
harder to access, as referred to by Adler & Adler (2012),
‘ a small number of cases, or subjects, may be extremely valuable and
represent adequate numbers for a research project. This is especially true for
studying…hard to access population such as …elites’ (in Baker & Edwards, p.12).
This, given the saturation of the data, meant that I was able to cease data collection at
ten participant interviews, having sufficient data to ‘generate a subjective
understanding of how and why’ (Baker & Edwards p. 8) my two local partnerships were
interacting with the national policy environment for translational clinical research, and
being in a position of theoretical saturation, where ‘additional cases’ were not
modifying ‘my coding frame’ (Hancock et. al. 2007). Should the data not have been
saturated, I would have continued with my data collection until such time as saturation
occurred.
Eighty codes emerged from the initial coding phase. Many were duplicating codes and
others were not relevant to the research question. During the focused phase of the
analysis, I reduced the number of codes to forty-eight and via a process of data
clustering, I observed that there was a great deal of synergy across both units of
analysis.
I discovered three consistent themes across the two partnerships, these being my
‘practitioner generated themes’ that in Huxham & Vangen’s framework of
collaborative advantage are those that participants (‘practitioners’) perceive to be of
importance to the success or failure of the partnership (Huxham & Vangen p. 38). My
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three themes, each contained categories (nine in total) and constituent codes. Thus, I
follow the framework suggested by Huxham & Vangen in presenting practitioner
generated themes, and within each theme, providing additional detail to provide a
greater understanding of the participants’ views and perceptions
The Huxham & Vangen theory of collaborative advantage is based around the
development of a series of ‘practitioner-generated themes’ (2001 p. 8) and is therefore
a ‘themes based theory of collaboration’ (2005 p. 30). I have followed this approach in
my data analysis and discussion, such that I present three key themes, which have
been developed out of the practitioner responses to my questions and represent the
practitioner perspectives of collaboration within the two NHS-University partnerships. I
analyse each of the themes in detail, drawing upon the categories and codes that
together make the theme, reflecting the complexity and richness of data that exist
within each theme. Strauss (1987) recognised that complexity that can exist within
social constructs and refers to the type of investigation that I have undertaken as a
‘detailed, intensive microscopic examination of the data in order to bring out the
amazing complexities’ (p.10).
Huxham & Vangen highlight that within a theme there can be divergence of opinion.
This does not mean that the theme is unworthy of inclusion, but rather illustrates that
attention to this particular theme is required in order to advance the collaboration,
and I suggest this applies equally to my study, where there are a range of views
expressed by the participants within each of themes.
The Tables 4.2 to 4.4 summarise the main three practitioner generated themes with
the constituent categories and codes, whilst the Mind Maps in Chapter Four present
the data in more detail. These mind maps draw upon the ‘conceptual frameworks’
presented by Huxham & Vangen in their 2003 research into partnership managers. In
this paper, they develop a linked series of clustered themes out of data gathered
ethnographically from thirteen public sector partnerships (p. 63). In presenting my
data in a similar fashion, I form a conceptual framework for NHS-University
partnerships in the context of delivering translational clinical research. My framework
is based around the three practitioner generated themes of external factors, people,
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and organisations.
Practitioner Generated Theme One: External Factors
Categories Codes
(1) Regionalism Academic Perspective
Policies
Localism
(2) Government Funding & Policies Drivers
Positive
Volume
(3) Clinical Academics Recruitment Policy
Pipeline
Cluster
Rare
Practitioner Generated Theme Two: People
Categories Codes
(4) Leadership Communication
Leaders
Models
(5) Communication Tension
Strategy
Language
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Practitioner Generated Theme Three: Organisations
Categories Codes
(6) Building a Joint Research Strategy People
Key Performance Indicators
Health System
Strengths
(7) Governance Barrier
Solution?
Disproportionate
(8) Cultures Higher Education Institutions (HEIs)
NHS
(9) Partnerships Benefits
Tables 4.1 to 4.3: Three themes, with categories and main codes
A set of data emerged that had a number of patterns within it, and I sought to capture
these patterns via a hermeneutic approach to coding analysis (Moses & Knutsen p.
134). The three overarching themes of ‘External Factors’, ‘People’ and ‘Organisations’,
as presented in Figure 4.1 below. In each of these Themes sit a number of constituent
categories, and these are presented within Figure 4.2. These provide a useful and
easily digestible way of understanding the commonality of participant data. The nature
of the interviews, being semi-structured and open, meant that I was able to gather and
code a large amount of supportive data that together make up the different
categories.
The entirety of this data is presented in a mind-map format at Figure 4.3. This
demonstrates that across the two units of analysis, the participants expressed views as
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regards NHS-University partnerships firstly in terms of the ‘External Factors’ that
impact upon the phenomena (and I have ordered these views into the categories of
Regionalism, Government Funding & Policies and Clinical Academics); secondly with
regards to ‘People’ (grouped into Leadership & the Power of Personalities and
Communication) and finally, with reference to ‘Organisations’ (Building a Joint
Research Strategy; Governance and Administration; Organisational Cultures, and
Partnerships). I draw upon Huxham & Vangen’s theory of collaborative advantage to
define these themes as ‘practitioner generated’, as they represent the perceptions of
my participants, all of whom are active members of the two case study partnerships.
Figure 4.1: Pie chart demonstrating three overarching practitioner generated themes
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Figure 4.2: Three themes with constituent categories
The Mind Map in Figure 4.3 below presents the nine categories with their constituent
codes.
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Figure 4.3: Mind map demonstrating nine categories and related codes
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A separate mind map is presented for each of the three themes, showing the constituent
categories and codes within a theme. A small number of participant quotations are
selected throughout as ‘in vivo’ codes, reflecting the fact that these views are a reflection
of the broader sentiments expressed by the participants within a particular area.
4.2 Theme One: External factors
Figure 4.4 below demonstrates that Theme One (External Factors) contains within it
Categories One (Regionalism) Two (Government Funding and Policies) and Three (Clinical
Academics). The codes that sit within each of the categories are also presented in Figure
4.4, and are discussed in the narrative below.
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Figure 4.4: Theme One: (External factors): Categories 1-3 with constituent codes
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4.2.1 Regionalism
‘Leave pride at the door’ (2:6)
Participants from across both units of analysis raised the importance of the region and
a sense of ‘place’ to NHS – University research partnerships. Table 5 presents the
seven codes that make up the ‘regionalism’ category, which, whilst not being a new
concept, was a highly topical one at the time of the interviews (2014-2015), as
evidenced by the Chancellor’s announcement in 2014 of a programme of devolvement
to new combined authorities working across regional footprints, which was followed in
2015 by the transfer of public health responsibilities from the NHS to Local Authorities.
Regionalism
• Regional NHS-University partnerships a conduit for improving research &
clinical outcomes via a regional approach
• Local rivalries within the region
• Leaders accepting need for regional approach despite local mistrust &
rivalry (more an issue for NHS Trust than universities)
o Compared to individual academics – most concerned with
international impact
• Divided national system: regional disparities
• Regional health system includes primary care
• Importance of physical location
o - It matters;
o - It doesn’t matter and can be counter-productive.
Table 4.4: Codes within the ‘Regionalism’ category
A number of my participants spoke of the unique opportunities that they believed
regional partnerships could bring to the organisation and delivery of specific research
themes. This was particularly prevalent within the group of participants that were
either leading a Faculty or Research Institute, and it is possible that they were being
influenced by the wider programme of regional devolvement that was taking place at
the time of my interviews,
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‘I would like to see a bringing together of the (names location) for genomics,
working as a single entity…making the (names location) the premier region in
the country’ (1:4) (Note that the identity of the location has been removed to
protect confidentiality).
‘I am looking….towards regional alliances’ (2:9)
However, a rather different view about regionalism was expressed by the clinical
academics, who did not have leadership responsibilities for a Faculty or Institute, and
who demonstrated a narrower definition of partnership. This group referred to the
concept of regionalism within the context of local competition,
‘So absolutely they are a competitor’ (2:6)
‘There is a competition between (regions) and so it’s about identifying the
ground that is unique to us’ (2:7)
‘There are some conflicts between the Trusts’ (1:1)
There were also some clinical academics that expressed a preference for an
international, rather than regional, focus to their research partnerships and
engagement,
‘The wider international community derives the collective benefit of the
research…. I'm not sure how we go that extra step in terms of making our
research visible to the people in the community around us’ (2:7)
‘If I want to achieve impact from my research, I’ll publish it in a journal, where it
will reach thousands of people and maybe at some point change practice, but
I’m not going to go and speak to the local partnership and maybe reach twenty
people’ (1:2)
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Despite this caution, there was a broad acceptance that NHS-University partnerships
need to move towards an increasingly collaborative approach within a regional
context. The quote below demonstrates a theme that became a constant thread
throughout my study – the need to ‘leave pride at the door’, in order to collaborate
with regional partners that in the past have been competitors, within closer and more
mature partnership arrangements,
‘We need to be honest and look at them and think about what we might have
that would be unique and different…Leave pride at the door’ (2:6) (emphasis
added)
The importance of physical location (specifically the proximity between the Hospital
and the Medical School) was an area of some divergence, with two different opinions
being expressed by the participant group. Again, a difference emerged between the
more senior respondents with wider leadership responsibilities, and senior clinical
academics operating at the level of active researcher but with less responsibility for a
Faculty or Institute. Below the views of the senior leaders are presented first, and later
these are contrasted with the perspectives of the clinical academics,
‘Unlike the other players, we don’t have a co-located university hospital. This
makes a big difference. If you are five miles away, you might as well be 50 miles
away. In order for us to change the culture of the hospital, actually have those
organic relationships, this is a major problem (2:9)
‘I would love to be on one site. It would make a huge difference to both
organisations…. At the moment there is a bit of the hospital that is the Medical
School behind a locked door with a swipe card and the message is we are
researchers and we research behind closed doors. And … I can’t get in because
my card doesn’t work’ (2:6) (emphasis added)
The sentiment above expressed by Participant 2:6 that academics ‘research behind
closed doors’ and ‘I can’t get in’, encapsulates the frustrations expressed by some of
the participants around the perceived barriers between University researchers and
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NHS clinicians with an interest in research. There was a strong sense from the NHS
participants that physical co-location would be a practical way of addressing this, but
many of the practicing clinical academics in my study saw things differently - the two
quotes below are taken respectively from one participant that is not co-located with
the partner NHS Trust, and who does not see any personal benefits in changing this,
and secondly from a clinical academic who, despite being co-located still feels
disconnected from the strategy of his NHS-University partnership,
‘Whilst it might make some things easier there are also advantages of
geographic distance so when there is a meeting taking place that they wanted
me to go, if I’m on site it is more difficult for me to say I can’t come or if I’m half
an hour drive away I can say with a clear head no I can’t come across for that’
(2:7)
‘I don’t think there are the means for us to feed in…. I’m pretty sure that if I
called (NAMES DELETED) and said, I really want to talk about how ….my
research could be a key theme…well I’m pretty sure that I would get short shrift
from that so I’m not going to do it’ (1:2)
With regards to the first of these two quotes, it is possible that the participant was
using distance as an excuse not to collaborate, an individualistic approach that
confirms a theme in recent literature around a lack of ‘collectivism’ within clinical
academic medicine (McKinn & Mannion 2015), and explored further within my
‘Conclusions and Recommendations’ Chapter.
The second of the two quotes can be linked back to the in vivo code for this theme.
This participant demonstrates an unwillingness to ‘leave pride at the door’ (2:6), and in
so doing illustrates one of the challenges that appeared to exist within both Case
Studies. This participant is demonstrating a frustrated ability to influence the direction
of the partnership, despite being a senior clinical academic and leader of a Research
Institute. His influence within the University does not appear to extend towards the
NHS-University research partnership, and this confirms the observation of Long et al.
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(2013) whose study of twelve NHS-University partnerships in Australia concluded that
‘key player activity in one setting may not necessarily carry across into another’ (p.8).
4.2.2 Government funding and policies
‘They can’t all be useful, and delivering – can they?’ (1:2)
The second category within the ‘External Factors’ theme was ‘Government Funding
and Policies’ with all of the participants expressing a view about the new national
policy framework for translational clinical research. The national drivers to improve
translational clinical research were broadly seen by the participants are useful, but not
enough. One participant summed up his view on this as,
‘There are external drivers at the national level to see common purpose, but
they are not really strong enough; they have not really had enough impact’
(1:1)
Within ‘Government Funding and Policies’ were six constituent codes, and these are
presented in Table 4.5 below:
Government Funding & Policies
• National drivers useful but not enough
• Too many initiatives and partnerships
• Timescales/shifting government policies
• CLAHRCs
• NIHR
• Unintended consequences of national initiatives
Table 4.5: Codes within the ‘Government funding and policies’ category
There is now a proliferation of national initiatives and partnerships, as outlined in
Chapter Two (Literature Review) that are meant to facilitate translational clinical
research, but within my two units of analysis, these appeared to creating a layer of
96
confusion and uncertainty across the Participant group. Two clinical academics
expressed their frustrations as follows,
‘I think most of us are aware of these different partnerships, but they can’t all
be useful and delivering can they? So we’ve got AHSCs, AHSNs, the Research
Design Service, the CLAHRC. How are we supposed to engage with all of those?’
(1:2) (emphasis added)
‘There are so many of these partnerships and networks now; it’s difficult to see
how we can engage with them all’ (2:5)
There was broad agreement that the NIHR and the CLAHRCs were both in turn
significant and useful additions to the NHS-University translational clinical research
environment, as evidenced by the quotes taken from each of the case studies below,
‘I think things like the CLAHRC initiatives are really important and have made a
big difference’ (1:3)
‘The NIHR bringing in funding streams such as Research for patient Benefit, that
had to come through the Trusts, was absolute genius. It got conversations going
that would never have happened before’ (2:6)
However, a number of participants worried that such programmes may be at the
‘whim of government’ (2:10) and hence not have the necessary longevity.
There was also evidence of some participants believing that there had been
unintended consequences of national initiatives,
‘Alan Millburn’s well-meant intervention to create structured contracts for
hospital consultants….funnily enough it made the consultants more annoyed
with the system. So we managed to pay more and upset people’ (2:9)
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4.2.3 Clinical Academics
The third and final category within the Theme ‘External Factors’ I have defined as
‘Clinical Academics: A crisis in academic medicine?’ which takes the latter element of
its title from the work by Aronson (2011) who asked this question in a national
context.
It may seem counter-intuitive to place ‘clinical academics’ within the Theme ‘External
Factors’, but I have done this precisely because other commentators such as Aronson
are defining this as a national challenge, one that exists outside of the two case study
partnerships, but is nonetheless critical to them.
However, whilst being a national challenge, my participants suggested that it is a
particular barrier for those partnerships that operate outside of the Southeast.
The in vivo code for this category is outlined below. It demonstrates the strong view
that emerged from the participants around the need to grow their own pipeline of
clinical academics, or,
‘… grow the next generation of investigators’ (2:7)
There are seven codes within the category and these are outlined in Table 4.6 below:
Clinical Academics: A Crisis in Academic Medicine?
• University recruitment policy
• Trust recruitment policy
• Changes to clinical training
• Practical challenges of joint appointments
• Developing a pipeline of clinical academics/recruitment policy
• Concentration of clinical academics in Southeast
• Challenges of attracting good people to a specific locality
Table 4.6: Codes within the ‘Clinical Academics’ category
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One study participant stated, ‘the problem we have nationally is that we have
managed to screw up our outstanding pipeline of translational researchers’. (1:4) My
case study participants felt that this is a particular issue for regions outside of London
and the Southeast,
‘Medical academics are now like pandas. They started off in the 1960s and
1970s as really quite fearsome carnivorous beasts but a number of pressures
mean that they are now quite sweet little things that have trouble reproducing,
only eat bamboo and you take them and you can’t transplant them out of their
environment. The bamboo rich areas are Imperial, UCL, Cambridge, Edinburgh,
Manchester (so long as it can keep itself) Kings, Queen Marys’ (2:8)
‘I talk to a lot of people around the country now and it’s really clear to me that
this type of work is getting concentrated in fewer places…. if someone is
excellent and wants to come here we will appoint them; but we will be looking
for years’ (2:9)
This problem is one with national and international ramifications. For example in the
US context, Pickering et al. (2015) spoke of the diminishing pipeline of physician-
scientists in the States and beyond, saying ‘the field of translational research has a
major personnel problem’ (p.808).
There was a degree of convergence amongst the more experienced of my participants
that the change to clinical training had inadvertently contributed to the staffing ‘crisis’,
‘In order to get a consultant’s position, clinicians used to have to do a research
project,…. now in order to expedite the training as quickly as possible, clinicians
don’t have to have a higher degree in order to become a consultant and that’s
actually underpinned a lot of the capacity to do research in the NHS’ (1:3)
The recruitment policies of both the NHS and the universities were seen by my
participants as important but not always joined up, an issue complicated by the
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specific pressures of the NHS to deliver clinical services, and the different perceptions
of a clinical academic within the different organisations,
‘When I am making an appointment here, we make an appointment of
somebody who publishes well, gets grants in well, and fits generally, but we
don’t really go out and find out how that works with the NHS Trusts locally’
(1:3)
‘The Trust is now recording a deficit. It wants clinical professors but in quantity
rather than quality’ (2:8)
My participants felt that there were many practical challenges to making joint
appointments work, and drew on their own experiences in making this point,
‘Lots of problems with joint appointments – the usual stuff about both
organisations wanting 100 percent and the poor person in the middle burning
out’ (2:5)
‘In this building around 90% of people are employed on research contracts and
there are already doing ten times more than the academic workload survey
suggests they should be doing’ (2:7)
‘What we find is say a clinical academic funded by the Trust, if they actually
leave, then the Trust really comes under tremendous pressure to change that
into a full-time NHS consultant because they get much more bangs for the buck’
(1:3)
Developing a pipeline of clinical academics that can deliver high standards of clinical
service whilst also being given the flexibility to engage in clinical research, was
emphasised as a priority by most of my study participants, with one stating that the
Trust and University needed to,
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‘Grow the next generation of investigators …in an environment that they can
be nurtured’ (2:7) (emphasis added to demonstrate that this Participant was
suggesting a localised approach to developing a pipeline of clinical academics
to sustain the partnership going forward)
4.3 Theme Two: People
The second theme that emerged from the data was, ‘People’, and it contains within it
the two categories of ‘leadership and the power of personalities’ and ‘communication’.
Figure 4.6 below presents Theme Two, with its constituent categories and related
codes.
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Figure 4.5 Theme Two People: Categories 4 and 5 with constituent codes
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4.3.1 Leadership of translational clinical research
The first category within the ‘People’ theme is ‘leadership of translational clinical
research’. Without exception, the participants referred to the impact that one
individual, or a small group of people, can exert upon the processes and structures
that underpin the delivery of translational clinical research. At the same time,
however, all the study participants expressed a frustration around the lack of suitable
leaders, with case study two partnership in particular demonstrating some real
concern around how, as a new NHS-University partnership, it would be able to attract
and develop leaders into key positions. Hence the in vivo phrase in the theme is that
provided by a participant from case study Two,
‘It’s a real issue-getting the right leaders’ (2:10)
There are two codes within the category, as demonstrated by Table 4.7 below.
Leadership of translational clinical research
• Leaders
• Communication
Table 4.7: Codes within the ‘Leadership of translational clinical research’ category
Recollecting specific examples of the impact of influential personalities encouraged
many of the participants to consider the merits or otherwise of having one jointly
appointed ‘leader’, working across both the University and the NHS. My study
participants were undecided about this, with some believing that it was a necessary
addition to the governance structure,
‘Having somebody being the Chief Exec plus the Provost, I think that helps, that
will align the strategy’ (1:4)
‘I think having common leadership helps’ (2:8)
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But others disagreeing, and doing so by drawing on their own experiences or on their
perceptions of the problems suffered by other NHS/University partnerships that had
attempted the joint leadership model,
‘The Director of R&D was also the medical lead for the Medical School…. My
perception was that he worked for the Medical School and not for the Trust….
When he left, it was decided at Trust level that we needed someone who was a
Trust employee’ (2:6)’.
‘Imperial had one (a joint university/NHS management structure) but it didn’t
work’ (2:9)
Leadership qualities were discussed in some detail, with the participants again drawing
heavily on their own experiences to encapsulate the characteristics of a leader that
they felt would create an environment conducive to translational clinical research,
‘Having a national role as well to bring a national perspective’ (1:4)
‘Still being a part of the NHS so that he or she understands us’ (2:6)
‘A consistent approach across both organisations’ (1:1)
The lack of strong and available leaders was cited as an issue, drawing synergies with
the earlier theme of regionalism, and the consequences of external funding policies
that have created a clustering of talent in defined geographical areas of the country,
‘It’s a big job and how many people are there out there?’ (2:6)
‘There aren’t many people you can get’ (1:2)
‘It’s a real issue, getting the right leaders. And not those that pass through –
this partnership needs some consistency now’ (2:10) (emphasis added)
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4.3.2 Communication
The second category within the theme ‘People’ is ‘communication’. There are eight
codes that make up the ‘communication’ category, which are presented in Table 4.10
below. The in vivo quotation that I have selected reflects the key message that
emerged from each of the two units of analysis, that participants recognise the
importance of communication, to translate a strong and clear message around
translational clinical research, but at the same time expressed a concern that
communication wasn’t working effectively within the partnership.
The in vivo quotation below suggests that in Case Study Two there was an issue of
translating the vision ‘from the top’ to those on the ground,
‘You can have the big vision from the top but actually people need to sit down
and have a cup of tea together and that’s what isn’t happening’ (2:6)
Communication
• Translating vision to practitioners
• Tensions – individuals
• Bring individuals together
• Tensions – between organisations
• Manage expectations: expect longer term gains rather than quick wins
• Benefit of Non-Executive Directors
• Talking a different language
• Lack of clear strategy – research & recruitments & redundancies
Table 4.8: Codes within the ‘Communication’ category
Participants from both Case Studies outlined some fundamental barriers to
communication, such as the participant below who believed that the communication
of the NHS-University vision was simply not reaching the scientists,
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‘If you were to go up to my lab, and ask the people upstairs who are working
day to day at lecturer level what it was, I think they would struggle to tell you
very much about it at all’ (1:3)
Some further research into the local NHS-University partnerships that have
successfully communicated a vision for translational clinical research would be a useful
addition to the current literature on this subject.
My participants also highlighted that tensions existed at both individual and
organisational levels, as evidenced by the two groups of representative quotes below.
‘Clinicians worry about being seen as the people that just provide the samples
and…. the basic scientists worry about being used as technicians, as analysts,
and overcoming that barrier is one of the big problems’ (1:3)
‘At the last minute they (NHS Trust) decided that the connection was not strong
enough, because they were honorary appointments, so they pulled out two
weeks before submission’ (2:5)
‘The Trusts in (city) fight against each other’ (1:4)
‘We are partners but our priorities are completely different’ (2:6)
The participants believed that such tensions were a barrier to achieving translational
clinical research, and that an important role of a successful NHS-University partnership
is bringing people together,
‘It’s when people start to understand where each other of them is coming from
that you get good non-clinical – clinical relationships. It tends to be very
personal of course, you get to know people’ (1:3))
‘Anything virtually was surmountable with the right relationships’ (2:5)
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Also within the ‘communication’ category, and having a resonance with the cultural
differences that were identified across the NHS and University, was the need to
‘manage expectations’. The NHS participants observed that the short-term nature of
NHS planning created a need within their organisation for a quick turn-around,
something that is often out of step with the time it takes to translate clinical research
outcomes into impact,
‘We don’t really get esoteric research. We are quite short termist really; all our
planning is on an annual cycle, monthly reporting’ (2:6)
The expectation for quick results was not confined to the NHS participants in my study
– the Universities also had expectations and this was particularly the case for the
University in case study two,
‘(the University) is not only ambitious it is also very impatient’ (2:8)
The bringing together of NHS Trusts and Universities within my two case studies to
achieve translational clinical research appeared to be a delicate process, that was
trying to serve two different masters. Leaders from both cultures were trying to
maintain equilibrium in the partnership to keep it together, whilst progress continued
gradually alongside it. But the often fragile nature of the partnerships was never far
away, as illustrated in the following quotes,
It is partly keeping the faith because it’s not going to happen overnight is it?
(1:4)
‘The Chief Execs have to realise that this is not an overnight solution; you have
to be able to invest in it to get the long term returns’ (2:10)
And we need a big thing, a national award or a major publication (2:19)
‘… we need some paradigm projects out there …then people will say ‘actually
yes I can see how it will start helping me as well’ (1:1)
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Achieving this joint approach to outcomes (or impact) from translational clinical
research appeared to have been made more difficult within the two units of analysis
by a difference in language across the NHS and University partners,
‘We meet with the University. And it is so difficult because they don’t speak the
same language’ (2:6) (NHS Participant referring to the University)
‘If you speak to some of our rheumatologists, the rheumatologists here that are
doing research, they are talking about specific problems that patients
experience and how you might overcome them; our researchers tend to be
taking much more of a longer term aim’ (1:3) (University Participant referring to
communication problems)
In this sense my study confirmed the views of Pickering et al. (2015) that ‘scientists
and physicians’ speak different languages’ (p. 810). This appeared to be a deep-rooted
problem that requires meaningful engagement to resolve within the context of an
NHS-University partnership. For example, the quotes above both came from
experienced NHS and University participants. It was clear from them that the
difficulties in reaching a common understanding often prevented real progress being
made.
4.4 Theme Three: Organisations
The third theme is ‘Organisations’, which consists of the categories ‘building a joint
research strategy’, ‘governance and administration’, ‘organisational cultures’, and
‘partnership’. The Theme with its constituent Categories and related Codes is
presented below in Figure 4.7.
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Figure 4.6: Theme Three: (Organisations): Categories 6-9 with constituent codes
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4.4.1 Building a joint research strategy
The first category within the Theme ‘Organisations’ was based around the way that
different organisations (the NHS Trust, the University) need to work together to build a
joint research strategy that does more than simply span across the two organisations.
The in vivo quotation below demonstrates the strong message that I received from the
data in this theme was that all of the participants within the case studies were
committed, at a personal and theoretical level, to the delivery of translational clinical
research in a joint context,
‘For research purposes the NHS provides a huge opportunity and
we have to embrace that’ (1:4)
However, the participant data revealed that, despite this commitment, the business of
actually developing a joint strategy that both organisations could buy-into was a far
from simple process.
There are five codes that make up ‘building a joint research strategy, outlined in Table
4.9 below.
Building a Joint Research Strategy
• Base around existing areas of clinical excellence and research strength
• Need to embed a research culture in the NHS in order to deliver a joint
strategy**
• Research in the NHS
• Lack of research time for NHS Staff
• Joint metrics or Key Performance Indicators an important factor
** this code is also relevant to the Category ‘Organisational Cultures’
Table 4.9: Codes within the ‘Building a joint research strategy’ category
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There was broad agreement, amongst the participants and across the two units of
analysis, that the most effective way of catalysing effective translational clinical
research was to build a research strategy around existing areas of NHS clinical
excellence and University research strength. However, what also emerged was a
divergence between the participants as to which strengths the two organisations
should work on together and this created a rather confusing picture, as demonstrated
by the two contrasting quotes below taken from case study two. The emphasis added
to each quote demonstrated that the University Participant (2.9) was seeking areas of
joint strength in the Trust and Medical School as themes on which to build. The NHS
Trust participant, in contrast, was saying that the Trust would build around their own
clinical strengths, whether or not these were aligned to the Medical School,
‘ What we have to try to do, I think, but it’s a tough one, is to identify areas
within the Trust that either already have the status of specialty services or
could do and where the medical school has research excellence, and focus
upon those as areas upon which you could being to build’ (2:9).
‘We are trying to build things around our clinical strengths, which may or may
not have alignment with our medical school’ (2:6) (emphasis added in both
quotes to highlight the difference in approach across the two case study
partnerships)
The second component raised by participants as key to the development of an
effective joint research strategy was the need for a research culture within the NHS
Trust. There was also broad agreement that the NIHR has done ‘really essential’ work
to embed a ‘research culture into the policy, procedures, and practices of the NHS’
(2.19). Another participant favourably compared the current environment to that of
the past,
‘Going from the Collier funding which was unidentifiable in trust budgets to ring
fenced money that has terms and conditions linked to it that will be revoked if
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you don’t follow the terms and conditions, I think that has been a revolution’
(2:7)
However, despite this, the participants concurred that NHS clinical pressures continue
to take precedence over research and this makes the building of an effective joint
strategy a difficult one. As one participant put it, ‘I think this whole thing about
releasing people and making time for them to do research is very difficult.’ (2:18).
Another provided a practical example of pressures faced by clinical academics that are
trying to find time to do research,
‘A number of our clinical academics are just run off their feet with clinical work.
It (research) is an objective for them, but the pressure of patients is such that
they are struggling to do that…. we’ve got a couple of very bright young
people….they really struggle to find any time to do research’ (1:3)
A participant in the other case study site confirmed this, stating,
‘One of our departments is running a vacancy rate of 18.4% on a service of only
30 people. And then I say I want two of your staff to do a research project for 12
months- it’s so difficult’ (2:6)
In terms of what a joint research strategy should look like, and how success should be
measured, the participants all sought to identify the types of performance indicators
that could be used to measure success. However, in analysing the participant views on
this, it was clear to me that different metrics appealed to those from the University
context, and those with more allegiance to the NHS Trust, and therefore finding a
common ground is not easy.
One participant accepted that it is a ‘problem’ trying to find ‘Key Performance
Indicators that are meaningful in both organisations’ (2.15). University staff talked
about the NHS ‘obsession’ (2.5) with patient numbers, something that doesn’t drive
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research in the university context and therefore can put the two organisations into
direct conflict with each other,
‘One other thing is a cultural barrier, is this obsession of the Trusts around
numbers of patients on trials…. It can be so counter-productive’ (2:5)
Most of the University participants could see the personal benefits for them in terms
of access to the NHS, as defined below,
‘The advantage to me is that maybe I can get access to patients for my research
more easily and therefore I can get better papers for the university, more
income’ (1:3)
But there was less agreement as regards joint performance measures that would
appeal equally to the NHS and the University, the same participant accepting that,
‘You can see the university benefiting, but the biggest challenge is to actually
show that the NHS is benefitting from this’ (1:3)
It was also interesting to note that whilst there was a fair amount of discussion about
how to engage the NHS in targets that matter to them, there was also a concern
amongst some clinical academics that this shouldn’t be taken too far. One participant,
when discussing the idea of the University placing a satellite Clinical Trials Unit into the
local hospital said,
‘It is something that will need to be carefully managed in terms of targets, so
that the expertise of the Clinical Trials Unit continues to be appropriately
focussed on getting in large grants….as opposed to resource that becomes
sucked into small projects led by clinicians’ (2:7) (emphasis added)
The emphasis has been added to the participant quote to draw attention to the fact
that NHS Trust projects were less worthy, in the view of the participant, than large
grants.
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Some of my study participants felt that targets, based around collaboration with the
respective organisations, directly linked to promotion criteria, would have the most
meaning to the clinical academic community, and that if the senior managers from the
NHS and University could embed such targets within their respective organisations,
there was a potential that individual behaviour would be more focussed on supporting
the partnership to achieve translational clinical research. One participant made a
direct comparison with the Research Excellence Framework, suggesting that this had
been proven to direct behaviours, and that a similar message should be given to
employees from both organisations with regards to joint objectives,
‘The REF signal is heard loud and clear and that does make people change their
behaviours. The signals that are sent about advancement, certainly up to chair
level, are very clear and do influence people’ (1:1)
It was therefore apparent that, across my participant group, there was a strong feeling
that the setting of agreed joint targets was some way off, despite this being seen as a
crucial driver for bringing together joint translational research projects. It also seemed
to be the case that the targets that were in existence were not helping the Case
Studies to achieve a joint approach. Rather, they were working against this, and
causing frustration at the level of the clinical academics.
4.4.2 Clinical research governance
The second category within the Theme ‘Organisations’ was ‘Clinical Research
Governance’, this being related to the NHS administration processes that must be
navigated by anyone wishing to deliver a research project that involves either NHS
staff and/or patients. Within the Category were the four codes outlined in Table 4.10
below, all of which were linked to a general feeling, particularly amongst the practising
clinical academics, that such systems of administration had become a key barrier to
clinical trials and health research.
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The in vivo quotation selected for this theme was the one that best reflected the
overall sentiments of the responses in this section,
‘Some of the Trusts are so slow at giving you the R&D clearance…. I think it
slows down the research to such an extent that it is nearly not possible to do
it (2:5)
Clinical research governance
• Governance of clinical trials as a barrier
• The new HTA system
• Increased role of Clinical Research Networks
• Over management
Table 4.10: Codes within the ‘Clinical research governance’ category
The governance of clinical trials emerged as an emotive subject, particularly from the
group of participants that are actively involved in delivering health projects in clinical
settings. The main issue cited were the governance checks that are carried out by the
NHS, as can be seen from the quote below,
‘We have had really big problems in trying to get through the University and
NHS governance…. we’ve had incredible delays in getting that work through’
(1:3)
A number of participants provided practical examples of the problems that they had
experienced,
‘We have one where we had the first approach to ethics and then it was over a
year before we could actually start’ (1:3)
‘We had 22 different trusts and it was awful. It has been a total pain’ (2:18)
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In case study partnership one, progress had been made to establish some joined up
systems of governance under the aegis of a Joint Research Office, and this was seen as
a very positive step, the following quote being representative of the general view,
‘The one thing that I do think is fantastic is the Joint Research Office; that is
terrific’ (1:2)
Case study partnership two had not progressed towards a Joint Research Office, but
along with the participants, in Case Study One, welcomed the planned improvements
to NHS Research Governance that were being introduced by Health Research Authority
(HRA) during 2015 and into 2016. This universal welcome of a potentially more
pragmatic approach to research governance can be illustrated by the quote from
Participant 2:10,
‘What I hope will be a really positive development will be the HRA development
around new R&D governance procedures’ (2:10)
However, some of the more experienced of those interviewed, who have seen systems
come and go, offered a cautionary note with regards to too much over management
and over regulation, believing this to be unnecessarily stifling of creativity and local
partnership. Participants drew on their experience to emphasise their point,
’But anyway if you look at British medicine we did do amazing things, and we
did it without having all of these structures and management…But then we
fragmented the system more by actually saying ‘you are university staff and
you’re separate, and those are separate, and so on’ (2:9)
‘Now what I think we are doing is trying to find solutions to problems we
created over the last 20 years’ (1:3)
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4.4.3 Organisational Cultures
The third category within the Theme, ‘Organisations’ was ‘organisational cultures’.
The two codes within ‘Organisational Cultures’ are presented in Table 4.11 below.
Organisational cultures
• Perceptions of university culture
• Perceptions of NHS culture
Table 4.11: Codes within the ‘Organisational cultures’ category
The category was based around the views that were expressed in the Case Studies
about the different cultures that exist within the NHS and the University
environments. There is no in vivo quote within this section, as the sentiments are
better expressed by the two quotations below, that different organisational cultures
exist between NHS Trusts and Universities at a macro level, but that there are also
differences within the research cultures of different Trusts within the NHS,
‘The health service is definitely different from universities; the universities
definitely have an individualised way of working which brings out a certain type
of personality and certain personality traits’ (1:1)
‘You get a different research culture in different trusts… it is a mistake to think
that you can just slot into an existing infrastructure’ (2:5)
4.4.4 Partnerships
The final category within the Theme ‘Organisations’ is ‘partnerships’ of which there are
six constituent codes, outlined in Table 4.12 below:
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Partnerships
• Selecting your partner
• Presenting a unified image
• Co-ordinated governance
• Strategic and tactical support
• Aligned strategies
• Promotions based around joint vision
Table 4.12 Codes within the ‘Partnerships’ category
There was an agreement that organisations should be free to look outside of the
partnership for collaborators, where there is a strategic rationale to do so,
‘As a medical school we were partnering with the closest….but (these)
objectives can probably also be realised by partnering with other NHS
organisations’ (2:7)
‘When I look at our local education partnerships and our research partnerships
…. With research we are still looking at half dozen’ (2:9)
However, alongside this acceptance was a view that by collaborating outside of the
partnership, there was a risk that a confusing vision would be presented to external
stakeholders,
‘I think potential funders and investors can be disappointed when they
encounter such a heterogonous group of organisations’ (1:1)
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Some of my participants felt that a more formal partnership could assist in helping
clinical academics to ‘overcome some of the governance hurdles’ (1:4), whilst also
offering more effective strategic and tactical support,
‘Matching people up for big funding opportunities, providing strategic and
tactical support for big funding opportunities’ (1:1)
‘It allows me to engage with the clinicians there and to see what are the things
that they are really interested in’ (2:5)
And as a means by which clinical and academic strategies could be aligned, thereby
creating joint strategies for translational clinical research,
‘Aligning strategies, understanding what they are doing, and them
understanding what we are doing, and then getting that interaction between
individuals working’ (1:3)
‘Because how often do the chief executives from the different trusts within the
region meet with each other–very rarely – so you know this actually brings
them together, and they agree a purpose – a common purpose – and that’s a
huge thing’ (1:4)
‘Signing up to long term commitment to do something in certain areas would be
a very useful thing’ (1:3)
There was also a suggestion that promotions for clinical academics could be formally
tied into a joint vision for clinical academic research,
‘I think people should be able to perceive that they are going to get the rewards
that they want for career advancement only within the framework of common
working’ (1:1)
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This idea of creating new incentives to support joint working may be aided by the
increasingly important Research Impact concept, which could over time create an
environment within universities that is more conducive to supporting impact, this in
turn being closely linked to translational clinical research.
4.5 Definition of translational clinical research
In Chapter 2, I presented examples of literature which demonstrates the complexities
that have existed around the definition of ‘translational clinical research’. (Boaz et al.
2011). My study participants were asked to provide their definition of translational
clinical research. The responses are provided below. Emphasis has been added to
demonstrate common themes that emerged from these definitions. In my literature
review, I demonstrated that there had been a lack of consensus as to the meaning of
translational clinical research, but in contrast, my study participants were in broad
agreement about what the term meant to them, therefore adding to the current body
of knowledge in this area.
Whilst individuals had their own experience of research to guide them in their
definition, some common themes emerged, particularly around translation being
concerned with public health and with getting research outputs into the clinical or
health care setting. It is therefore possible that the political tensions and complexities
demonstrated in the literature around the definition of translational clinical research
simply don’t translate to the local level. Alternatively, it could also be that the
increased funding that is now available from the NIHR means that stakeholders are
less concerned with fine-tuning the definition,
‘It’s taking something that is fit for one purpose and adapting it to another…..
And that can be medicine, or it can be a psychological intervention, or it can be
a pathway of care within health care’ (1:1)
‘Everything that we do in the Institute is translational research….I’ve been
falling out recently with (name) about this – she says that I can’t class our
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research as research and Knowledge Exchange. Why not? It is both of those
things’ (1:2)
‘There are four different gaps in translational research….number one is
discovery number two is clinical validity and clinical utility number three is
implementation and number four is public health’ (1:4)
‘It actually slightly annoys me if people say about implementation it’s just
‘bench to bedside’ because it is about actually getting it used in practice. Both
are important and it’s not one or the other. It’s pointless getting it to the
bedside if no one uses it’ (2:5)
‘I see the continuum and I work on the T2 gap and getting stuff that we find on
the campus into the clinic through doing randomised controlled trials’ (2:7)
‘It’s simply translating science and discovery into tangible benefits for human
and public health’ (2:9)
(Emphasis has been added throughout to demonstrate key phrases)
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Chapter Five: Data analysis and recommendations
5.1 Drawing on the theory of collaborative advantage
In Chapter Four I presented a number of practitioner derived themes that had
emerged following a period of detailed data analysis. Huxham and Vangen (2005)
contend that the themes derived from consistently raised practitioner perspectives are
‘extremely complex under the surface’ (p. 31), and my three overarching themes are
underpinned by my detailed analysis of the categories and codes that make them up.
This is in line with the approach suggested by the theory of collaborative advantage,
being ‘concerned with further exploration of the issues underlying the themes’ (p. 33),
and advocating that a detailed exploration of issues within each theme can be
undertaken to bring new knowledge to a range of collaborative structures.
At the core of the theory of collaborative advantage is a stated desire to be useful to
practitioners in a real-life settings. However, Huxham & Vangen do not claim that their
theoretical framework offers any ‘simple prescriptions’ (p. 34) for future best practice.
Instead, they argue that by conceptualising the views and concerns of practitioners
within a thematic structure, they provide a different lens through which practitioners
can view the challenge of collaboration, and this both informs and allows for a more
reflective assessment of next steps,
‘simply understanding that the problems that are being experienced are
inevitable can be empowering’ (p. 39-40).
In drawing upon this theory, in the preceding chapter I presented a series of
practitioner generated themes that would make sense to others that are seeking to
collaborate in similar settings. These themes each consisted of a series of categories
and codes, as outlined in the Mind Map that was presented as Figure 4.3, and is
represented below as a reminder of the detail that lies beneath each themes:
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Figure 4.3: Mind map demonstrating nine categories and related code
123
Huxham & Vangen’s theory of collaborative advantage has within it twelve practitioner
based perspectives, or themes. These are,
‘common aims, working practices, resources, communication and language,
commitment and determination, culture, power, trust, compromise,
accountability, democracy and equality, and risk’ (2005; p. 59).
However, they do not provide a detailed analysis of each one, this being something
that can develop over time in reflection of the evolving nature of the themes within
the theory. Likewise, I have selected for detailed analysis in this chapter those
categories which emerged as the strongest in terms of consistent or high volume
practitioner perspectives. The others have been presented in the mind-maps to
demonstrate the breadth of data gathered.
I present a picture for practitioners within NHS-University partnerships that is relatable
to their practical experiences, and is of practical use to them. I follow the approach
taken by Huxham & Vangen (2000) under which ‘gradually clusters of related ideas
began to emerge. Concepts deriving from the literature were also included and linked
to data items or interpretations’ (p. 1163).
The approach that I have taken highlights those areas that senior practitioners and
leaders shall have to give attention to, in order for the NHS-University partnerships to
successfully deliver translational clinical research (Huxham & Vangen 2005; p. 40-41),
without providing any firm conclusions, this also being in line with my interpretative
methodological perspective, which accepts the hermeneutic nature of reality as a
learned experience in a social world that is forever changing.
In my study, some of the policy generated themes outlined in my literature review
were either not mentioned by my participants, or were not seen by them as significant
concepts. This was particularly the case in two key areas, ‘research impact’ as a new
concept with regards to the Research Excellence Framework, and the importance of
124
precisely defining ‘translational clinical research’. Huxham & Vangen record a similar
observation with regards to the concept of leadership, which, although not referred to
by their participants, was never the less seen as an important concept for policy
makers.
In light of their desire to be a practice based theory with future application, Huxham &
Vangen recognise that policy makers frame and perceive challenges to collaboration in
a different way to practitioners, and given the impact of policy on practice, they
therefore include policy generated themes in their theoretical model. I have followed
this structure, including both ‘research impact’ and the ‘definition of translational
clinical research’ in my discussion, as ‘policy generated’ themes.
In this Chapter, I add a further layer of analysis and rigour to the data analysis that was
presented in Chapter Four, by contrasting the data outcomes with relevant academic
and policy literature, calling upon my comprehensive documentary analysis of policy
and academic literature to highlight gaps into which I bring new knowledge and those
areas in which my research adds further weight to an existing body of literature
This approach also draws upon the theory of collaborative advantage, which contains
within its’ model both policy and academically driven themes. Utilising this approach, I
am able to present a series of recommendations, for future practice, specifically for
practitioners attempting to deliver translational clinical research within NHS-University
partnerships, and for future policy and research. Within each category, where a
recommendation arises from my data analysis and the supportive literature, I present
it such that a series of recommendations are built up throughout the chapter.
The theory of collaborative advantage also provides a list, or ‘ten tips for collaboration’
(p. 41) which serves as a helpful framework that can be applied across a range of
collaborative ventures. My recommendations are specifically focussed on NHS-
University partnerships and are intended to provide a practical outcome from my
research, serving as a set of recommendations for practitioners but also providing a
template from which future research could be pursued. At the end of the chapter, I
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pull together the full list of recommendations into Table 5.1, for ease of reference, and
to allow for the entirety of the recommendations to presented in one format.
In those cases where there is a synergy between the Huxham and Vangen theme, and
the one presented by my participants, I have included this into my analysis, adding
further linkages between my model for collaboration within NHS-University
partnerships, and the theory of collaborative advantage more generally.
However, not all of my themes were present in the Huxham and Vangen framework,
and therefore in these areas I bring a new perspective to the theory of collaborative
advantage. My reflections on this are outlined in Chapter Six. Huxham & Vangen also
include two research generated themes in their model, ‘social capital’ and identity’ (p.
38), and I explore these towards the end of the analysis.
The discussion within this Chapter illuminates the areas in which my research data has
confirmed and added weight to existing literature, and those areas in which new
knowledge has been brought to the challenges faced by NHS-University partnerships
when trying to deliver translational clinical research. My recommendations are
particularly pertinent to NHS-University partnerships that operate outside of the highly
successful Golden Triangle where funding is plentiful, and in this sense brings a new
perspective to the subject area, and one which is highly relevant in the present policy
environment that is developing around different regional and local governance
structures.
5.2 Practitioner generated themes: Analysis
In this section, I present a discursive analysis of my practitioner perspectives in the
three themes of external factors, people and organisations. In each of the sub-
sections, I contrast my participant data with relevant policy and academic literature,
presenting recommendations where these arise. Linkages to similar themes from the
theory of collaborative advantage are also presented where it is appropriate to do so.
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5.2.1 Theme One External Factors: Category (1) Regionalism
My study participants felt that a regional approach, with devolved local powers, would
bring fresh opportunities for NHS-University research partnerships operating outside
of the Golden Triangle. The policy literature in this area suggests that the idea of local
devolvement is one that is being pursued by the present Government,
‘The government encourages universities to strengthen local collaboration and
will continue to reward proposals that build on regional strengths, including
through funding streams such as the Research Partnership Investment
Fund.’(Summer Budget 2015.) (Emphasis has been added to demonstrate the
regional agenda in Government discourse at the time of my study).
This wider contextual framework for regional devolution adds weight to the views of
my participants, that the present policy environment may provide the potential for
increasing power to local NHS-University partnerships, under which decisions around
funding priorities could be made in a more localised context.
It is possible that the Government’s strong policy statements with regards to regional
devolution are an attempt to direct a change in behaviour, and there was evidence
that this was happening within the two Case Study partnerships, with my participants
thinking around the possibilities that a more formalised regional partnership could
offer to the delivery of translational clinical research. (‘I am looking….towards regional
alliances said Participant 2:9 for example).
The idea of an increasingly regionalised approach to health partnerships is also
supported by the literature on UK health research spending, which highlights that a
regional in-balance exists. For example, the Foresight Report by Harding and Nevin
(2015) stated that investment into research from 1965 onwards had been heavily
weighted towards London and the Southeast, and the report by the UK Clinical
Research Collaboration (‘UK Health Research Analysis 2014’) confirmed that London,
the Southeast, and East Anglia (Golden Triangle) received 60.7 percent of health
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research spending in the UK, whilst the rest of England received 22.7 percent. Table
5.1 below presents the regional split of health research spend.
Both of the two Case Study partnerships operate outside of London and the Southeast,
and one can see that the possibility of rebalancing health investment on the basis of
devolved regional partnerships would therefore be attractive to them:
Region Percentage of health research spend
(91 funders) (%)
London 32.1
Southeast (including Oxford) 15.8
East Anglia (including Cambridge) 12.8
TOTAL 60.7
Northwest (including Liverpool and Manchester) 6.1
Yorkshire & Humberside (including Leeds and
Sheffield)
4.5
South West 3.7
East Midlands (including Nottingham) 3.7
North (including Newcastle) 2.4
West Midlands (including Birmingham) 2.3
TOTAL 22.7
Wales 3.4
Scotland (including Edinburgh) 11.8
Northern Ireland 0.8%
Table 5.1 Geographical distribution of health research spend over ten years (UKCRC
2015)
My data revealed that the participants felt that a deal of counter-productive time was
spent within the case study sites trying to make an unwieldy national system work at a
local level, and there was some evidence of what Huxham & Vangen would term
‘collaborative inertia’ in trying to fit local delivery into a national system,
‘They can’t all be useful, and delivering – can they?’ (1:2)
In addition to the health research funding data, as presented earlier, from Harding &
Nevin (2015) and the UK Clinical Research Collaboration (2014) which highlight a
regional in-balance in funding received, there is also strong evidence that England’s
policy environment is shifting towards an increasingly regional approach to delivery
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and planning - the Centre for Cities reporting in May 2016 that five cities will
‘introduce a metro mayor in 2017 – Greater Manchester, Sheffield City-Region,
Liverpool City-Region, the NorthEast, and the West Midlands’. This follows earlier
announcements in the Summer Budget 2015 of a regionalised approached to large
scale science investment, and the 2013 shift of responsibility for public health to Local
Authorities, deemed by the Local Government Association to be ‘one of the most
significant extensions of local government powers for a generation’.
This political environment, in its push towards an increasingly regional approach,
appears to offer much potential for those NHS-University partnerships that can
function effectively enough to convince Government and other stakeholders that they
have the ability to deliver in the context of regionally devolved structures. However,
this would require a functioning NHS-University partnership that could give a clear and
consistent message to funders and policy makers about local strengths in clinical
medicine and research, and my theme of ‘regionalism’ is therefore linked to my other
themes of ‘communication’ and ‘leadership’, confirming Huxham & Vangen’s
argument that the themes within a model of collaborative advantage are often linked
(2005; p. 34).
To deliver a partnership within a devolved local context would require ‘leadership
rather than management’ (McCaffrey 2010 p.79). With devolvement would come
increased responsibility and a locally led NHS-University partnership would require the
right kind of leadership. Currie et al. (2013) suggest that ‘more emphasis might be
placed on those that…have the capability to work across organizational and
professional boundaries’ (p.38).
In addition to the opportunities presented by a move towards regional devolvement,
there exists a parallel risk that those partnerships that are not deemed strong or
functional enough for devolvement, are left behind. To an extent, this two-tier system
has already been created by the current network of accredited NIHR Academic Health
Science Centres, many clustered in London, Cambridge the South-East, which receive
funding in excess of the network of non-accredited partnerships that have developed
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elsewhere. The health research data referred to throughout this thesis demonstrates
the in-balance in funding that is received by different geographical areas.
It is important that these other local NHS-University partnerships, which are critical to
local health economies, and to national and local health outcomes, find a way to be
competitive within the national landscape and to be as productive as possible with the
funding that they receive.
In a partnership with greater devolvement of power, universities and NHS Trusts could
work more closely together to achieve translational clinical research by making
decisions based around local research expertise and clinical need. In order to progress
this, partnerships would have to understand the wider political position with regards
to local devolution in their area.
My first recommendation is therefore that the two NHS-University partnerships
should,
‘Engage with the wider regional devolvement agenda in the locality of the NHS-
University Partnership. Understand what form any potential shared governance
structure would take and work to ensure that health and research are
considered as part of this’ (Recommendation One).
5.2.2 Category (2) Regionalism: Code: (1) Physical proximity
A strong code within the Category ‘Regionalism’ was the issue of physical proximity.
Here there was a complexity and divergence to the views expressed by my
participants, with some being strongly of the view that physical co-location is a natural
facilitator of increased collaboration, whilst others demonstrated a lack of enthusiasm
for any such strategy, seemingly based around personal, rather than collaborative,
drivers as the two quotes below demonstrate,
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‘I would love to be on one site. It would make a huge difference to both
organisations’ (2:6)
‘Whilst it might make some things easier there are also advantages of
geographic distance’ (2:7)
This diversity of views across my practitioners in key themes is something that Huxham
& Vangen suggest is a common feature within collaborative ventures (2005; p. 34). In
recognising this complexity, the theory of collaborative advantage supports an
approach whereby the issues raised by participants are highlighted as areas requiring
management attention, and this would be the case with regards to the ‘physical
proximity’ category in my data analysis.
It is an issue that the participants of both my case study partnerships should give some
further consideration to, in order to better understand the opportunities, and
challenges, that could accrue from a co-located physically proximate location of NHS
and University staff. I suggest that there is a link between this category of physical
proximity and the ‘building a research strategy’ category, as, in order to decide which
clinical academics need space to collaborate, the partnership requires clarity on its key
research themes, such that actions are driven via a strategic vision around key
strengths.
In terms of the opinions expressed by some of my participants that co-location would
be useful, there is a body of literature to support this view. For example, Cremades et
al. (2014) studied the strategies employed by a high performing Spanish Research
Institution, which included clinicians from the hospital and academics from the
university. They did so by analysing data collected during eight in-depth, semi-
structured interviews with participants working at different levels of the Institution
(p.368), and found that the ‘establishment of knowledge sharing spaces foster inter-
disciplinary knowledge creation and inter-individual knowledge transfer’ (p.380)
(Cremades Baulbastre-Benavent, & Dominguez. 2014), whilst Long et al. (2014), in
their ‘online whole network survey’ into ‘clusters within networks’; (p.3) in an
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Australian Translational Research Network (TRN), gathered data from ’68 members of
the network’ and concluded that ‘patterns of collaboration are based around a
clustering of geographic proximity’ (p.13).
Dzau, Yoediono, Ellaissi, Cho (2013) refer to the fostering of innovation by ‘clustering’
(physical co-location) and ‘cloistering’ (where a small group of people combine to
focus on one key challenge) stating that such initiatives at Stanford University have
extended outside of clinical research and incorporated physics, chemistry and
mathematics, reporting ‘impressive achievements in translating basic research to
patient care and commercialization, particularly in medical devices’ (p. 1426).
Therefore, the literature concurs with my data within this theme that co-location
should be considered more thoughtfully by those within both of my case study
partnerships. This does not necessarily mean, or require, co-location, but it does
suggest that some physical spaces for people to come together to think about working
collaboratively are required and this forms my second recommendation as outlined
below,
‘Create physical and virtual spaces for collaborative thinking across institutions
and across scientific disciplines’. (Recommendation Two).
5.2.3 Theme One External Factors: Category (2) Government funding and policies
My participants believed that external factors were highly influential with regards to
the delivery of clinical research within both case study partnerships; see for example
the quote below,
‘I think things like the CLAHRC are really important and have made a big
difference’ (1:3).
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This confirms the argument made in the relevant literature that external policies have
a strong impact on local conditions. For example, the report by the UK Clinical
Research Collaboration (‘UK Health Research Analysis 2014’) records that there has
been a shift in the public funding ‘from basic to translational research’ and links this
directly to the work undertaken by the OSCHR to implement the Cooksey (2006)
recommendation to increase funding for translational medicine (p. 32).
The UK CRC report makes the same point with regards to investment by the Medical
Research Council (MRC), saying that,
‘the 2007 Spending Review allocation for the MRC allowed new funding of
£132m to be directed towards translational research in support of the priorities
set out in the 2006 review of health research chaired by David Cooksey’ (p.43).
Thus, there has been a shift in government investment priorities that has led to an
increased amount of funding to be available for clinical translational research. One of
my participants referred to this in his interview,
‘We are probably doing less industry research now because we are able to do
more academic research because the funding and infrastructure is there for us
to do that’ (2:7)
However, a number of my participants also referred to ‘initiative overload’, as one put
it,
‘So we have got AHSCs, AHSNS, the Research Design Service, the CLAHRC. How I
are we supposed to engage with all of those?’ (1:2).
This evidence that my participants were becoming weary of different partnership
initiatives is similar to that which Huxham & Vangen (2004) define as ‘partnership
fatigue’ (p. 195) but do so with reference to the challenges of multiple alliances and
partnerships faced by many of those in collaborative ventures.
133
In contrast, my study data reveal what I shall call ‘initiative fatigue’ and is less about
the number of partners within the partnership and more about the numbers of
different government programmes that they are expected to respond to. Participants
also referred to the uncertainty that surrounds government programmes for
translational clinical research, with one saying,
‘will it (the partnership) survive the changing whims of government?’ (??)
Despite the concerns expressed by some of my participants about ‘initiative overload’,
there did not appear to have been any discussions locally about how best to deal with
this. The present national system within which local NHS-University partnerships does
not allow for local decision making in which partnerships could select which initiatives
they did or did not want to engage with. A move towards regionalised partnerships,
discussed in the previous theme, may go some way to counteract this, but is
dependent on a range of external factors and it is therefore important that the NHS-
University partnerships find ways of handling this ‘inertia’ or ‘fatigue’.
5.2.4 Theme One External Factors: Category (4) Clinical academics
The ‘clinical academic’ emerged as a key category within the ‘external factors’ theme,
in terms of firstly attracting and retaining clinical academics, with a feeling that this
was a particular challenge for those operating outside the Golden Triangle, and
secondly in terms of facilitating the delivery of research by clinical academics, who
have many demands on their time.
In this section I focus initially on this first challenge, encapsulated by one participant as
follows,
‘Medical academics are now like pandas. They started off in the 1960s and
1970s as really quite fearsome carnivorous beasts but a number of pressures
mean that they are now quite sweet little things that have trouble reproducing,
only eat bamboo and you take them and you can’t transplant them out of their
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environment. The bamboo rich areas are Imperial, UCL, Cambridge, Edinburgh,
Manchester (so long as it can keep itself) Kings, Queen Marys’ (2:8)
The concern amongst my study participants of a declining number of young clinical
academics, allied to a clustering of talent in specific geographical regions, was seen as
a barrier towards building effective systems for research for those outside of those
areas.
A lack of clinical academics has also been recognised as a problem outside of the UK.
Pickering et al. (2015) refer to an ‘international need for translational researchers’ (p.
806) but point out that the numbers of new scientist-physicians in the US are declining,
‘currently only 1.3% of all physicians being trained in the US are also pursuing a
research career’ (p.807). In England, there have been some high profile attempts to
address what is seen by policy makers as a national problem. The 2005 ‘Walport
Review’, recommended that a more integrated and easily accessible clinical academic
training programme be established for clinical academic research at under-graduate
level.
Cooksey (2006) also referred to the shortages of clinical academics, and suggested that
a further 50 applied fellowships per year were required. The medical community
responded positively to this with an editorial in Clinical Medicine saying,
‘This element of the Cooksey review is particularly welcomed and represents
further recognition of the need to support and develop academic medicine in a
systematic and sustained manner’ (Smyes & Wynick 2007) (p.543)
The NIHR too has attempted to address clinical academic staffing shortages. Its
‘Integrated Academic Training Pathway’ contains provision for partnerships of
universities, NHS Trusts, and Local Education Training Boards, to provide Academic
Clinical Fellowships and Clinical Lectureships that allow ‘medical and dental trainees to
undertake 25% research and 75% clinical training over 3 years …and 50% research and
50% clinical training over 4 years’ respectively. The idea being that by embedding
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research into educational training, the number of trained clinical academics will
increase over time. However, only 250 Academic Clinical Fellows and 100 Clinical
Lectureships are available nationally each year. Figure 4.5 below shows the first
destination data for Academic Clinical Fellows (ACFs) as at 2014, and demonstrates
that 5% cite ‘clinical academic’ as a first destination career. Some 40 percent of this
cohort enter a clinical only career.
Figure 5.1: NIHR ACF progression data - first destinations: as of April 2014
My participants felt that the NIHR developments ‘were useful but did not go far
enough’ (1:1), and none of the policy developments outlined specifically address the
issue raised by participants around a geographical imbalance, with partnerships
outside of London and the Southeast having the increased challenge of trying to
attract clinical academics to what are perceived to be less attractive health systems.
The comment by one Participant that they would try to ‘grow our own’ (2:6) clinical
academics is an interesting one, which loops back to the previous theme around the
granting of increased powers to regional partnerships. There is a possibility that within
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these potential new governance arrangements, NHS-University Partnerships could
explore the development of regional training programmes for clinical-academics that
could run alongside the national initiatives outlined above, with a view to both
increasing and re-balancing the pipeline of clinical academics across the different
English regions.
The second issue raised by my participants in the ‘clinical academic’ category was the
pressures faced by clinicians in the NHS that wish to deliver research.
At the time of writing, a national debate was being held around the Government’s
proposed changes to the contracts of junior doctors. Ahmed et al. (2015) made the
point in The Lancet that the proposed changes affected more than pay and conditions,
and would likely increase the difficulties faced by clinicians that wish to engage with
research, thereby creating another challenge for local NHS-University partnerships that
is being driven through at a national level, and impacting on local level delivery,
‘The proposed contract penalises clinicians who take time out of their training
to pursue their interests in research’ (p. 20).
My participants felt that there is a real challenge for NHS-University partnerships
focussed around the pressure faced by clinicians within the partnership to dedicate
time for research,
‘A number of our clinical academics are just run off their feet with clinical work.
It (research) is an objective for them, but the pressure of patients is such that
they are struggling to do that…. we’ve got a couple of very bright young
people….they really struggle to find any time to do research’ (1:3)
‘One of our departments is running a vacancy rate of 18.4% on a service of only
30 people. And then I say I want two of your staff to do a research project for 12
months- it’s so difficult’ (2:6)
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The policy literature suggests that these challenge may increase as the NHS heads into
a period of multiple pressures, including for example new productivity targets.
In October 2015, the NHS was set a challenge of delivering an estimated £22bn of
productivity improvements by 2020/21’ by its own Chief Executive (Alderwick et al.
2015, p.3). who doubt that this productivity challenge can be achieved within these
timescales, highlighting that, ‘between 1995 and 2010, for example, although NHS
funding more than doubled its productivity rose by only 0.5 percent per year’ (p. 9).
It is clear therefore that translational clinical research will be operating within a highly
challenged NHS, and this links back to my previous observation with regards to
collaborative inertia, in that the NHS-University partnerships shall have to factor this
into their thinking when trying to encourage clinical academics in partnership
activities.
My data revealed a strong feeling that the current demands placed on clinical
academics by two masters via joint contracts of employment, had a high personal
impact,
‘In this building around 90% of people are employed on research contracts and
they are already doing ten times more than the academic workload survey
suggests they should be doing.’ (2:7)
‘ A number of our clinical academics are just run off their feet with clinical work’
(1:3).
Lots of problems with joint appointments – the usual stuff about both
organisations wanting 100 percent and the poor person in the middle burning
out’ (2:5)
These tensions may only be heightened by the challenges that the NHS itself is under,
as outlined above.
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There was a strong message emerging from my study data that the dual role of the
clinical academic was not nurtured by either the NHS or the University, with
Participant 1:3 demonstrating that both the University and the Trust are focussed on
single organisational, rather than collaborative, factors when employing clinical
academics,
‘When I am making an appointment here…we don’t really go out and find out
how that works with the NHS Trusts locally’ (1:3)
‘The Trust really comes under tremendous pressure to change (a clinical
academic appointment) into a full-time NHS consultant because they get more
bangs for the buck’. (1:3).
It was clear from my study data that clinical-academics face multiple challenges in
trying to deliver across two roles in two organisations. This problem of dual
responsibilities is not unique to clinical research. In their study of Canadian University
Research Centres, Mendes et al. (2014) draw the same conclusion with respect to
faculty that are expected to engage in applied research with the community. This
places pressure on the individual who at times struggles to meet the different
demands of the two organisations (p.174). Mendes et al. also found that the career
progression of academics could be hampered by them giving too much attention to
applied research, as this is not recognised in the promotion criteria of research
universities (p. 174).
In the context of my study, ‘role strain’ relates to the pressures that the participants
observed with reference to clinical academics, and the expectations placed on them by
both the University and the NHS Trust. Boardman & Bozeman (2007) published a study
into ‘role strain’ (p. 431) of academics who are affiliated to both a ‘traditional
academic’ department as well as to a University – Industry Research Centre (p.31).
They interviewed 21 academics that were aligned to a university department and a
research centre, and concluded that there was a difficulty for the University in
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recognising the achievements of the academics within the research centres, because
these metrics were not included within the University’s promotions criteria (p.453).
The authors suggest that universities need to evolve their internal processes to better
recognise the achievements of academics that are working with an increasingly
complex research environment, characterised by ‘dual and multiple allegiances’ (p.
453).
Clinical academics themselves belong to a distinct group and appeared not to have a
strong connection to the NHS-University partnerships. In addition, the clinical
academic group is placed under pressure by each organisation to deliver against
targets or key performance measures. In the case of the NHS, this could be around the
numbers of patients recruited onto trials and the time taken to recruit the first patient,
or open the first site. The University on the other hand would most likely be more
concerned with research grant success rates, research income secured for clinical
research, and translational research that demonstrates impact in a REF sense. This
was demonstrated by one participant,
‘This obsession of the Trusts around numbers of patients on trials…it can be so
counter-productive’. (2:5).
My study data confirms Horton (2015) who argues that ‘our approach to clinical
leadership has gone badly wrong’ (p.120). In my two partnerships, there was a strong
feeling that clinical academics were critical to the success of the partnership, that
these individuals were in scarce supply, and that those that the partnerships did have
were being overworked. Given that my participants were all clinical academics
operating at a senior level, it is reasonable to ask why these individuals themselves
could not bring some leadership to this area.
Kulkari (2014), a core surgical trainee writing in the British Medical Journal, offers a
perspective on this, arguing that clinical academics are not asked to direct change
because they are viewed as being ‘culturally resistant’ to it, and consequently
therefore change is forced on them ‘from the outside’ (p. 481). McKinn & Mannion
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(2015) also suggest that ‘individualism rather than collectivism’ is a particular trait of
clinicians, this being a direct result of their training paths, which encourage an
individual approach, and therefore traditionally have not been proactive in leading
change.
One of the external changes that now have a significant effect on clinical academics is
the demand from the NIHR for NHS and University organisations to work together in
collaborative ventures in order to access funding. My study data suggests that this is
creating a new pressure for clinical academics and it is important that this group are
empowered to bring some leadership to this new environment.
I suggest that this is therefore an important cultural issue that if left to evolve naturally
by my two case study partnerships, may continue to impede the delivery of
translational clinical research. My data suggests that local NHS Trusts and their
University partners should engage with clinical academics to understand how best they
can be supported to deliver clinical care whilst also having time to research. In return,
the clinical academic must step outside of their own group and take a more inherently
collaborative approach, something that should in the future be more embedded within
clinical training - this being something that local NHS and University partnerships
should themselves take a proactive role in.
The two case study partnerships should consider how to place the ‘clinical academic’
at the heart of their structures in a way that allows them to have an influence on the
way that research is supported and delivered.
I offer three recommendations that are focussed upon the importance to the NHS-
University partnerships of high quality clinical academics:
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‘Recognise the importance of the clinical academic, and place him/her at the
centre of your thinking. Encourage a more collaborative approach to clinical
research, commencing in your clinical training programmes’. (Recommendation
3).
‘Challenge cultural understandings of the ‘individual clinician’ or the ‘individual
academic’ and create incentives for collaboration. Allow people the space to
make delegated decisions where it is appropriate to do so’. (Recommendation
4)
‘Develop strategies of recognition and promotion that reward clinical
academics for collaboration with the NHS, and vice versa so that this important
stakeholder group is both valued and genuinely supported to deliver
translational clinical research. Demonstrate to the Trust Board and University
Executive that this is line with both NHS (the inclusion of research in the NHS
contract) and University (the research impact agenda) policy and delivery
objectives.’ (Recommendation 5).
The idea of ‘growing our own’ pipeline of clinical academics was suggested by one
participant, and this could be assisted by a programme of formal mentoring. Whilst
mentoring was not suggested by any of my participants, it could go some way to
addressing the ‘individualistic’ behaviours that I observed, which McKinn & Mannion
(2015) argue is engendered by the singular nature of a clinical academic training
programme. I therefore argue that a mentoring programme is worthy of consideration
by both of my case study partnerships, and a particularly interested example is
suggested by Byington et al. (2015), who produced a paper that reviewed the
mentoring programme of the University of Utah in the United States. This was a
‘matrix’ approach to mentoring clinical academics at the University, as distinct from
more traditional 1-1 mentoring. The matrix includes a senior established Professor, a
small group of scientific mentors, grant writers and a select number of appropriate
peers, who together deliver a structured programme of mentoring to an individual.
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Around 50% of applicants are granted entry to the programme, and once accepted,
the mentee, the senior mentor and the Chair of Division draw up and sign a contract
outlining goals and setting out a series of agreed milestones. An important element to
the matrix approach is that the senior mentor (the experienced Professor) sits outside
of the mentee’s Division and can intervene if necessary in cases where the mentee
may not be getting the support he or she requires, or conversely where the mentee
themselves is not delivering the necessary levels of self-mentorship.
Aronson (2011) cites the ‘reduced numbers of academics to act as role models for
clinical academics’ (p.7) as a particular problem and given that the need to develop a
pipeline of clinical academics was a key theme in my study, the ‘Utah’ approach struck
me as one that was worthy of inclusion here. A note of caution must be struck with
regards to the embryonic nature of the programme; it commenced in 2013, and, whilst
the results in 2015 were encouraging (by 2015, 92% of mentees had at least one grant
as a Principal Investigator and 99% remained in clinical academic medicine (p.4) a
longer term review would be required to truly evidence the results..
Strong institutional buy-in would be required for this this to be sustained over the
medium-long term. However, given the challenges that are faced by both NHS-
University partnerships to both attract and retain clinical academics, I suggest that a
collective approach to mentorship as one of my recommendations,
‘Support the development of a strong pipeline of clinical academics by the
development of a matrix and collective approach to mentorship that spans
both organisations’. (Recommendation 6).
Some of the recommendations offered by Aronson to counter the declining numbers
of clinical academics are reflected in the strategy of The Francis Crick Institute, a new
partnership between MRC, Cancer Research UK, the Wellcome Trust, UCL, Imperial
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and Kings College London, which has an ambition to create a world-leading clinical
eco-system. Notes of a meeting of the Crick Executive in 2011 state that,
‘Basic and clinical scientists require an environment that breaks down cultural
difference; Crick PhD students – clinical and non-clinical – should be grouped
together in thematic programmes’.
My study participants did not refer to research taking place outside of the Medical
Schools, such as Clinical Engineering, Chemistry and so on, despite the fact that a desk-
based review identified that within both case studies there is evidence of collaboration
in clinical research that extends outside of the Medical School. I suggest that the case
study partnerships may wish to explore the viability of a wider eco-system approach to
their health research partnership, learning from innovative practice elsewhere,
‘Observe and learn from initiatives such as the Francis Crick Institute, which is
attempting to implement adopt and develop a full eco-system approach to
translational clinical research. There may be ideas here that could be applied to
your local NHS-University partnership’. (Recommendation 7).
5.2.5 Theme Two People: Category (4): Leadership
My participants agreed on, and in many cases drew upon their own experiences of, the
impact that a strong individual or small group of individuals can have on the delivery of
NHS-University partnerships. Leadership was seen as a key concept and one that was
important to get right if the partnership was to succeed.
The fact that leadership emerged as a key category in my participant data contrasts
with the experiences of Huxham & Vangen that ‘practitioners seldom explicitly refer to
leadership’ (2000; p. 1172) basing their view on actions research data that they have
gathered from a range of partnerships in the public sector.
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My participants perceived there to be a great challenge in identifying the right leaders
for their partnership, and this, aligned to the short term nature of leadership across
both the Medical Schools and NHS Trusts, was cited as a key issue, as evidenced by the
participant quote below,
‘It’s a real issue, getting the right leaders. And not those that pass through –
this partnership needs some consistency now’ (2:10).
The importance of leadership as a practitioner based theme is a different outcome to
that reported in the theory of collaborative advantage, where Huxham & Vangen have
identified ‘leadership’ as a policy, rather than practitioner driven, concept. This is
therefore an area in which my subject matter offers a complementary dimension to
the theoretical framework. It suggests that there may be factors unique to the NHS-
University setting that provide for a more practitioner focussed emphasis on the
matter of leadership.
There is literature that attempts to bring some knowledge to the specific area of
leadership within the NHS-University collaborative environments, including Currie
Lockett, & El Enany (2013), who undertook a longitudinal study into the nine CLAHRCs
that were established in 2008 by the NIHR.
Four of the nine CLAHRCs were selected by Currie et al. for in-depth analysis via ‘70
interviews’ of NHS and University managers, academics, clinicians, and leaders. The
authors concluded that the leadership of the CLAHRC tended to rest in one influential
individual, and that this person’s view of translational research would be highly
directive of the future delivery over the proceeding five years. Currie et al. (2013)
suggest that policy makers should be aware of this, and think carefully about the
‘selection of the leaders’ of such initiatives, suggesting that ‘more emphasis might be
placed on those that…have the capability to work across organizational and
professional boundaries’ (p.38).
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This concurs with my participant data, which suggests the need for leadership that can
span organisations. However, my participants offered a range of perspectives as
regards the type of leadership model that would best suit their organisations, with
reflections being offered on the strengths and weaknesses of both a joint and separate
approach to leadership, as the two contrasting participant quotes demonstrate,
‘I think having common leadership helps’ (2:8)
‘The Director of R&D was also the medical lead for the Medical School…. My
perception was that he worked for the Medical School and not for the Trust….
When he left, it was decided at Trust level that we needed someone who was a
Trust employee’ (2:6)’.
The contrasting strengths and weakness of joint, joined, or separate, leadership across
NHS-University partnership has also been debated in the literature. Here too there is a
lack of consensus, and therefore in this sense my study data adds weight to the
argument that there is not a simple solution to the challenge of leadership in the new
NHS-University models.
Ovseiko, Davies, Buchan. (2010) noted that Imperial Health Partners was the only
AHSC to engender a joint governance approach, having a University Dean who was also
the CEO of clinical service, an academic chair who was also the chief of clinical
enterprise, and a Chief Academic Officer that had overall executive authority. The
merits of this model were revisited in a later paper (Ovseiko, Heitmueller, Allen,
Davies, Wells, Ford, Darzi, & Buchan. 2014), in which the authors state that it was very
successful in the first phase of the AHSC, during establishment and initial formation of
academic clinical programmes. However, they argue that the partnership was not
equipped to deal jointly with the subsequent financial challenges faced by the
University and the Trust and in this respect a decision was taken on the resignation of
the joint Dean/CEO, for Imperial to move towards the more common AHSC model of
joint partnership, rather than joint leadership.
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The authors believe that this demonstrates that different phases of the partnership
development may require different forms of governance and leadership models –
during formation joint leadership was key, but in the financial downturn, a different
approach was required in order for each organisation to deal with its separate fiscal
challenges.
In contrast, a study into the different clinical-academic partnerships in the United
States (US) suggests that the ‘authority of the Clinical Academic Officer’ (p. 116) is a
key element of the most successful partnerships, alongside an integrated clinical and
academic enterprise (Weiner, Culbertson, Jones, Dickler. 2001).
Therefore, neither the literature nor my participants were able to reach a consensus
views as to the most effective form of leadership. The theory of collaborative
advantage does not require themes to have a consensus, rather that the themes be
highlighted as key areas for the continued delivery of the collaboration, and I would
suggest that leadership would fall into this category.
One of my participants referred to the notion of ‘distributed leadership’ (2:10) and
whilst this was not referred to across the interviews, it is included here as it is an idea
that finds some support in the academic literature. A US Study (Michener, Cook, Syed,
Yonas, Ciyne-Beasley, Aguilar-Gaxiola. 2012), recommends the appointment of
‘champions’ as an example of a distributed form of leadership, which has a specific
meaning in the NHS, of devolved authority being granted to people throughout the
organisation, allowing decisions to be made at different levels of that organisation,
rather than being passed up the hierarchy before action can be taken.
Currie & Lockett (2011) unpack the concept of ‘distributed leadership’ in English health
and social care settings, and argue that it is increasingly being utilised for initiatives
such as the new Clinical Research Fellows that are intended to ‘provide clinical
leadership to drive reforms’ (p.293) and the new networks (CLAHRCs, AHSNs for
example) (p.294) that are being created to distribute decision making in a different
way.
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Collective leadership is similar, but has a stronger cultural leaning towards all
individuals within the organisation taking responsibility for decision making, within a
cultural context that gives people the confidence to do so. West et al. (2014) ‘make the
case for collective leadership’ in the NHS (p.2) and stress that there is ‘a need for
clinical leadership at every level’ (p.18). They recommend that collective leadership
involves a distribution of responsibility, authority, and accountability to every level of
the organisation and must therefore be supported by ‘all the systems within the
organisation’ (p.21) such as the HR processes for recruitment, training, and succession
planning. However, McKinnon & Mannion (2015) and Kulkari (2014) suggest that the
culture amongst clinical academics is individualistic rather than collective.
Sarah Massie (2015) draws on West et al. (2014), and provides advice to all public
sector organisations that wish to develop successful leadership and undertake
effective succession planning. Massie states that the ‘ability to deal with complexity
and ambiguity’ is particularly important for leaders in healthcare (p.12) and points out
that the average tenure for a Chief Executive in the NHS is only two and a half years
(p.14) which creates a lack of consistency in leadership, that in turn impedes progress.
This could be seen in both of my case study partnerships; one of the NHS Trusts
changed Chief Executives during the two years of the study and both of the
Universities had seen a change of Dean within the previous two years. Huxham &
Vangen see this constant transition as a problem, saying that ‘role or job
changes…often mean that the continuity required to maintain the loop is not present’
(2000; p. 1171).
Massie also observed that the NHS is ‘often described as having a high challenge, low
support culture’ (p.15) and my study data adds weight to this observation, with my
participants suggesting that clinical academics were not nurtured by either the
University of the NHS Trust, as illuminated by one participant as,
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‘Lots of problems with joint appointments – the usual stuff about both
organisations wanting 100 percent and the poor person in the middle burning
out’ (2:5)
The notion of ‘leadership’ within NHS-University partnerships needs to be addressed at
a national level. The continuing binary divide of universities and the NHS leadership at
the level of Government, serves to reinforce this important issue, and therefore it
needs to addressed at a national level. My study data suggests that the efforts by the
NIHR to create more collaborative NHS-University is not having a strong impact on the
style and culture of leadership at a local level.
Across my two case study partnerships, leadership emerged as something that the
participants were looking to others for. Some of the participants spoke of themselves
as leaders in their own organisation, but nobody referred to themselves as leaders of
translational clinical research across the NHS and University organisations. I
recommend that the NHS and University organisations dedicate time to reviewing local
models of leadership,
‘Spend some collective time to review what form of leadership model would
work best for the partnership, at that time, including into this consideration
some thought as to how behaviours at individual, collective, and organisational
levels may need to change in order to support real and sustainable change.’
(Recommendation 8).
5.2.6 Theme Two: Communication: Category (5) Communication
My participants expressed a frustration around the challenges that they faced in
developing an effective joint vision for translational clinical research in the two case
study environments, where language and expectations are different and in which the
participants value outcomes in a different way to each other. However, there was
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evidence, based upon the personal experiences of some of the participants, that
developing a personal relationship can overcome any perceived or actual barriers,
‘with the right relationships anything was possible’ felt participant 2:5.
This confirms the observation of Boivin (2009) that,
‘It is not uncommon for researchers and clinicians working in the same
organisation to have limited conversations and dialogue. Yet when they come
together solutions to challenging problems are often enabled by merging
unique perspectives and the sharing of knowledge’ (Boivin et al. 2009 cited by
Davidson, Duffield, Campbell, & Ward (2011).
Kinge (2004) also argues that whilst senior buy-in is crucial, the partnership cannot
succeed without the positive engagement of individual practitioners (p. 837) and Fish,
Chantler et al. (2013) who argue that trust is more important that a formal partnership
arrangement (p.6).
Professor Steve Smith in a piece for the Lancet in 2009 that was written when he was
the joint NHS-University leader of Imperial Health Partners, suggested that difficulties
of communication would be overcome by the establishment of the new Academic
Health Science Centre (AHSC) governance structures. Smith believed that the
establishment of an AHSC would transform communication across NHS and University
organisations, by achieving a greater understanding of innovation, research, and
clinical care, across the partnership,
‘This integrated model for an Academic Health Science Centre has the potential
to bring about transformational change in universities and hospitals. The NHS
will have higher regard for innovation and the contributions of research and
development from the university, and in turn universities may come to view
the delivery of high-quality care in such a centre as a legitimate academic goal
and output.’ (Smith, 2009) p.1057) (emphasis added).
150
Neither of my case study partnerships operate within an accredited AHSC, and indeed,
there is no certainty from the literature that the formation of such governance
structures would necessarily aid communication (Ovseiko, Heitmueller, Allen, Davies,
Wells, Ford, Darzi & Buchan 2014).
There was evidence within my case study partnerships that communication routes at a
senior level had been sufficient to address some high level issues, as evidenced by the
two quotes below,
‘The Trust took our partnership with (NAME) extremely badly, that created a big
wedge’ (2:9)
‘The Director of R&D was also the lead for the Medical School…(but) he worked
for the Medical School and for the Trust’. (2:6).
However, there was a strong acceptance that more needed to be done, at all levels of
the partnership,
…. At the moment there is a bit of the hospital that is the Medical School
behind a locked door with a swipe card and the message is we are researchers
and we research behind closed doors. And … I can’t get in because my card
doesn’t work’ (2:6) (emphasis added)
This confirms the views of Martin et al. (2013), Nelson et al. (2013) and Kinge (2004)
that effective communication routes, at every level of the collaboration, are required,
whilst Malby et al. (2012), Buys & Bursnall (2007) and Macpherson (2012) all argue
that early and open communication supported by pro-active leaderships are essential
in the early phases of the partnerships with Herald et al. (2012) asserting that
proactive communication ‘ is the lifeblood of an alliance’ (p. 154).
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Some practical ideas for improving communication were offered by my study
participants, including physical co-location where possible. This is not always practical,
so there needs to be other ways of bringing people together to talk, collaborate, and
build bridges. Regular ‘sand-pits’ (informal groupings of individuals from across
organisations) around themes of interest to clinical academics, and clear routes of
communication within and across the partner organisations, could be useful additions
to both NHS-University partnerships.
There is a constant need to provide forums and opportunities for communication
between individuals from the two organisations, within a culture of mutual respect.
This could help to develop a common understanding of the specific challenges faced by
the individual organisations, explain some of the drivers behind individual behaviours,
and provide an opportunity to establish areas of potential collaboration.
My two recommendations in the area of ‘communication’ are focussed on the need for
NHS-University partnerships to recognise the importance of establishing effective
routes for communication within and across partner organisations:
‘Develop different forums for communication throughout your partnership.
These should operate at practitioner level right up to senior management, and
should provide the opportunity for open debate and information sharing.’
Recommendation (9)
‘Take time to develop a communications strategy and action plan. This needs to
make sense to both internal and external stakeholders and should be honest
about the need for prioritisation. It should be a dynamic document that is
supported by regular workshops, briefing sessions, and other forms of
communication’. (Recommendation 10).
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5.2.7 Theme Three: Organisations: Categories (6): Building a joint research strategy
and (8) Organisational cultures
My study data demonstrated strong links between the two categories relating to
building a joint research strategy and the pressures of working within different
organisational cultures and I have therefore presented the two together in this
analysis section.
My study participants stated that the pressure of NHS workloads were a barrier to
research being developed and delivered, within both case study partnerships,
‘A number of our clinical academics are just run off their feet with clinical work’
(1:3)
‘this whole thing about releasing people and making time for them to do
research is very difficult.’ (2:18).
This confirms the conclusions of Williams, Perillo, & Brown (2014) whose review of 49
articles identified problems of workload as ‘the most frequently identified barrier’ to
the NHS engaging in research and evidence based practice (p.36). A similar
observation was made in a study of Primary Care staff in Sweden, who ‘emphasised
the difficulty finding time for R&D projects during working hours’ (Morténius, Baigi,
Palm, Fridlund, Björkelund, & Hedberg 2015 p.241). The same problem has been
observed and cited within US literature on the subject; Pickering et al. (2015)
concluding that clinical-physicians are under ‘constant pressure to increase clinical
time/revenue’ (p. 814).
One of my participants suggested that one of the primary aims of the NHS-University
partnership should be aimed at addressing these challenges,
‘Our partnership should get involved in job planning for clinical academics to
allow them protected time for research.’ (1:3).
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In attempting to build joint strategies for clinical research, my case study partnerships
reported a problem of attempting to integrate different clinical and research
objectives, as the two quotes below highlight,
‘We meet with the University. And it is so difficult because they don’t speak the
same language’ (2:6) (NHS Participant referring to the University)
‘If you speak to some of our rheumatologists, the rheumatologists here that are
doing research, they are talking about specific problems that patients
experience and how you might overcome them; our researchers tend to be
taking much more of a longer term aim’ (1:3) (University Participant referring to
communication problems)
Therefore, my research confirms the assertion of Huxham & Vangen (2000) that
‘differences in professional…language’ is one of the key contributory elements that
make up collaborative inertia and has the potential to de-rail, or at least significantly
slow down, progress towards the overall aims of the partnership (2000; p. 773).
My participants also outlined a sense of frustration with regards to the time it takes to
see a benefit from strategies to deliver translational research,
‘We don’t really get esoteric research. We are quite short termist really; all our
planning is on an annual cycle, monthly reporting’ (2:6),
‘(the University) is not only ambitious it is also very impatient’ (2:8)
However the reality is that ‘research rarely produces short-term gains’ (Swales 2000
p.1637). In the same article for The Lancet, written as a retrospective opinion piece
following three years as the NHS R&D Director, Swales says that the challenge of
joined-up thinking is made more difficult by the binary divide between NHS and
University performance indicators at Government level,
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‘(Health) Ministers’ priorities, reasonably enough, are such things as waiting
lists for hospital admission and “trolley waits” (the length of time a patient has
to wait on a trolley in accident and emergency corridors). Responsibility for the
country’s scientific strengths lies elsewhere in government’ (p.1638)
My participants confirmed that this divide causes a problem at the local level, with one
saying that,
‘What we find is say a clinical academic funded by the Trust, if they actually
leave, then the Trust really comes under tremendous pressure to change that
into a full-time NHS consultant because they get much more bangs for the buck’
(1:3)
There was also evidence from the participant data that some University academics saw
clinically led NHS projects as a threat to their resources, and not being of sufficient
quality to merit too much investment,
‘the expertise of the Clinical Trials Unit (should continue) to be appropriately
focussed on large grants…as opposed to resource that becomes sucked into
small projects led by clinicians’. (2:7).
Buys & Bursnall (2007) recognised that a similar perception existed within the
Australian higher education system, in the context of community-university
partnerships, citing a ‘perception that collaborative research may lack rigour’ (p. 74).
They also observed that, in the context of university-community research partnerships,
there was likely to be a mismatch between the expectations of the university and the
community organisation as regards the potential outcomes. Drawing on the in-depth
data provided by seven academics with experience of developing such partnerships
within the Australian higher education system, they recommended that partners
spend some time at the outset talking through the goals of the project, so as to
develop a joint understanding and agreement for these (p.83).
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My participants referred to the difficulties of developing and embedding joint
performance measures,
‘We meet with the University and its so difficult because they don’t speak the
same language’
There was evidence in my data that the new policy-led partnerships for translational
clinical research have not in themselves managed to improve the issues of dual
cultures, languages, and practices, these remaining a barriers to progress in both of my
case study partnerships.
This problem, of embedding new working practices, has been researched in different
settings. Zakaria (2015) for example, reviewed attempts to embed a set of
performance measures and service delivery improvements into a private sector
company. They observed that this was only possible via a process of ‘cultural change’
(p.934), that included a move towards a set of new principles being embedded within
the day-to-day operation of the company, including ‘face to face meetings’ (p.938)
between operational and senior managements, with senior managers having an open
door policy and delivering against the same set of performance measures, and
meetings across different teams and in different locations of the business so as to
involve all of the stakeholder groups (p.939).
Although this example is drawn from a different context, my study data suggests that a
more inclusive approach to target setting would be worthy of consideration in both of
my Case study partnerships. This would require a move away from a hierarchal
management model into a more inclusive and collective approach, and can be linked
back to the comment by Participant 2.6 that ‘people need to sit down and have a cup
of tea together’. It would take more time and collaborative effort in the development
phase, but may be more likely to produce a set of metrics that mean something to all
parties, and which have a chance of being delivered on the ground.
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In terms of embedding different cultures, there have also been a number of studies
delivered outside of NHS-University environment that offer useful insights into how
strategies for delivery can be embedded within complex organisations. For example,
Barker, Ingersoll & Teal (2014) looked at how Corporate Social Responsibility (CSR)
could be embedded into wider organisational culture. Defining CSR as the ‘expectation
that organisations engage in socially and environmentally responsible practices’ (p.25),
Barker et al. found that local sub-cultures were highly influential and should be
factored into any strategy to embed CSR into an organisation’s standard delivery
models (pp. 29-30). This links back to my previous section, and associated
recommendations, around clinical academics which my data suggests are a powerful
‘sub-culture’ within NHS-University partnerships, with the ability to impede delivery if
not properly engaged with.
The challenges of different NHS-University cultures have also been recognised by a
2015 study that reviewed the literature around Health Service-University partnerships
in North American and England. It stated that,
‘Although the role of organisational culture in post-merger integration and
inter-organisational collaboration is widely recognised, little empirical evidence
exists to help academic and clinical leaders identify differences in culture and
resolve cultural issues early in post-merger integration’ (Ovseiko et al. 2015; p.
4).
Ovseiko et al. present a series of observations around one partnership in particular,
this being the merger of two NHS Trusts and one University, to create the Oxford
University Hospitals Trust and these demonstrate the power of cultures and sub-
cultures,
‘A major issue for respondents was to reconcile different priorities in academic
and clinical innovation and service delivery’ (Ovseiko et al. p. 10).
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Partnerships are at the best of times, ‘organizations characterised intermittently by
both conflict and collaboration’ (Strier 2014; p.157), and my two sites demonstrated
that cultural differences, the individualistic nature of clinical academics, and problems
of miscommunication, do not make the drafting of a joint NHS-University research
strategy simple or straight forward. However, participants within both case study
partnerships agreed that achieving translational clinical research requires a joint
strategic approach that has equal buy-in from both the University and the NHS Trust.
There was evidence within my data of a genuine desire to work across organisational
boundaries, and an acceptance of the strengths that the NHS and University had to
offer, take for example the participant quote below,
‘because, you know, the NHS is a fantastic institution…for research purposes it
provides a huge opportunity and unless we can embrace that…’ (1:4).
However my data confirms that at a local level, in my two case study partnerships,
there is evidence of ‘collaborative inertia’, caused by a difficulty around defining a
‘joint purpose’ (Huxham & Vangen 2000; p. 773). Mu study data adds weight to
Huxham & Vangen’s contention that an inability to negotiate ‘joint purpose’ is a key
factor that may lead to collaborative inertia. My data adds new knowledge to this
concept with reference to the new NHS-University partnerships for translational
clinical research, demonstrating how difficulties of culture and language are powerful
enough to prevent progress being made in my two case study partnerships.
In light of my own data in this area, as well as the relevant literature, I suggest that
every effort must be made to have at least a cohesive framework of mutually agreed
key priorities within which translational clinical research can be progressed. I
recommend that the two partnerships should,
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‘Take a fresh approach to performance measures. Where this is an
opportunity at a local level to define collaborative performance, take
this. In cases where national metrics are non-negotiable for one or
other organisation, ensure that this is understood across the
partnership and embed this into your thinking.’ (Recommendation 11)
‘Accept that your partnership cannot excel in all areas of translational
clinical research. Understand where you have clinical and research
excellence and build your strategy around these. Extend this to your
training and recruitment programme.’ (Recommendation 12).
My data supports Huxham & Vangen’s argument that there is ‘inherent difficulty’ in
specifying collaborative goals (2003; p. 63). Subsequently, they attempt to characterise
the complexity of different aims within a partnership by drawing attention to three
stratifications that are at play within a partnership, these being collaborative,
organisational, and individual aims. They argue that at different times in the
partnerships, these aims will change, some shall be explicit and others hidden, and the
more partners that are involved in a partnership, then the more ‘tangled the web’
(2009).
However, in the case of my study, the data suggest that there is a general consensus
across the two organisations at individual and organisational levels as regards the
common aim of the partnerships, with there being common agreement that the aim
was to collaborate in order to compete successfully for investment into translational
clinical research projects. However, my data indicate that understanding how to
measure progress towards this point is a challenge for the participants, and Huxham &
Vangen’s stratified approach is useful as a reflective tool in serving to remind
collaborators that there are a number of different drivers to collaboration at play at
any one time, even within seemingly straight forward and small partnerships. (2009;
pp. 93-95).
159
There was a distinct contrast between my study data and the observations of Huxham
& Vangen with regards to ‘negotiating purpose’ across collaborative partnerships. In
this area of their conceptual framework, the authors draw upon their practical
experiences of collaborating partners having a number of challenges to overcome in
terms of ‘hidden agendas’ (2005; p. 109), ‘disinterested organisations’ (p. 111) and
organisations that join simply to ‘spy’ on the progress being made (p. 113).
My data suggests that NHS-University partnerships operate in a different context to
this, and therefore the ‘negotiating aims’ element of the Huxham & Vangen is less
useful here than other areas of the framework. Within the two NHS-University
partnerships in my study, despite the cultural differences that were evident, there was
a general consensus across the organisations as regards the aims of the partnership, it
was rather the method of measuring and understanding success that was a challenge.
I suggest that more directly relevant to NHS-University partnerships, is the concept of
‘a goals paradox’, that Huxham & Vangen introduce in a later (2012) paper. This
highlights the complexities that persist when attempting to set goals across different
organisational settings (p. 732). My study data confirms that this is a challenge, even
when there is a large degree of convergence around the overall, long term aims of the
partnership. My data therefore reveals that an acceptance of long term goals is not
enough for NHS-University partnerships to collaborate effectively.
I suggest that there are some measures that cut across both Universities and NHS
Trusts that could be applied to understand the pace of progress in terms of
translational clinical research. These are presented in Table.5.2 below. They are not
intended to be a definitive list, but are presented to provide a starting point from
which NHS-University partners could commence a discussion regarding joint
performance measures for the delivery of translational clinical research:
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Proposed joint NHS-University performance measures
• Number of Fellowships attracted (early, mid-career, and senior)
• NIHR funding attracted, split between the different Programmes;
• Engagement, as either a lead or a partner, in a Biomedical Research
Centre
• Delivery of one or more accredited Clinical Trials Unit within the health
eco-system, providing clinical trials services to local investigators
• Narrative accounts of research and/or innovation leading to patient
benefit, some of which will be worthy of inclusion in a future REF as a
research impact case study
• A centre of excellence focussed in an area of clinical strength and
research expertise, thereby being a genuinely joint exercise
• Industry engagement with clinical trials delivered within the health eco-
system
• Engagement across the spectrum of research such as this pertains to
translational clinical research (chemistry, engineering, for example),
with at least one joint research project with a non clinical medicine
discipline
• Development and delivery of a system of shared governance for the
support of translational clinical research, comprising such functions as
joint costing, contracting and sponsorship arrangements
• Provision of regular opportunities for NHS and University staff to meet
and discuss ideas – either by the provision of ‘satellite offices’ within
the Hospital and/or via regular forums – to support the development of
trusting relationships
Table 5.2: Proposed joint NHS-University performance measures
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5.2.8 Theme Three: Organisations: Category (7): Governance and administration
There was a strong feeling amongst my participants that clinical research governance
was a barrier to the successful delivery of translational clinical research, and this
confirms the views of influential groups such as the Academy of Medicine Science
(AMS), which said in 2011 that the ‘process of obtaining NHS R&D permissions is the
most significant barrier to health research in the UK’ (p. 38).
In response to the perceived problems with administrative process, the two
partnerships in my study had developed different structures and local policies within
the overarching national framework. Case Study One for example had a formal system
of committees within which decisions around governance were made, whereas in Case
Study Two, the committees were much less powerful and relied more heavily on the
local governance teams. Despite the different approaches, participants reported high
levels of dissatisfaction about the systems, but seemed unable to improve the systems
themselves.
‘We have one where we had the first approach to ethics and then it was over a
year before we could actually start’ (1:3)
The AMS recommended in its 2011 report that the NHS governance systems be
centralised systems, to speed up clinical research administration. Government
responded by establishing the Health Research Authority (HRA) in the same year, with
a mandate to improve systems for clinical research governance.
Subsequently, in 2015, following a period of review and consultation across the NHS,
the HRA announced the phased roll-out of a new centralised system for NHS Research
& Development approval. At the time of writing, the new HRA system applied only to
non-interventional projects, but interventional clinical trials will be brought into the
new central system by ‘the end of March 2016’ (www.hra.nhs.uk accessed 10 October
2015). Hemminki (2015) reviewed and compared the clinical research regulations in
four countries, England, USA, Canada and Finland and suggested that, if successful,
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the developments promised by the HRA could be replicated by other health systems
(p.9).
However, the impact of the new HRA system is as yet untested, and there are some
academics in the current literature that strike a note of caution as to whether the
potential benefits may have been overstated, such as Van der Laan and Boenink (2015)
who argue that a pre-occupation with external factors incorrectly assumes that all of
the challenges exist outside the underpinning science, when in reality this may not
necessarily be capable of translating into clinical outcomes (pp. 46-49), and Kearney et
al. (2014) conclude that the HRA changes should be approached with caution as they
may not in themselves speed up the time it takes to recruit patients onto trials. They
researched delays to a multi-centre, phase IV trial with over one hundred clinical sites,
by logging each delay on a fortnightly basis.
The trial took place after Government policy drivers to include time to trials had been
implemented (including the government target of ’70 days’ to first patient following
Site Specific Information (SSI) applications and the NIHR CRN target that NHS Trusts
should ‘approve valid applications within 30 days’ p.2) but concluded just before the
HRA announcements of its new single sign off governance system.
Kearney et al.(2014) observed that whilst the external targets demonstrated a
reduction in the time to R&D approval, ‘from around 40-45 days to 16 days’, delays
had simply been pushed further down the system so for example NHS sites took a
mean of 9.7 months from NHS ethics approval to open, and in some cases there was
evidence that R&D Departments were delaying the submission of the SSI in order to
meet their 70 day target, whilst not in practice speeding up time to site (p.6).
The three main reasons for delays were, the time taken to negotiate and clarify excess
treatment costs with the NHS, the gathering of research team CVs for each site
application, and the negotiation around site logistics with different NHS Trusts. It is not
clear what impact if any the new HRA system would have in each of these areas, and
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therefore it may be the case that the new national systems do not provide all of the
solutions.
It is too early for my two case study partnerships to provide an insight into the impact
of the new HRA systems, but I suggest that this would be a useful area for some
research in the future, given the importance to delivering research that my
participants placed upon it.
There is some relevant literature on the subject of merging governance structures and
processes. Allen, Ripley, Coe & Clare (2013) found an example in the United States of
an organisation that used the approach of ‘Plan, Do, Study, Act’ drawn from Deming
(1986, 1993), to take forward the integration of translational clinical research support
services. The case study within Allen et al’s work was Virginia Commonwealth
University, in the United States. The authors reviewed the approach that was taken by
the University to merge the functions provided by two previously separate units of the
General Clinical Research Centre and the Clinical Trials Office into a new combined
service called the Clinical Research Service.
The University reviewed the services and infrastructures within the two units, and
identified the limitations of the approach, including for example, a lack of effective
budgeting on clinical trials. They moved towards a new combined unit that delivered
‘(1) co-ordination and nursing (2) laboratory services (3) research facilities (4)
bioinformatics (5) budget development and negotiation’ (p.499) under one overall
Director. This sounds like a significant move, but Allen et al. do not explain how the
decision was communicated taken forward, and received. They also do not document
how (and if) services improved as a result of the merger.
In summary, there was a great deal of opinion offered by my participants about clinical
research governance systems in their organisations, and this concurs with the views of
the wider community, as demonstrated by the Academy for Medical Sciences (2011)
report which has led to the development of new, centralised systems. However, there
is academic literature in this area that suggests a cautious approach to the potential
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benefits of such a system (Kearney et al. (2014) and in any event it is still the case that
an element of decision making around clinical trials shall remain with local Trusts.
Given the embryonic nature of the new centralised systems of research governance, it
would be a matter for a future research project to understand how and if these are
assisting local partnerships to more effectively deliver translational clinical research in
collaborative NHS and University settings.
5.3 Practitioner generated themes: Summary
Throughout this analysis I have offered practitioner recommendations, where these
have arisen out of the data analysis. These recommendations are based upon my study
data and relevant policy and academic literature, which together provide a supportive
justification for each recommendation. The entirety of the recommendations are
presented here together for ease of reference, and to reflect Huxham & Vangen’s
approach to the ‘top tips’ for collaboration:
i. Engage with the regional devolvement agenda in the locality of the NHS-
University partnership. Understand what form any potential shared governance
structure would take and work to ensure that health and research are
considered as part of this.
ii. Create physical and virtual spaces for collaborative thinking across institutions
and across scientific disciplines.
iii. Recognise the importance of the clinical academic, and place him/her at the
centre of your thinking. Encourage a more collaborative approach to clinical
research, commencing in your clinical training programmes.
iv. Challenge cultural understandings of the ‘individual clinician’ or the ‘individual
academic’ and create incentives for collaboration. Allow people the space to
make delegated decisions where it is appropriate to do so
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v. Accept that your partnership cannot excel in all areas of translational clinical
research. Understand where you have clinical and research excellence and
build your strategy around these. Extend this to your training and recruitment
programme.
vi. Support the development of a strong pipeline of clinical academics by the
development of a matrix and collective approach to mentorship that spans
both organisations’
vii. Observe and learn from initiatives such as the Francis Crick Institute, which is
attempting to implement adopt and develop a full eco-system approach to
translational clinical research. There may be ideas here that could be applied to
your local NHS-University partnership.
viii. Spend some collective time to review what would form of leadership model
would work best for the partnership, at that time, including into this
consideration some thought as to how behaviours at individual, collective, and
organisational levels may need to change in order to support real and
sustainable change.’
ix. Develop different forums for communication throughout your partnership.
These should operate at practitioner level right up to senior management, and
should provide the opportunity for open debate and information sharing
x. Take time to develop a communications strategy and action plan. This needs to
make sense to both internal and external stakeholders and should be honest
about the need for prioritisation. It should be a dynamic document that is
supported by regular workshops, briefing sessions, and other forms of
communication.
166
xi. Take a fresh approach to performance measures. Where this is an opportunity
at a local level to define collaborative performance, take this. In cases where
national metrics are non-negotiable for one or other organisation, ensure that
this is understood across the partnership and embed this into your thinking
5.4 Policy generated themes
There were two themes which emerged from the literature review that were either
not referred to by my participants, or if referred to, were not seen as significant
Staying true to the theory of collaborative advantage, these are presented in this
section in light of the fact that policy has an impact on practice.
5.4.1 Definition of translational clinical research
Unlike the literature, which contains within it a level of controversy with regards to the
definition of ‘translational clinical research’, I demonstrated in the preceding chapter
that my participants were both relaxed and in broad agreement about it.
The definition that most closely aligns to those offered by the participants can be
found in Kenneth & Pienta (2010),
‘Translational research encompasses the effective movement of new
knowledge and discoveries into new approaches for prevention, diagnosis, and
treatment of disease’ (p. 316)
However, whilst my study data did not reveal any controversy at the level of the local
partnerships, the literature demonstrates that it is important for policy makers to
actively define translational clinical research as separate to basic science and to
continue to directly fund this stage of research.
167
5.4.2 The impact of ‘Research Impact’
‘Research impact’, for the purposes of my study, is defined within the context of the
Research Excellence Framework 2014 (REF). In the REF 2014 ‘383 impact case studies
were submitted’ within the Clinical Medicine Unit of Assessment, The outcomes
recorded in these case studies included, ‘increased life expectancy, (and) reduced
morbidity ’ (p.10), many of which had been developed out of joint NHS-University
projects (REF 2014: Overview report by Main Panel A & Sub-Panels 1-6 p. 26).
Section 2.2 of Chapter 2 (Literature Review) discussed the literature that has
developed with regards to research impact in the REF (Grant, Brutscher, Kirk, Butler, &
Wooding 2010; Ovseiko, Oancea, & Buchan 2012; Wooding, Hanney, Pollitt, Grant, &
Buxton 2014; Kings College London & Digital Science 2015), and the Dowling Review of
business-university collaborations, published in 2015, stated that the inclusion of
research impact in the REF had influenced a change in academic behaviour,
‘the inclusion of impact in the REF has helped to stimulate a more
positive attitude amongst academics towards collaboration with
business’ (Dowling Review 2015 p. 4).
I therefore anticipated that ‘research impact’ would emerge as a category or theme
within the participant data. However, the term ‘research impact’ was not mentioned
by any of the participants, despite the fact that both universities within the case study
partnerships had recently emerged from submitting research impact case studies into
the REF 2014. This appears to be a missed opportunity to collaborate around an area
that shall continue to be of great importance to universities – the recent Government
Green Paper (2015 p. 72-73) indicated that the percentage of the REF dedicated to
research impact is set to increase, therefore having a direct effect on the funding for
research received by universities in the future. However, it also raises questions as to
the wide applicability of Dowling’s view above that the REF 2014 has changed
academic behaviours across the sector.
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5.5 Research generated theme
The theory of collaborative advantage contains within it the research generated theme
of identity (2005; p. 187). Huxham, writing with Beech in 2003, argues that the identity
that individuals place on themselves, as well as the identity that others presume for
them, influences actions and inter-actions and is therefore of relevance to the
navigation of collaborative settings. Beech & Huxham also argue that organisations can
also be given an identity, often one which is too broad to adequately define a member
of a collaboration, but which is relevant because it has a meaning to the person using
it, and also therefore impacts on the way that they interact with the partnership.
This complex picture is summed up by the authors as the ‘identity formation melee’,
(p. 37) and it has some use in the context of my study data, in which a number of
identities were revealed. I observed the following identities within my study data, the
clinical academic (my participants had their own views on this identity, and views are
also offered in policy and academic literature), the governance administrator (widely
recognised in my study data and the literature as individuals that are working within a
system that is impeding research), the NHS (applying this as an identity within the
partnership is something that Beech and would term a ‘phantom’ concept if it were
not adequately defined by the individual and therefore not used in a way that others
totally grasp in terms of the meaning of it and the identity it construes; p. 47), and the
University (another potential ‘phantom’ concept).
Huxham & Beech advise that having awareness within the partnership of these
different perceptions of identity, helps partners to understand actions and interactions
and thereby is an important part of learning to collaborate. My study data suggests
that there is an understanding and acceptance across the NHS and University partners
of the different goals of the two organisations, but some space in which they could
consider their conceptualisation of identities would be a useful process.
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5.6 Conclusion to chapter 5.
This chapter has drawn upon my study data outlined in Chapter Four, analysing these
data alongside an examination of relevant policy and academic literature. This has
supported a detailed investigation of the issues outlined by my participants in the
areas of regional devolvement, physical proximity, government funding and policies,
clinical academics, leadership, communication, joint research strategy, organisational
cultures, and governance. In each of these areas I have offered recommendations for
future practice, these being based upon the dual analysis of participant data and
related literature.
I also analysed my data with respect to the policy generated themes of the definition
of translational clinical research and non-academic research impact, highlighting the
differences between my data and the literature in both areas, and finally, the research
generated theme of identify is found to have a relevance to both my case study
partnerships, that contain within them the identities of the clinical academic, the
governance administrator, the NHS and the University.
In the next Chapter I apply what I have learnt to the central research question, as well
as offering my reflective remarks, outlining the limitations of the study, and suggesting
future potential research into the subject area.
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Chapter 6. Conclusion and Reflections
6.1 Bringing New Knowledge to the Research Question:
My study brought new knowledge to the question,
‘How can NHS-University Partnerships collaborate to deliver translational
clinical research?’
It did so by analysing the local responses to the evolving policy environment, through
the lens of two NHS-University partnerships, assessing practitioner, research, and
policy generated data with reference to Huxham & Vangen’s theory of collaborative
advantage.
The environment within which the two case study partnerships operate comprises
macro level national policies, meso level organisational challenges, and micro
characteristics determined by key individual stakeholders, as demonstrated in Figure
5.1 below.
Figure 6: 1 Macro, Meso, and Micro elements of my two case study partnerships
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My documentary analysis of the macro level policy environment demonstrated that
Government’s intention was to create an environment in which organisations and
individuals could collaborate more effectively to deliver successful translational clinical
research. However, my participant data demonstrated that there are a number of
factors which impeding the ability of both partnerships to achieve this. These data are
particularly relevant to NHS-University partnerships that operate outside the ‘Golden
Triangle’ of highly successful collaborations that exist in London and the SouthEast.
There is a deal of literature that has developed around Academic Health Science
Centres (Weiner et al. 2001; Ferris et al. 2004; Currie & Suhomlinova 2006; Grainger
2010; Michener et al. 2012; French et al. 2014), Collaborations for Leadership in
Applied Health Research Centres (Currie et al. 2013; Davies et al. 2015;) and other
educational and research based collaborations (Long et al. 2014; Schwartz et al. 2015;
Rajasekhar et al. 2014). However, these are focussed either on international examples
of health partnerships, or more formalised partnerships in the UK context.
My study brings new knowledge to this body of work by focussing specifically on two
partnerships operating outside of the Golden Triangle, that are not formally
constituted AHSCs or CLAHRCs. Both of the case study partnerships were formed in an
attempt to increase the likelihood of securing funding for translational clinical
research, and there shall be other such arrangements that are being created
elsewhere in the country for the same reason.
Understanding the specific challenges faced by such partnerships is important, and my
study brings new knowledge to the area by providing an increased understanding into
the particular challenge that are faced, as perceived by the clinical academics that are
operating within these new forms of partnership.
The data revealed a strong feeling amongst the participants that the national and
international shortage of clinical academics (Cooksey 2006; Pickering et al. 2015) is a
particular challenge for collaborations operating outside of the Golden Triangle. Whilst
there was evidence that there are strategies to address this at a local level, I suggest
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that this is an area in which national and local policy makers and leaders should come
together to develop a longer term approach that is geared towards not simply
increasing the numbers of clinical academics, but also at ensuring there are sufficient
numbers of appropriately qualified people based in the localities that need them. This
would require a move away from the present clustering of clinical academics in
defined geographic areas.
A regionalised approach to addressing this problem was suggested by the participants,
and this has support from the wider policy literature that exists around the broader
concept of regional devolution in England (Summer Budget 2015). Linked to this notion
of regionalism was evidence of what Huxham & Vangen would term ‘collaborative
inertia’ (2003; p. 62), rooted in a frustration around the difficulties faced by local
partnerships trying to work within a national policy system which, in terms of the
funding data at least, appears to be best suited to the Golden Triangle partnerships
(UK Clinical Research Collaboration 2015).
However, my results offer a different view to Huxham & Vangen’s ‘inertia’, which is
based around their concept of ‘partnership fatigue’ (2004; 195). In contrast, the inertia
in my study was created by what I have termed ‘initiative fatigue’. This data is
specifically relevant to partnerships operating outside of the Golden Triangle in that it
demonstrates the frustrations that were expressed around the need for the two local
partnerships to comply with a plethora of national initiatives, some of which were
deemed to be unnecessary and unhelpful.
My participants did not agree on the issue of physical proximity and whether this was
necessary for the building of NHS-University research projects, a diversity of views that
is not unusual within partnerships (Huxham & Vangen 2005), but presenting a more
complex picture than is presented in the literature around co-location of researchers
which is largely in agreement that this is a positive thing that support joined-up
working (Dzau et al. 2013; Cremades et al. 2014; Long et al. 2014).
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Leadership was a key factor raised by all of my participants, a result which is in stark
contrast to the experiences of Huxham & Vangen who have remarked that
‘practitioners seldom’ refer to it (2000; p. 1172). Whilst leadership was raised as a key
component in the success of my case partnerships, my study data demonstrated a lack
of clarity as to what the best model might be, and this adds to the existing body of
literature in which there is little agreement as regards the most suitable type of
leadership for NHS-University partnerships (Ovseiko et al. 2010; Weiner et al. 2001;
Michener et al. 2012).
Huxham & Vangen 2000; and Adams et al. 2015) argue that the difficulties faced in
negotiating and agreeing joint performance measures can derail a partnership, and my
study brought new, detailed knowledge to this in the specific area of NHS-University
partnerships operating outside of London and the SouthEast. My participant data
demonstrated how the different NHS and University cultures can be a significant
barrier to progressing the overall aims of the partnership, and I therefore suggested a
suite of performance measures that could be used by NHS and University partners in
the future. This is an attempt to address what Huxham & Vangen term the ‘goals
paradox’ (Huxham & Vangen 2012).
6.2 Potential future research
In the ‘methodology’ chapter, I outlined the Huxham & Vangen framework for
collaborative advantage alongside the concept of absorptive capacity (Cohen &
Levinthal 1989) and explained that I had selected the former due to its practitioner
focussed approach to understanding collaboration in partnership settings. I also
argued that there was a lack of clarity around the specific external factors that NHS-
University partnerships need to absorb to deliver translational clinical research.
Subsequently my data suggested that these factors include regional devolvement,
physical proximity, government funding and policies, clinical academics, leadership,
communication, joint research strategy, organisational cultures, and governance.
Future research could test the two partnerships’ absorptive capacity with specific
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reference to one or a combination of these factors, following the example in the
literature around absorptive capacity which has recently been applied to the
knowledge and higher education sector (Belderbos et al. 2016; Denicolia et al. 2016).
For example, one of the findings of my study was the need to develop a new culture of
joint working in order to attract higher levels of clinical academics to the partnerships.
A future research project could investigate the absorptive capacity of my case study
organisations with regards to their ability to assimilate new models of working, making
recommendations, if possible, that could be transferred into practice.
Huxham & Vangen’s theory of collaborative advantage would also be a suitable
framework within which to bring further in-depth analysis to any one of the factors
that emerged as important from my research data. The framework assisted me to
understand the nuances between practitioner, research, and policy generated themes
of collaboration within the context of NHS-University partnerships for translational
clinical research. As I have outlined above, by viewing the two case studies through
this theoretical lens, I was able to frame my research project such that the data
revealed new knowledge, whilst also supporting a series of practitioner focussed
recommendations for future actions.
My pre-research hypothesis was that the new national policy environment was not
sufficient to support effective translational clinical research across the country, and my
study has confirmed that whilst progress is being made, there is more to be done.
I anticipate that the new phenomena of NHS-University partnerships will be the
subject of further academic research. My own study raises some theories that are
worthy of future investigation. A number of future research projects naturally arise
from my study data, including more investigation into possible regionalised approach
to NHS-University management, leadership and delivery, and into the different
cultures that are required, at both organisational and individual level, for partnerships
to succeed in the new environment.
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Currie et al. (2013) have suggested that a new form of leadership, one which can span
organisational boundaries, is required to support NHS-University partnerships, but
there remains a knowledge gap around the way in which individual clinical academics
could participate to partnerships, as leaders and champions. My data revealed a lack of
collaborative leadership at the level of senior clinical academics, and therefore further
research to understand the factors, cultural, organisational, individual, that influence
this, would be useful.
6.3 Study Limitations
My study refers to a small qualitative data set and is limited in that respect, although I
believe that is does bring a new perspective that can be tested in other local
constructs.
Sandelowski (1986) made the point that a small sample size can provide in depth data,
as demonstrated in the example of Cremades et al. (2014) who interviewed eight
participants in a successful Research Institute in Spain to explore issues of
management culture with regards to the successful translation of research from
‘medical research to clinical practice and to the productive sector’ (p.380). They
accepted that the single case study approach would not produce generalizable results
but argued that their research added useful thinking to the area by virtue of being an
‘in-depth study of a phenomena in a particular context’ (p.382). My research builds on
this approach; although the number of participants was small, the data that I collected
was meaningful and provided new insights into the delivery of translational clinical
research within the two case study partnerships, and moving on knowledge in this area
of NHS-University collaboration more broadly, by presenting a series of common
themes from the data set.
My own practitioner perspectives must also be recognised, and I have been clear
about this throughout. My interpretive approach allowed me to embed my own
subjectivity within the research method, though I was careful to reduce bias.
Nonetheless, I am aware that there are elements of both case study partnerships that I
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may not have been aware of as an outsider researcher and these also serve as a
potentially limiting factor.
I was careful to minimise the risk that my interview questions were overly influenced
by my pre-existing knowledge, and status as a practitioner-researcher, with some links
to both case study sites. I was fortunate to have been able to enlist a community of
critical friends, on which to trial my questions, an invaluable process that allowed me
to refine the format before commencing the formal interviews. This also allowed me
to spot any overly subjective questions. I was careful to select as participants those
individuals that I had not worked closely with – the small sample size made this
possible. On balance, the benefits of being a practitioner researcher outweighed the
challenges, but it remains the case that my study must be viewed with the knowledge
that I had a professional interest into the area.
6.4 Concluding remarks
I came to the end of my research enlightened both by the literature that I accessed,
and the data that I collected and analysed. It is apparent from my qualitative study
that the new phenomena of NHS-University partnerships, created as a result of a
national policy framework, are not easy things to define, work within. Nor do they fit
comfortably within wider, overarching structures, each being unique to their own local
context.
One of my study participants encapsulated the challenge as one in which we are
‘trying to find solutions to the problems we created over the last 20 years’ (1:3).
My study demonstrates that this journey towards a new approach for the delivery of
translational clinical research has begun. Where it leads us will be influenced by
actions at a national, local, and organisational level. The interplay between these shall
be crucial to the way in which policy intentions are translated into the delivery of
clinical research by our hospitals and universities.
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Appendix B: Participant information sheet
Research Study
How can NHS-University Partnerships collaborate to deliver translational clinical research?
A comparative case study of local responses to the evolving external policy environment
You are being invited to participate in a research study; before you make a decision about this,
it is important that you understand why the research is being done and what participation will
involve. This information is presented in this Participant Information Sheet. Please read it
carefully and let me know if you require further information.
I must stress that you do not have to accept this invitation, and should only agree to participate
in the study if you wish to do so.
Thank you.
1. Purpose of the study
Since the establishment of the NIHR in 2006, there has been a succession of Policy and Funding
initiatives that have aimed to improve the clinical research environment. But how have these
translated in practice, within University-NHS partnerships operating in different local contexts?
This research study aims to bring new knowledge to that question, by exploring the opportunities
and barriers that exist within two anonymized University-NHS partnerships, and the ways in which
these might be addressed at national and local levels.
2. My Role
I am undertaking this Study as a Student on the University of Liverpool’s EdD Programme.
3. Why you have been chosen to take part
The study involves the interviewing of twelve individuals, all of whom have experience of
delivering and/or supporting NHS-University clinical trials.
You do not have to take part in the study; participation is entirely voluntary, and, even if you do
agree to participate, you may withdraw at any time without explanation.
4. What happens if you do take part?
Participants in the study will be invited to attend an interview with me. This will take place in a
suitable location of your choice and will take around thirty minutes. The interview will be semi-
structured, with all interviewees being asked the same question. The session, with your
permission, will be tape recorded and transcribed by me. A copy of the transcript will be provided
to you after the interview and you will have the opportunity to make any corrections that you think
are required. The digital recording will be stored, identified by interview number, in a secure
password protected file area on the University server. Your identity will be removed from the
transcript, and the table giving the link between your identity and the data file will be stored in a
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separate secure file area on the University server. All subsequent analysis will be performed on
the anonymized transcript. Following the completion of all twelve interviews, a thematic analysis
of the responses will be undertaken.
5. Expenses / payments
Expenses or payments are not offered to participants in this study.
6. Are there any risks in taking part?
There are no risks associated with participation in the study.
7. Are there any benefits in taking part?
The research is applied in nature and will bring new knowledge to the local delivery of clinical
trials, this being relevant to your own professional area.
8. Will my participation be kept confidential?
Your interview will be recorded and stored digitally on a password-protected secure file area
within the University computer system. The local copy of the recording will be destroyed as soon
as the interview is transcribed, but the copy on the University file server will be retained for a
period of up to ten years. Your name will not appear on the recording, which will be identified only
by interview number.
The anonymised transcript will be sent to you for annotation and editing, and stored in a
separate central file on the University server. A thematic analysis of the interviews will be
undertaken, using written notes and mind-mapping software. Notebooks will be stored in a
secure locked cabinet during the duration of the research and destroyed thereafter.
9. Publication
The Study is undertaken as part of an own-funded EdD with the University of Liverpool. Subject
to the Thesis meeting the required standards, it will be available through the British Library. Other
publications will include articles for peer-reviewed journals, which will not contain any identifying
features.
Results from the Study will also be shared with the Participants in separate briefings, unless
people do not wish to do so.
10. What if I am unhappy or if there is a problem?
The University has a complaints procedure that is open to you should you be unhappy about
any element of the Study. Should this be the case, please contact Professor Morag Gray
morag.gray@online.liverpool.ac.uk who will try to assist you. Should you remain unhappy,
please contact the Research participant advocate liverpoolethics@ohecampus.com providing
the name or description of the study, the researcher(s) involved, and the details of the complaint
you wish to make.
11. Contacts
Student: Catherine Anne Cochrane (catherine.cochrane@online.liverpool.ac.uk)
Principal Investigator: Professor Morag Gray (morag.gray@online.liverpool.ac.uk)
Appendix C: Interview Schedule
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• What is the vision for translational clinical research in the University andthe Trust?
• How well understood is this vision (with clinical academics with non-clinical academics)?
• Is it focused on particular groups or themes at the moment – why is that?
• What have the NHS and University done to engage with each other at seniorand operational levels?
• What do you think are the main opportunities for the University/NHS Trustin terms of engagement with the local NHS trust(s)?
• How should the organisations manage these?
• What do you think are the main challenges for the University/NHS Trust interms of engagement with the local NHS Trust(s) and how should theUniversity manage these?
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